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Abstract 
In the UK in 2008 over 1,800 people died from oral cancer.  Despite advances in surgery and 
therapy the survival rates for those diagnosed with oral cancer have not significantly improved 
over the past 20 years. There is a need for both better detection and treatment. Early detection 
could reduce these mortality rates but unfortunately diagnosing oral cancer, which is often 
symptomless, in the early stages of the disease is incredibly challenging.  More targeted 
treatments for oral cancer are also needed which can be administered to the site of disease with 
higher efficiency and accuracy to reduce side effects and allow higher concentrations of 
therapeutic agents to be delivered to tumour cells. 
This project used a tissue engineered oral mucosa model to develop models of oral cancer 
progression. These oral cancer models incorporated many pathological features of oral cancer 
progression including features seen in dysplastic epithelia, carcinoma in situ and early invasive 
squamous cell carcinomas. Multi-cellular tumour spheroids were created from an oral cancer 
cell line to model solid expanding tumour masses.  
The tissue engineered models of oral mucosa and the multi-cellular tumour spheroids were 
used to test the behaviour of polymersomes, a novel drug delivery system, in three dimensional 
tissues.  Polymersome distribution and penetration in the tissue engineered models was 
examined over time, to investigate the potential of polymersomes to deliver therapeutic agents 
into and/or across the oral mucosa and into solid expanding tumours. Drug delivery agents that 
are able to reach the central hypoxic region of solid expanding tumours are particularly 
important as these cells are often resistant to both radio- and chemotherapy and correlate with 
poor patient prognosis.  In addition, we explored the potential of polymersomes to cross the 
oral epithelial permeability barrier and act as delivery vehicles for topical delivery of therapies 
for oral mucosal diseases and as an alternative to parenteral administration for the systemic 
delivery of drugs.  Results showed good penetration of polymersomes into the oral mucosa and 
the multi-cellular tumour spheroids demonstrating the potential to develop these drug delivery 
vehicles to deliver anti-cancer drugs and other therapeutic agents in the future. 
The tissue engineered models of cancer were next utilised to test four non-invasive diagnostic 
technologies.  These included a cell metabolism marker, impedance spectroscopy, Fourier 
transform infra-red and optical coherence tomography.  The results obtained from these 
different techniques showed varying degrees of promise with the images from OCT 
demonstrating that this technology has real diagnostic potential.  The 3D models proved useful 
test-beds for some but not all of these diagnostic imaging techniques. They provide convenient 
models to tackle some of the key issues in the preclinical development of novel diagnostic 
technologies for oral cancer and oral dysplastic lesions. 
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FDA   Food and Drug Administration 
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GFP   Green Fluorescent Protein 
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GPC   Gel Permeation Chromatography 
g   gram 
h   hours 
HCl   Hydrochloric acid 
HGF   Hepatocyte Growth Factor 
HIV   Human Immunodeficiency Virus 
HNSCC  Head and Neck Squamous Cell Carcinoma 
HOE   Human Oral Epithelium 
Hz   Hertz 
i3T3   irradiated Swiss mouse fibroblasts 
IDMEM   Iscove's Modified Dulbecco Minimum Essential Medium 
IU   International Units 
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IR  Infra-red 
KGF   Keratinocyte Growth Factor 
L   litre 
LSM   Laser Scanning Microscopy 
µ  micro 
m  milli-  
m   metre 
M  Molar 
MCGs  Membrane Coating Granules 
MCTS   Multi-cellular tumour spheroids 
MD   Michelson Diagnostics 
MMP   Matrix metalloprotinase 
MRI   Magnetic Resonance Imaging 
MTT   (3-(4,5-dimethylthiazol-2-yl)-2,5 diphenyl tetrazolium bromide) 
n   nano 
NA   Numerical Aperture  
NaOH   Sodium Hydroxide 
NCI-DTP   National Cancer Institute Developmental Therapeutics Programme 
NIR   Near Infra-Red 
NOF   Normal human Oral Fibroblasts 
NOK   Normal human Oral Keratinocytes 
OCT   Optical Coherence Tomography 
OSCC   Oral Squamous Cell Carcinoma 
PAA   Poly (acrylic acid) 
PBS   Phosphate Buffered Saline 
PCL   Polycaprolactone 
PDPA  poly(2-(diisopropylamino)ethyl methacrylate) 
PEG   Poly (ethylene glycol)* 
PEO   Poly(ethylene oxide)* 
pH   potentiometric hydrogen ion concentration 
pKa  Acid dissociation constant 
PLA   Poly (lactic acid) 
PML   Potentially Malignant Lesions 
PMPC  2-((methacryloyloxy)ethyl phosphorylcholine) 
PS  Poly (styrene)  
R   Reflectance 
rBM   Reconstituted Basement Membrane 
RFP   Red Fluorescent Protein 
rho  Rhodamine 
RNA  Ribonucleic acid 
RPMI   Roswell Park Memorial Institute (cell culture medium) 
rpm   revolutions per minute 
SCC  Squamous Cell Carcinoma 
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s.d.   Standard deviation 
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SLED   Superluminescent light emitting diode  
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Chapter 1: Introduction 
1.1 Oral mucosa 
 The Normal Oral Mucosa 
Human oral mucosa is comprised of a stratified squamous epithelium and a connective tissue 
component, separated by a basement membrane (Figure 1.1) (Nanci 2003).  Adjacent to the 
basement membrane lays the basal keratinocytes; these cells are “stem-like” proliferative cells 
which repair and replenish the epithelium.  Superficially to these are the partially differentiated 
supra-basal cells which are also highly proliferative.  Above the supra-basal cells lies the 
prickle cell layer or stratum spinosum.  In the prickle cell layer cells are joined by 
desmosomes, these desmosomes remain attached between cells during histological processing 
however, the cells shrink, making cells appear prickly.  In keratinized regions of the oral cavity 
(gingivae and hard palette) the most superficial layer of the epithelium is made up of 
terminally differentiated keratinocytes (Nanci 2003; Salamat-Miller et al., 2005).  In non-
keratinised areas like the buccal mucosa there is less keratinisation of superficial layers which 
are then termed para-keratinised.  The keratinised layer contains a large amount of keratin and 
the cells are flattened with little or no nuclei.  In the connective tissue the predominant cell 
type is fibroblasts. These are responsible for producing extracellular matrix proteins and 
releasing factors important in epithelial development (Mackenzie and Fusenig 1983).  The 
connective tissue also contains cells involved in the immune system and a vasculature 
component. 
The oral mucosa has potential as a site for local drug delivery for mucosal diseases and for the 
trans-mucosal systemic delivery of drugs without the need for injections (reviewed in 
(Hearnden et al., in preparation; Sankar et al., in preparation)).  
 Permeability of the Oral Mucosa 
The permeability barrier of the oral mucosa is responsible for preventing exogenous and 
endogenous materials entering the body via the oral mucosa and prevents loss of fluid from the 
underlying tissues to the environment. The permeability barrier is predominantly due to the 
lipid content of the upper layers of the epithelium.  As supra-basal cells differentiate they form 
strong intercellular desmosomal junctions and membrane coating granules (MCGs) on their 
apical surfaces (Shimono and Clementi 1976; Shojaei 1998).  These MCGs release lipophilic 
material into the intercellular spaces to ensure epithelial cohesion. This lipophilic material 
slows the passage of hydrophilic materials across the epithelium (Salamat-Miller et al., 2005).  
It has also been hypothesised that tight junctions play a role in permeability barrier function 
however, these are not commonly found in the oral epithelium (Shimono and Clementi 1976).  
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Kulkarni et al. looked at the permeability of the epithelium and the connective tissues using 
varying thicknesses of porcine buccal mucosa and mathematical derivation (Kulkarni et al., 
2009).  It was shown that the epithelium is the major barrier to permeability with the 
connective tissue providing some resistance to lipophilic materials due to the connective 
tissue‟s high level of hydration.  
 
 
Figure 1.1 Structure of the oral mucosa and the oral epithelium (insert)  
Image reproduced from (Hearnden et al., in preparation).  
 
There is variation in permeability across different regions of the oral mucosa due to the 
differing thickness of the epithelium and degree of keratinisation at different sites.  Keratinised 
tissues display a lower permeability than non-keratinised tissue, this is however, due to the 
lipid composition of the membrane coating granules in the keratinised vs. non-keratinised 
tissues rather than the content of keratin itself (Ganem-Quintanar et al., 1997). The degree of 
permeability is least in keratinized gingiva followed by the buccal mucosa with the most easily 
permeated area of the oral cavity the sublingual mucosa (Squier and Hall 1985). 
There are three methods of diffusion across the oral mucosa‟s permeability barrier (i) passive 
diffusion including trans-cellular (through cells) and para-cellular (where material passes 
through lipid rich domains around the cells),  (ii) carrier mediated transport and (iii) 
endocytosis/exocytosis where material is actively taken up and excreted by cells via the 
endocytic pathway (Li et al., 2005; Salamat-Miller et al., 2005; Sudhakar et al., 2006). The 
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most easily diffusible materials are lipid soluble and non-ionized species and those with low 
molecular weights. Dextran with a molecular weight below 20,000 Da is diffusible however, 
dextrans with larger molecular weights are not (Hoogstraate et al., 1994). The route of passive 
diffusion taken by a particular material depends on the material‟s lipophilicity, partition 
coefficient between lipophilic and hydrophilic regions and the diffusion coefficient of the 
substance in the intercellular space (Sood et al., 2005).  Drugs which have a high pKa (acid 
dissociation constant) diffuse across the mucosa better (Madhav et al., 2009). For drugs that 
act on intracellular targets the trans-cellular route is desired.   
 Advantages of the Oral Mucosa For Drug Delivery 
Applications 
The oral cavity has been proposed as a potential topical delivery site for the delivery of local 
and systemic delivery of therapeutic agents.  When compared to parenteral delivery the oral 
mucosa is appealing to patients as the administration is painless, it can be self-administered 
and is easily withdrawn (Sudhakar et al., 2006).  The oral cavity has advantages over other 
mucosal membranes as it is well tolerated by patients, it is easily accessible and is rapidly 
repaired after damage or trauma.  This short recovery time limits potential damage caused by 
long term topical drug delivery and the rich blood supply to the oral cavity makes systemic 
delivery viable and very rapid (Sudhakar et al., 2006).  There are also fewer Langerhans cells 
found in the oral mucosa compared to the skin reducing the risk of an allergic response, a 
drawback commonly experienced in transdermal delivery.  The oral cavity is also versatile 
with different areas of the oral cavity exhibiting different permeability characteristics.  The 
oral mucosa is between 4 and 4000 times more permeable than the skin (Galey et al., 1976). 
The high permeability and excellent blood supply and rapid onset of action make the oral 
mucosa an ideal drug delivery site for acute conditions such as angina and pain. Delivery via 
the oral mucosa can enable rapid delivery to the circulation, smaller dosing and better 
bioavailability for some drugs.   
 Limitations and Drawbacks of the Oral Mucosa 
For Drug Delivery Applications 
There are problems associated with transmucosal delivery which include: (i) finding drugs that 
can overcome the permeability barrier, (ii) protecting biological drugs such as peptides and 
proteins from enzymatic degradation, (iii) finding drugs that are able to penetrate the mucus 
coating of the epithelium, (iv) finding drugs that have an acceptable taste to patients and (v) 
designing delivery devices that are not easily swallowed by accident (Sudhakar et al., 2006).  
The oral mucosa has a small surface area compared to skin and limited exposure times make 
this delivery route most appropriate for drugs exhibiting high therapeutic potency as relatively 
small quantities of drug can be delivered (Madhav et al., 2009).   
Chapter 1:Introduction 
 
19 
 
The oral cavity is constantly bathed in saliva, produced by the salivary glands to provide 
protection and lubrication in the mouth.  The volume of saliva varies but it is usually between 
0.5 and 2 L per day with a pH between 5.5 and 7 (Shojaei 1998).  The constant washing of the 
oral cavity by saliva can limit the length of exposure to a drug or delivery system, dilution of 
the drug in the oral cavity and washing of a drug into the gastrointestinal tract.  Saliva can also 
be beneficial in providing a highly hydrated environment in which to dissolve the drugs and 
wash drugs around the entire oral cavity.  Mucoadhesive systems enable longer exposure of a 
delivery system to the mucosa (Madhav et al., 2009).  
Mastication, the action of chewing, can both hinder drug delivery in the oral cavity and 
enhance it.  Mastication can cause damage to or loss of mucoadhesive drug delivery systems 
however, it can also be utilised by loading drugs into chewing gum which are released when 
the gum is chewed (Maggi et al., 2005). 
Efforts to overcome some of these problems include research into permeability enhancers and 
enzyme inhibitors (Shojaei 1998). However, as of yet no oral mucosal products are available 
commercially that use permeability enhancers (Madhav et al., 2009).  
1.2 Head and Neck Cancer: The Clinical 
Challenge  
 Introduction to Head and Neck Cancer 
Head and neck cancer is the 15
th
 most common cancer in the UK with around 5,000 new cases 
being diagnosed every year (CancerResearchUK 2009).  In all regions of the UK male 
incidence rates are higher compared to female incidence, a trend seen across the world (IARC 
2004). Worldwide there were an estimated 405,000 new cases of oral cancer in 2002 (IARC 
2004; CancerResearchUK 2009). The incidence of oral cancers worldwide varies widely 
between countries.  Figure 1.2 gives a pictorial idea of the variation seen worldwide in men 
and women (IARC 2004). 
Oral cancer includes cancers of the mouth cavity (30%), tongue (30%), oropharynx, 
hypopharynx and piriform sinus (combined 30%) and lip (6%) (CancerResearchUK 2009). 
The majority of oral cancers (over 90%) are oral squamous cell carcinomas (OSCC) 
(CancerResearchUK 2009), predominantly caused by epithelial exposure to alcohol and 
tobacco (Argiris et al., 2008). Figure 1.3 shows how combined alcohol consumption and 
tobacco increases the relative risk of developing OSCC (CancerResearchUK 2009).   Those 
who smoke and drink heavily are over 35 times more likely to develop oral and pharyngeal 
cancer compared to those who abstain from both (Blot et al., 1988).  In South Asia the 
incidence of oral cancer is high due to the habit of chewing betel quid (also known as paan) 
and related areca nut use (CancerResearchUK 2009).   Human papillomavirus (HPV), poor 
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oral hygiene, immunocompromised individuals including those suffering from HIV/AIDS, 
deprivation, infections such as syphilis and candidiasis, diseases including diabetes and low 
fruit and vegetable intake have all also been identified as factors which contribute to OSCC 
(Scully and Bagan 2009). 
 
Figure 1.2 Incidence of oral cancer globally for females (top) and males (bottom).  
Reproduced from (IARC 2004). 
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Figure removed for copright purposes 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.3 Relative risk of developing oral and pharyngeal cancer based on tobacco and 
alcohol consumption (US measures).   
Graph reproduced from (CancerResearchUK 2009) 
 
 
The outlook for patients diagnosed with cancer of the head and neck is poor, especially if 
diagnosed with late stage cancer.  For the one third of patients who present with stage I or II of 
the disease there is an 80% or 65% chance of being cured, respectively (Yao et al., 2007).  
Unfortunately, for the two thirds of patients who present in the late stages of the disease the 
prospects are worse as treatment becomes harder and the disease progresses to other parts of 
the body.  Stage III is defined as when the tumour can be seen in the lymph nodes and stage IV 
when the tumour is metastatic (CancerResearchUK 2005).  5 year survival rates for patients 
who present with stage III or IV are  between 10 and 40%.   
One reason for this poor survival rate is because detection of OSCC is difficult and always 
requires histological verification, often leading to late detection.  A recent study by Rogers et 
al., looked at the reasons patients delayed in presenting symptoms of oral cancer to a medical 
specialist (Rogers et al., 2010).  The majority of patients felt the initial symptoms (non-healing 
ulcers, sore mouth or a persistent lump) were trivial and believed they would heal of their own 
accord.  This study highlights the need for greater awareness of the symptoms of oral cancer to 
encourage patients to present their symptoms earlier, and improve disease outcomes (Rogers et 
al., 2010).   
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Despite advances in surgical techniques and post-operative therapy, there has been no 
significant improvement in patient survival rates over the last 20 years (Scully and Bagan 
2008).  Hence, there is a major focus for developments in novel diagnostic and drug delivery 
systems for OSCC (Harrington et al., 2005).    
 From healthy oral mucosa to OSCC 
Figure 1.4 shows the various stages of squamous cell carcinoma development from healthy 
epithelium to carcinoma in situ. The terminology used to describe different stages of OSCC 
varies; however, here we will use the oral scheme of terminology which has been 
recommended by the World Health Organisation (WHO) (Speight 2007).  There are five 
distinct categories of diagnosis which relate to a variety of different architectural and 
cytological features.  Hyperplasia is used to describe potentially malignant lesions such as 
leukoplakia and erythroplakia which do not show signs of dysplasia.  The features of the 
different grades of dysplasia are described in Table 1.1. 
 
 
Figure 1.4 Examples of the appearance of haematoxylin and eosin stained histology 
sections showing the progression from mild dysplasia (A), to moderate dysplasia (B), severe 
dysplasia (C) and carcinoma in situ (D) in patients. 
Image from (Speight 2007) 
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 Table 1.1  
Features of the different stages of dysplasia.  (Information from (Speight 2007)) 
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Some pathologists describe carcinoma in situ as a pre-malignancy however, others see 
carcinoma in situ as a malignant lesion, without visible signs of invasion (Speight 2007).  
Diagnosis of invasive carcinoma can be difficult and is often subjective.  In some cases 
breaches in the basement membrane make it clear that the lesion is invasive although 
inflammatory infiltrates and the position of the pathological section make it unclear (Speight 
2007).  Islands of epithelial cells with keratinisation in the connective tissue are a clear 
indication of invasion.   
 Current treatments for OSCC 
The majority of OSCC cases are treated by surgical resection followed by radiation therapy 
(Argiris et al., 2008).  Recently, focus has moved towards using chemotherapy alongside 
surgery and radiotherapy (Yao et al., 2007).   
 Surgical intervention 
The anatomy of the oral cavity along with its role in essential functions means removing 
tumours by surgery whilst maintaining speech and swallowing, is very challenging.  Surgical 
advances, such as transoral laser microsurgery, have improved the prognosis with improved 
maintenance of function (Argiris et al., 2008). However, there are still limitations, the most 
significant being the difficulty of identifying all the cancerous regions of the oral mucosa 
leading to incomplete excision of tumours and disease recurrence (Argiris et al., 2008).   
 Radiotherapy 
Radiotherapy is used instead of surgery to treat early tumours or if the tumour location means 
there will be serious functional loss from surgical excision (Argiris et al., 2008).  Radiotherapy 
works by exposing cancerous tissues and associated lymph nodes to ionizing radiation.   This 
radiation damages the DNA within cells either directly or through the production of free 
radicals from ionized water.  This DNA damage can lead to cell death via apoptosis or reduced 
cell division.  Cancer cells have a reduced ability to repair damaged DNA compared to healthy 
cells however, healthy cells surrounding the tumour are also damaged leading to severe toxic 
side effects (Argiris et al., 2008). Research into radiotherapy aims to improve the effectiveness 
of treatment whilst limiting toxic side effects including mucositis and xerostomia (dry mouth).      
Fractionated radiotherapy is a method which increases the dose intensity of radiotherapy while 
reducing the overall exposure time compared to conventional radiotherapy.    An analysis of 15 
randomised trials on fractionated dose radiotherapy found an 8% improvement in 5 year 
survival rates with hyperfractionated radio therapy (delivering 2-3 fractions daily with a 
reduced dose per fraction) compared to conventional fractionated radiotherapy (1 fraction per 
day) (Mazeron et al., 2009).   
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 Chemotherapy   
Chemotherapy was previously used to alleviate symptoms of OSCC.  However, it now plays a 
central role in curative programmes particularly for more advanced or inoperable tumours 
(Argiris et al., 2008).  The chemotherapeutic agents most commonly used in the treatment of 
OSCC include Doxorubicin, Paclitaxel, Cisplatin and 5-Fluorouracil (5-FU), although many 
more anti-cancer drugs exist.   
Unfortunately, chemotherapy is associated with high toxicity and severe side effects which 
often limit their effectiveness.  Attempts to reduce systemic toxicity and improve the anti-
tumour effects have led to the development of complex chemotherapy regimes which use 
multiple drugs delivered in pulsed or phased delivery schedules.  Chemotherapy requires good 
vasculature to deliver chemotherapeutic agents into cancerous regions.  The centres of solid 
tumours have a poor blood supply making it difficult to deliver chemotherapeutics into these 
areas.  This poor blood supply also makes the central regions hypoxic and resistant to 
radiotherapy (Ljungkvist et al., 2000). Fortunately, OSCC cancers have relatively good 
vasculature compared to other cancers making chemotherapy more effective.  
 Chemoradiotherapy 
Chemoradiation therapy, i.e. combined chemo and radiotherapy, gives survival rates similar to 
surgical excision for early lesions but function preservation is improved with chemoradiation 
(Yao et al., 2007).  For more advanced tumour progression chemoradiation therapy is often 
combined with surgical excision.  When compared to radiotherapy alone, four out of five 
randomised trials showed a significant improvement in overall survival using chemoradiation 
(Yao et al., 2007). Platinum based chemotherapeutic agents, such as Cisplatin, demonstrated 
greatest improvement and the majority of benefit from concomitant chemoradiotherapy is seen 
in locoregional disease control with only marginal effects seen at metastatic sites (Mazeron et 
al., 2009).  
It is believed chemoradiation gives improved survival rates by preventing regrowth of tumours 
between doses of radiation and inhibiting the repair of radiation damaged DNA (Yao et al., 
2007). Unfortunately, local morbidity, mucositis and toxicity are high following 
chemoradiation (Yao et al., 2007).  There are a number of studies investigating the best 
combination of chemotherapeutics and dosages with the aim of reducing morbid effects (Fuwa 
et al., 2007).   
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1.3 Current problems with OSCC drug 
delivery  
 Methods of delivery  
Systemic administration of chemotherapeutics by intravenous injection is the most common 
method of delivery. The drug is delivered directly into the circulation and ensures a known 
concentration of drug is delivered.  Systemic circulation avoids problems experienced with 
oral delivery of drugs including drug degradation in the acidic and enzymatic environment of 
the gastrointestinal tract and drug loss caused by the first pass effect. The main drawback with 
intravenous drug delivery is that it is non-specific which results in drugs reaching all areas of 
the body.  This causes side effects in many healthy areas of the body but also enables 
chemotherapy to reach and treat unknown metastasises.  Problems associated with systemic 
delivery include the permeability of drugs into poorly vascularised regions of tumours, 
systemic side effects and solubility of hydrophobic drugs into injectable liquids at therapeutic 
concentrations.     
For the treatment of accessible solid tumours, drugs can be directly injected into the tumour.  
Intra-tumoural delivery does not rely on vasculature or penetration of drug across tissues to get 
the drugs to the disease site.  The drug must still be able to diffuse throughout the tumour 
tissue once it has been injected to ensure complete distribution of drug within the tumour.  
Intra-tumoural injection is not common and can be painful; however, there is research into its 
use in particular circumstances including this Phase II study for locally recurrent tumours 
(Duvillard et al., 2004).  
Local drug delivery is the delivery of drugs topically directly to the site of disease.  The main 
advantages of local drug delivery include (i) reduced off target side effects, (ii) more efficient 
delivery: less drug is wasted or lost elsewhere in the body, (iii) targeted delivery: drugs can be 
targeted to the site of action more easily when delivered locally. Topical drug delivery may be 
a possibility for dysplastic lesions and early invasive SCC.  It is probably not viable for larger 
more established OSCC and stage IV metastatic disease.  There are several challenges which 
need to be overcome for topical delivery to be successful, most importantly the permeability 
barrier of the oral mucosa (described on page 16).   
 Targeting cancer 
The ability to target drugs directly to tumours would greatly improve chemotherapies enabling 
higher doses to be used and better efficacy and cure rates to be achieved.  Unlike antibiotics 
which act on foreign organisms within the body and target bacterial proteins; cancer treatments 
act on cancerous human cells which are inherently similar to healthy human cells making 
treatment more challenging.  Many chemotherapeutics target highly proliferative cells by 
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preventing cell division or damaging DNA, this however, leads to damage elsewhere in the 
body with healthy rapidly dividing cells. The normal oral mucosa is particularly susceptible to 
such damage, which presents as oral mucositis, due to the high proliferation rate of basal oral 
keratinocytes.  
 Molecular targeted therapy  
There is currently great interest in developing drugs which target specific molecules which are 
found in higher concentrations in cancer cells compared to in healthy cells.  Molecular targets 
such as growth factors, growth factor receptors, signal transduction genes, oncogenes and 
hormones are all being investigated as potential sites for targeting chemotherapy (Hamakawa 
et al., 2008).  Attempts to inhibit cell motility, inhibit tumour angiogenesis and to increase 
apoptosis have also been investigated using molecular targets involved in these processes.  
Targeting epidermal growth factor receptors (EGFRs) to inhibit OSCC proliferation is 
attractive as EGFRs are over expressed in many solid tumours including head and neck 
tumours and this is often an indication of poor prognosis (Nicholson et al., 2001).  EGFRs are 
targeted by tyrosine kinase inhibitors such as Gentifinib which cause cell cycle arrest and thus 
prevent proliferation of malignant cells (Hamakawa et al., 2008). An in vitro study into the 
effect of Cetuximab (Erbitux®) (a monoclonal antibody which acts as an antagonist to the 
EGFR), resulted in reduced cell proliferation, enhanced radio-sensitivity and increased 
apoptosis of OSCC (Huang et al., 1999).  Cetuximab was later shown to improve survival rates 
of patients with stage III/IV recurrent and/or metastatic OSCC in a Phase III clinical trial 
(Vermorken et al., 2007).  Another target is the enzyme cyclooxygenase 2 (COX-2).  Levels of 
COX-2 are increased in several cancers including head and neck relative to healthy 
surrounding tissue (Hamakawa et al., 2008).  Elevated COX-2  levels decrease radio 
sensitivity so it is hoped that by targeting COX-2 the effects of radiation therapy can be 
improved (Hamakawa et al., 2008).   
Research into predictive markers which are able to indicate the effectiveness of a specific 
molecular therapy based on the molecular finger-print of an individual patient‟s disease could 
increase the effectiveness of these therapies in the future.  Predictive markers could also 
prevent treatments being dismissed during development when they may only be effective in a 
subset of OSCC cases.  Molecular targeted therapies and their future use is reviewed in (Lorch 
et al., 2009).  
 Passive targeting 
The next method of tumour targeting described here utilises the unique pathophysiology of 
tumours compared to healthy tissues. Rapidly growing tumours require a good supply of 
nutrients and oxygen which is achieved with extensive angiogenesis in and around the 
tumours.  This disorganised and leaky tumour hypervasculature along with poor lymphatic 
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drainage and an increase in permeability enhancing factors can be exploited to encourage 
passive targeting of macromolecules to tumours; a process known as the enhanced 
permeability and retention (EPR) effect (Maeda et al., 2000).   
First discovered in 1986 (Matsumura and Maeda 1986) the EPR effect passively targets and 
retains macromolecules in all but a few solid tumours.  As the tumour endothelium is poorly 
formed it is no longer a continuous barrier to materials in the blood stream enabling materials 
not usually able to leave the vasculature to pass into the tumour. Macromolecules above 40 
kDa (the renal excretion threshold) accumulate in solid tumours and can be seen at 
concentrations 10-30 times higher in tumours than in systemic blood.  If the macromolecule is 
delivered via the tumour feeding artery this difference in concentration can be up to 2000 times 
(Maeda et al., 2009).  Not only are these macromolecules found at higher concentrations in 
tumours, poor lymphatic drainage means they are also retained within the solid tumour for 
days to weeks (Maeda et al., 2000; Maeda et al., 2009).  
This passive targeting by the EPR effect can be seen in all hypervascular tumours (Maeda et 
al., 2009), and has led to significant interest in the development of macromolecular cancer 
therapies.  Currently, the majority of chemotherapy agents are low molecular weight 
compounds and therefore there is great interest in encapsulating traditional low molecular 
weight drugs into macromolecular carriers including: micelles, liposomes and most recently 
polymersomes (Discher et al., 2007).  The EPR effect is already utilized in imaging of solid 
tumours, for example the accumulation of radioactive gallium (Maeda et al., 2000).   The EPR 
effect also has potential to be exploited in the field of polymer therapeutics which includes 
macromolecular polymer drugs and polymer drug conjugates (Duncan 2003).  The enhanced 
retention of materials by the EPR effect does not necessarily lead to increased uptake of the 
material intracellularly (Wang and Thanou 2010).   
 Gene Therapy  
Gene therapy is the delivery of DNA or RNA into cells to treat diseases which have a genetic 
basis, or to deliver a gene into the body to perform a specific function, for example converting 
pro-drugs into cytotoxic agents within target cells for cancer therapy.  Gene therapy has been 
the subject of much research for many years yet no gene therapy treatments have so far gained 
FDA approval for clinical use (FDA 2009).  One of the biggest challenges associated with 
gene therapy is the efficient and safe delivery of genetic material intracellularly at high enough 
concentrations to exert a therapeutic effect.  In some cases gene therapy must also be targeted 
to specific cells so the effect is only delivered where it is therapeutically required (Harrington 
et al., 2005).  Many of the problems with gene therapy are associated with the use of viral 
vectors to deliver therapeutic genes into cells.  There has therefore been a growth of interest in 
developing non-viral delivery vectors such as liposomes and polymersomes. 
Chapter 1:Introduction 
 
29 
 
There has been a lot of research into gene therapeutics for oral cancer (Xi and Grandis 2003). 
However, despite promising results in vitro and in animals there is still no strong evidence to 
suggest that gene therapy for oral cancer is effective in humans (Shillitoe 2009).  Gene therapy 
for head and neck cancer has been recently reviewed in (Scully and Bagan 2008; Thomas and 
Grandis 2009). 
1.4 Novel delivery vectors 
 Drug Delivery Vectors 
In order for the issues highlighted in the previous section regarding the challenges associated 
with drug delivery to OSCC and other cancers to be overcome there needs to be novel methods 
and techniques to deliver drugs.  One area of research which has been extensively studied is 
that of novel delivery vectors.   
Drug delivery vectors work on the principle that encapsulated drug molecules within a delivery 
device can be protected from damaging biological environments, have improved transport 
characteristics and can provide a method to target drugs to a specific site.  These 
improvements can be achieved without altering the structure or activity of the drug and 
provides an opportunity to design a delivery vector which is able to optimally deliver the drug 
to its site of action and thus improve bioavailability.  Delivery vectors can also be designed to 
give controlled release profiles, improved circulation times and better penetration across the 
epithelium.  Materials such as some peptides and nucleic acids which are highly hydrophilic 
and highly susceptible to enzymatic degradation show limited diffusion across epithelia and 
could benefit greatly from an appropriate delivery carrier (de la Fuente et al., 2008).   
Drug delivery vectors are currently being studied for both local and systemic delivery 
purposes.  For local drug delivery, vectors should be designed to deliver their payload into the 
epithelium, at the site of disease.  For diseases such as OSCC and potentially malignant 
lesions, this means delivery across the permeability barrier and into the basal cells.  For 
systemic drug delivery, delivery vectors have been designed to protect the drug from excretion 
and immune or reticulo-endothelial destruction once in the circulation.  “Stealth” 
nanoparticles, coated in a material not detected by the immune and reticulo-endothelial 
systems are also being developed as a means to increase circulation times.   
Most drug delivery carriers can be categorised as hydrophobic or hydrophilic.  Hydrophobic 
drug carriers have the advantage of exhibiting slow sustained release but can be unstable in 
biological fluids, show poor interaction with biological surfaces and poorly encapsulate 
hydrophilic macromolecules (de la Fuente et al., 2008).  Hydrophilic drug carriers on the 
contrary adhere well to biological surfaces, show a strong affinity to hydrophilic 
macromolecules but have a fast release profile (de la Fuente et al., 2008). Combination 
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therapies such as hydrophilic coatings on hydrophobic nanoparticles have been designed to 
improve transport across mucosal surfaces whilst retaining the slow release profile of 
hydrophobic carriers.  These hydrophilic coatings include materials such as poly(ethylene 
glycol) (PEG) and chitosan.   
 Copying nature: phospholipid membranes 
Many drug delivery vectors which have been studied in recent years, and the delivery vectors 
used in this project, utilise the self-assembling properties of amphiphiles in aqueous solutions.  
Self-assembling amphiphiles, which produce stable and versatile delivery vectors, are based on 
the properties of the plasma membranes of cells.  Phosopholipid cell membranes are comprised 
of many amphiphilic phospholipids containing a hydrophilic (polar) head group and two 
hydrophobic (non-polar) fatty acid chains (Alberts et al., 2002).  Amphiphilic molecules such 
as these self-assemble into vesicular or cellular structures when in aqueous solution to achieve 
the most entropically favourable configuration.   
Lipid bilayer membranes are essential for the cell to maintain well defined, intra- and extra-
cellular environments (Alberts et al., 2002).  This compartmentalisation allows the cell to have 
discrete compartments within the cell for specialised functions.  All organelles within the cell 
are enclosed by membranes, enabling biochemical gradients to exist between parts of the cell 
and allowing distinct biochemical reactions to take place in the right place and at the right time 
within the cell.  The permeability of materials across the cell membrane is determined by 
Fick‟s law of diffusion.  If a material is highly hydrophilic it will not be soluble in the 
hydrophobic membrane and therefore will not diffuse across the membrane, this is the case for 
salts.  If however, a material is partially soluble in the membrane and soluble in water then the 
material is able to passively diffuse across the membrane, this is the case for glucose. If a 
material is highly hydrophobic and not soluble in water then this material will remain trapped 
within the membrane.   Therefore, the transport of materials which are not able to diffuse 
across these membranes is regulated and controlled by transmembrane proteins.  Without this 
segregation the level of complexity within the cell would not be possible on such a small scale.  
 Liposomes 
The first membrane-enclosed structures designed in a laboratory in the 1960s were liposomes 
made from naturally derived phospholipids (Figure 1.5) (Bangham 1961). Bangham used these 
liposomes to look at the effects of various stimuli and substances on cell membranes as well as 
to study membrane permeability.  Liposomes have now been developed for use as drug carriers 
for hydrophobic drugs as well as carriers of DNA for transfection (Lasic and Papahadjopoulos 
1998). Liposomal preparations of anti-cancer therapies are clinically available for a number of 
agents including Daunorubicin and Doxorubicin (Park 2002). Liposomes are used to increase 
the solubility of lipophilic therapeutic agents and show passive targeting to tumours via the 
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EPR effect, described on page 27.  However, there are several limitations with liposomal 
preparations.  Liposomes exhibit low circulation times in the bloodstream due to removal by 
macrophages and the reticulo-endothelial system.  The release profile of materials 
encapsulated into these liposomes is also hard to control; some material leaks out quickly 
while other material is never released (Lasic 1997; Duncan 2003; Discher et al., 2007). 
To increase circulation times, stealth liposomes coated with poly(ethylene glycol) (PEG) to 
reduce detection and removal by the reticulo-endothelial system, have been developed (Lasic 
1994).   
 Polymer amphiphiles 
The difficulties experienced with liposomes led to the generation of drug delivery vectors 
comprised of synthetic, polymer amphiphiles.  The configuration created by the self-assembly 
of polymer amphiphiles depends on the concentration of the molecules and the ratio of 
hydrophobic to hydrophilic portions within an amphiphilic block co-polymer (Discher et al., 
1999; Discher and Eisenberg 2002; Du et al., 2005; Smart et al., 2008).  Configurations 
include spherical micelles, worm-like micelles, lamellar gels and polymersomes (Figure 1.6) 
(Battaglia 2005).   The morphology is dictated by the time-average molecular shape the 
diblock co-polymer has in an aqueous solution.  This could be a cylinder (membrane or 
vesicle), a wedge (worm like micelle) or cone shaped (spherical micelle) (Discher and 
Eisenberg 2002).  This is described by the packing parameter, p.   
p= v/alc   
The packing parameter (p) is defined by the volume of the hydrophobic block (v), the length of 
the hydrophobic block (lc) and the surface area between the two blocks at the interface between 
them (a) (Figure 1.7) (Battaglia 2005). 
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Figure 1.5 Illustration of liposomes and polymersomes and their building blocks.  
Diameters are generally between 50 – 500nm. 
  
Chapter 1:Introduction 
 
33 
 
 
Figure 1.6 Macromolecular structures depend on the packing 
parameter, p. 
Reproduced from (Battaglia 2005) (Smart et al., 2008) 
 
 
1/2 < p ≤ 1 
 
 
 
 
1/3 < p ≤ 1/2 
 
 
 
 
 p ≤ 1/3 
. 
 
 
 
Figure 1.7  Geometric parameters of a block co-polymer amphiphile. 
Reproduced from (Battaglia 2005) 
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Major advances in polymer chemistry, such as reversible addition–fragmentation chain transfer 
(RAFT) and atomic transfer radical polymerisation (ATRP) have opened up limitless 
possibilities for block co-polymer formulations and therefore numerous structures 
(Matyjaszewski and Spanswick 2005).  The versatility of block co-polymers mean structures 
created from them can be designed for a desired application with different stabilities, fluidities 
and dynamic behaviours depending on the molecular weights and chemistries of the blocks 
used (Discher and Eisenberg 2002).   
 Micelles 
Polymeric micelles are self-assembling polymer structures which contain a hydrophobic core 
surrounded by a hydrophilic corona.  Anti-cancer drugs can be chemically conjugated to 
polymers within the micelle or physically trapped within the micelle by taking advantage of 
the hydrophilic effect. For this reason there has been great interest in developing micelles as 
anti-cancer delivery vehicles. There are clinical trials underway including: Phase I trials for 
micelles encapsulating cisplatin (NC-6004) and SN-38 (NK102) and a Phase II trial of the 
paclitaxel-incorporated micelle, NK105, against stomach cancer (Matsumura 2008).  
 Polymersomes 
This project investigates the use of the membrane-enclosed vesicle structures known as 
polymersomes (Figure 1.5).  Polymersomes, also known as polymer vesicles, are created via 
the self-assembly of synthetic amphiphilic block co-polymers (Discher et al., 1999).   
One of the most extensively studied applications for polymersomes is as a delivery vector for 
therapeutic agents.  The membrane-enclosed core is hydrophilic and can encapsulate 
hydrophilic materials in aqueous solution; whereas the core of the membrane, defined by the 
bilayer interdigitation of the co-polymer chains, is hydrophobic.  This means that 
polymersomes can also be used to encapsulate hydrophobic materials such as anti-cancer drugs 
(Battaglia et al., 2007) (Lomas et al., 2007), hydrophilic materials such as nuclei acids (Lomas 
et al., 2007) or can be used to deliver hydrophilic and hydrophobic materials simultaneously 
for synergistic treatment of cancer (Discher and Ahmed 2006).  
Polymer amphiphiles can have higher molecular weight polymer chains compared to 
phospholipids creating highly entangled bilayer membranes with improved stability compared 
to liposome membranes (Battaglia and Ryan 2005). Both liposomal bilayer membranes and 
polymersome membranes have the ability to remodel and heal if damaged due to the 
hydrophobic effect (Aranda-Espinoza et al., 2001).    
The permeability of polymersome membranes can be adjusted using different chemistries.  It is 
possible to make polymersome membranes 10 times less permeable to water than phospholipid 
bilayers (Discher et al., 1999) or more permeable to select materials (Battaglia et al., 2006) 
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depending on the application.  This adjustment of polymersome properties means they can be 
designed to be less leaky and more retentive than liposomes, ideal properties for drug delivery 
vectors. Li et al., have developed polymersomes which are stable for 4 months at 4 °C (Li et 
al., 2007).  Comparing this to liposomal formulations, some of which only have a shelf life of 
1 month, highlights one advantage of polymersomes for clinical applications (Epstein et al., 
2008). 
Many anti-cancer compounds are only effective once delivered inside the cell or the nucleus.  
It is therefore desirable to deliver anti-cancer drugs intracellularly reducing off-target toxicity 
and clearance by the lymphatic system.  Duncan et al., have shown that the safe dosing of 
Doxorubicin (DOX) can be four or five times higher when it is conjugated to the co-polymer 
N-(2-hydroxypropyl) methacrylamide and delivered intracellularly, suggesting toxicity is due 
to extracellular DOX (Duncan 2003).  The versatility of polymersomes allows them to be 
designed to be internalised by cells (Discher and Eisenberg 2002; Ahmed et al., 2006). The 
degradation and subsequent release of cargo from polymersomes can also be adjusted. pH 
sensitive polymersomes (Du et al., 2005), oxidative species (Cerritelli et al., 2007) and 
biodegradable polymers all degrade within the body in response to different stimuli (Meng et 
al., 2005; Ben-Haim et al., 2008; Rameez et al., 2008) allowing them to be tailored to the 
specific application and drug/destination of interest.  For example, the pH sensitive 
polymersomes studied in our laboratory release their cargo into the cytosol when the 
polymersomes experience a drop in pH in the cell‟s endosomal compartments (Lomas et al., 
2008; Massignani et al., 2010).  These polymersomes are able to deliver encapsulated material 
into the cytosol of cells when internalised via endocytosis (Massignani et al., 2008).   
Materials thus far encapsulated into polymersomes include DNA for transfection (Lomas et 
al., 2007; Lomas et al., 2008), anti-cancer drugs for intercellular delivery (Discher et al., 2007) 
and contrast agents for in vivo imaging (Ghoroghchian et al., 2005).  The chemotherapeutic 
agents which have been successfully encapsulated include Doxorubicin (Choucair et al., 2005; 
Upadhyay et al., 2009), Paclitaxel (Li et al., 2007), Docetaxel (Upadhyay et al., 2010) and a 
combination therapy of Paclitaxel and Doxorubicin (Ahmed et al., 2006).  Other groups have 
developed polymersomes which can act as haemoglobin substitutes (Arifin and Palmer 2005; 
Rameez et al., 2008).  
Ahmed et al. have shown that using polymersomes affects not only the distribution of the 
chemotherapeutic agent but also the efficacy of the cancer therapy (Ahmed et al., 2006).  In an 
in vivo murine breast carcinoma xenograph model they showed increased tumour shrinkage 
with systemically delivered doxorubicin and paclitaxel encapsulated in PEG-PLA 
(poly(ethylene glycol) poly(lactic acid)) polymersomes compared to free drug administration  
(Figure 1.8) (Discher and Ahmed 2006). Saline and empty polymersome controls showed no 
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effect on the rapidly growing tumours whereas the free drugs slowed the growth but did not 
reduce the size of the tumour compared to the size at the time of treatment.  Further analysis 
showed the level of apoptosis (programmed cell death) was twice as high with the 
encapsulated drug when compared to free drugs alone (Discher et al., 2007).  This has yet to 
be shown for oral cancer or for topical delivery.  Polymersome delivery into a xenograft 
murine model of oral carcinoma has been investigated in (Murdoch et al., 2010). 
 
 
Figure 1.8  Polymersomes loaded with anti-cancer drugs shrank tumours compared to free 
drug and polymer alone in this in vivo study (Discher et al., 2007).  
 
 Targeting nanoparticles 
There are different ways to target drugs to cancer cells and thus reduce side effects.  These 
include the molecularly targeted therapies described previously on page 27.  Targeting via 
cancer specific biomarkers is growing in popularity.  These biomarkers which include: mutant 
genes, RNAs, proteins, lipids, carbohydrates and small metabolite markers are specific to the 
cancerous tissue and can provide a specific target for drug delivery systems (Wang and 
Thanou 2010).  Combining knowledge of biomarkers and development of nanoparticle 
delivery systems has made attaching ligands or bio-recognition molecules onto the surface of a 
drug delivery system possible.  This enables targeting of the delivery system to sites of disease 
and means the drug can be favourably delivered there, reducing side effects.  Many biomarkers 
investigated are cell membrane receptors, as ligands to these can not only target the delivery 
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systems but also promote receptor mediated endocytosis, delivering the drug intracellularly, 
where the drug will be active (Wang and Thanou 2010).    
Important considerations when functionalising a nanocarrier with bioactive molecules include: 
(i) the stability and half-life of the targeting moiety (e.g. peptides are quickly degraded in the 
circulation), (ii) the orientation/accessibility of the target when assembled with the nanocarrier, 
(iii) the affect attaching a targeting moiety will have on the hydrophilic:hydrophobic ratio of 
the nanocarrier and the affect this may have on the configuration (e.g. micelle or 
polymersome) and (iv) if the ligand is also expressed by healthy cells (potential side effects).   
Hammer et al., have engineered polymersomes which model the binding of leukocytes to a 
surface which is coated with the inflammatory adhesion molecules (P-selectin and ICAM-1) to 
mimic the endothelium (Hammer et al., 2008; Robbins et al., 2010).  Their leuko-
polymersomes are functionalised on the outer surface with biotin and utilise the avidin-binding 
mechanism to attach a biotin conjugated antibody against ICAM-1 and a biotinylated selectin 
ligand sialyl-Lewis
x
 to the corona of the polymersomes.  Hammer et al., demonstrated these 
leuko-polymersomes were capable of specific adhesion to inflammation adhesion molecules at 
physiological flow rates usually experienced by leukocytes (Hammer et al., 2008).  It is 
possible these leuko-polymersomes, if combined with therapy or an imaging modality, could 
be useful in the diagnosis and/or treatment of inflammatory diseases and cancer. 
 Nanoparticles for imaging 
Nanoparticles also have the ability to help in imaging cancer and diagnosing tumours. 
Ferumoxtran-10® is used as a contrast agent for the magnetic resonance imaging (MRI) of 
lymph nodes (Wang and Thanou 2010).   Iron oxide particles covered in dextran are taken up 
by macrophages which populate healthy lymph nodes (as well as liver and spleen).  In patients 
with malignant cancers the lymph nodes get colonised by malignant cells reducing the number 
of macrophages, and therefore changing the appearance of the lymph nodes when examined 
using MRI (Leung 2004).  Zhou et al., also produced polymersomes capable of enhancing 
ultrasound imaging by developing air-encapsulated biodegradable polymersomes which were 
acoustically active (Zhou et al., 2006).  Ghoroghchian et al., made polymersomes which could 
be imaged through 1cm of solid tumour tissue in an animal model (Ghoroghchian et al., 2005).  
Their polymersomes encapsulated multi(porphyrin), near infra-red (IR) fluorophores, into the 
hydrophobic membrane of the polymersomes with controlled inter-spatial separation of the 
fluorophores (Ghoroghchian et al., 2005).   The ability to image polymersomes in vivo not 
only has applications for cancer imaging and diagnosis but also for studying the bio-
distribution of polymersomes without needing to sacrifice the animal in in vivo experiments 
(Levine et al., 2008).   
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 Degradation and clearance of polymersomes 
The degradation and safe clearance of nanoparticle delivery vectors such as polymersomes is 
as important as the initial delivery.  In order for nanoparticles to be well tolerated by the body 
they must either degrade into non-toxic by products, which can be easily excreted (as is the 
case with PEO-b-PCL poly (ethylene oxide)-(poly(caprolactone) polymersomes) or the 
delivery vector itself must be able to be excreted (Levine et al., 2008).    Toxicity from bioinert 
polymers or by-products which cannot be excreted will hinder the usefulness clinically of 
nanoparticles.  
 Commercially available nanoparticle drug delivery 
systems 
There are two nanoparticle delivery systems which are currently FDA approved and 
commercially available (Wang and Thanou 2010).  The first of these is Doxil®, a liposome 
formulation designed to improve the delivery of doxorubicin for recurrent ovarian carcinoma 
and AIDS-related Kaposi‟s sarcoma (Gabizon et al., 2003).  This PEGylated liposome 
formulation shows good circulation times and reduced cardio-toxicity, an adverse effect which 
often limited the maximum dosage of free doxorubicin that could be delivered (Gabizon et al., 
2003).   The circulation times and bioavailability of doxorubicin were improved with Doxil® 
compared to free drug (Safra et al., 2001; Gabizon et al., 2003).  Abraxane®, the second FDA 
approved nanomedicine, is an albumin taxol conjugate approved for the treatment of metastatic 
breast cancer (Wang and Thanou 2010).  Abraxane® provides a safer and more efficient 
method of delivering Paclitaxel compared to the previous delivery carrier Chremophor EL 
(which is used to increase solubility of hydrophobic drugs) (Harries et al., 2005).  Albumin is a 
natural carrier of endogenous hydrophobic materials in the circulation.  It aids endothelial 
transcytosis, encourages caveolae formation and binds to osteonectin, found in breast, lung and 
prostate cancers.  Albumin therefore provides a safe material for the delivery of hydrophobic 
agentss and has a natural capacity to target and bind to some cancers making it a popular 
choice in the field of nanomedicine research (Wang and Thanou 2010).   
 The future of nano drug delivery vectors 
Personalised therapies are now looking possible as more biomarkers are discovered and 
methods to characterise the biomarker profile of a particular patient‟s cancer can be achieved.  
In the future this could lead to delivery vectors being designed with targeting moieties attached 
that are designed for individual‟s biomarker profile, enabling the delivery of higher doses of 
drug to the target area.   
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1.5 Tissue engineering: Progress and 
Limitations 
 Tissue Engineering  
Tissue engineering is a multidisciplinary field which incorporates materials scientists, cell 
biologists, and clinicians with the aim of producing organotypic tissues for use in tissue repair, 
replacement and research.   Tissue engineered replacements for skin (Chakrabarty et al., 1999), 
bladder (Atala et al., 2006) and urethra (Bhargava et al., 2004; Bhargava et al., 2008) have all 
been successfully used in patients.   Some tissue engineered products are available 
commercially including Carcitel®, autologous cultured chondrocytes for repair of focal 
articular cartilage defects and Infuse®, a device designed to release bone morphogenic protein 
2 (BMP-2) for spinal fusion.  Other engineered tissues including cornea (Deshpande et al., 
2009), nerve (Madigan et al., 2009), and blood vessels are all showing promise in in vitro 
experiments (Hunziker et al., 2006). 
Historically, most in vitro biological research has relied on two dimensional monolayer cell 
culture studies.  Whilst these can provide valuable information regarding cell behaviour and 
responses, they are poor at replicating the three dimensional (3D) behaviour of tissues and are 
not always clinically relevant or representative of the in vivo situation.  Furthermore, because 
of differences in the cell microenvironment, cells grown in three dimensions behave differently 
than those cultured as monolayers (reviewed in (MacNeil 2007), (Gottfried et al., 2006; 
Moharamzadeh et al., 2007)).   
Tissue engineering allows scientists to study tissues in a more physiologically relevant way 
compared to traditional two dimensional cell cultures and reduces the need for animal studies.   
 Tissue engineered oral mucosa 
There are several tissue engineered oral mucosa models being developed for in vitro and 
clinical applications, reviewed extensively in (Moharamzadeh et al., 2007).  Uses of tissue 
engineered oral mucosa include (i) the replacement of tissues damaged or removed as a result 
of disease or surgery (Lauer and Schimming 2001; Bhargava et al., 2004; Ohki et al., 2006; 
Rameez et al., 2008) (ii) a model to study biological and pathological aspects of oral 
epithelium (Costea et al., 2003; Duong et al., 2005) and (iii) as a substitute for animals when 
testing the safety and efficacy of pharmaceuticals and other consumer products (Schmalz 
2002; Schmalz et al., 2002; Klausner et al., 2007).  Tissue engineered oral mucosa and oral 
epithelial sheets have not only been developed for the replacement of oral tissue (Lauer and 
Schimming 2001; Rameez et al., 2008), but for other tissues including urethral (Bhargava et 
al., 2004; Bhargava et al., 2008; Selim et al., 2010), oesophageal (Ohki et al., 2006) and ocular 
(Inatomi et al., 2008) epithelium replacement.  This is partly due to the ease with which oral 
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mucosal tissue can be harvested for tissue engineering but also because of the excellent healing 
properties and lack of scarring associated with oral mucosa wound healing. 
 Epithelial models 
Keratinocytes cultured according to the method described by Rheinwald and Green 
(Rheinwald and Green 1975) to form confluent sheets of epithelial cells are the simplest form 
of epithelial substitute. Cultured epithelial cell sheets have been used to repair oesophageal 
mucosa post surgery (Ohki et al., 2006).  After submucosal dissection of oesophageal 
carcinomas severe inflammation, scarring and stenosis can occur.  Ohki et al., used autologous 
epithelial sheets attached to a polyvinylidene difluoride support membrane to repair damaged 
oesophageal tissues in patients. Complete wound healing could be seen 4 weeks after 
transplantation with no sign of stenosis.  Cultured oral epithelial sheets were able to reduce the 
amount of contraction and promote wound healing through the release of various growth 
factors and cytokines in the oesophagus (Ohki et al., 2006).  
Lauer et al., used large (75cm
2
) epithelial sheets cultured from autologous biopsies to repair 
intraoral defects resulting from the removal of squamous cell carcinomas (Lauer and 
Schimming 2001). These large grafts provided a good epithelial covering with normal patterns 
of differentiation in 5 out of 6 patients. Although all grafts contracted post application, speech 
and tongue mobility was improved in all patients (Lauer and Schimming 2001).     
Oral epithelial sheets proved effective in the above examples however, in other applications 
the simplicity of the epithelial sheet, difficulty in handling and potential for blistering post 
grafting made them unsuitable (Cooper et al., 1993; Feinberg et al., 2005).  Epidermal sheets 
were tested for use as skin grafts in athymic mice but they did not form a good attachment with 
the dermal component.  They lacked basement membrane proteins collagen IV and laminin, 
did not result in a mature epithelium after 42 days and did not show features such as rete ridges 
(Cooper et al., 1993).   
 Commercially available multi-layer epithelium 
models 
Cells behave differently in three dimensions and cells grown in 3D better model the conditions 
seen in vivo.  Multilayer epithelial only models have been developed commercially for use in 
in vitro testing. These models provide researchers with a, quick and reproducible alternative to 
animal testing (Corporation 2008; SkinEthic 2008), but they are extremely expensive and are 
not commonly used in research laboratories. Since March 2009 there has been a ban by the 
European Commission on testing any cosmetic products, ingredients or combination of 
ingredients in animals (EuropeanCommission 2010) creating a need to develop alternative 
testing methods.   One multilayer epithelium only model is the commercially available 
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SkinEthic (Nice, France) buccal mucosa model.  The SkinEthic model is cultured from the cell 
line TR146, a cell line derived from OSCC (SkinEthic 2008).  The model is not keratinised 
and the cell behaviour is different to that of a healthy oral epithelium because of the 
immortalised nature of the cell line used (Moharamzadeh et al., 2007).  Multilayer models 
such as EpiOral
TM
 and EpiGingival
TM
 developed by MatTek Corporation (Ashland, MA, USA) 
differ from the SkinEthic models in utilising normal epithelial cells derived from humans 
grown on a collagen gel matrix compared to the polycarbonate membrane of the SkinEthic 
model (Klausner et al., 2007; Moharamzadeh et al., 2007; Corporation 2008). Klausner et al. 
have evaluated the effect of various mouthwashes and toothpastes on cell viability in the 
EpiOral
TM
 and EpiGingival
TM 
models (MatTek, USA) (Klausner et al., 2007; Corporation 
2008).  These models were highly reproducible within and between different batches.  
However, no comparison was made with results from currently accepted established toxicity 
test methods such as animal models (Klausner et al., 2007). It is likely these types of models 
will be very important for high throughput experiments to test the effects of substances on oral 
epithelia during product development.   
 Full thickness tissue engineered oral mucosa 
The above mentioned models only contain epithelial components however, MacKenzie et al. 
and many others have demonstrated that fibroblasts and subepithelial connective tissue 
influence the formation of epithelia (Mackenzie and Fusenig 1983).  Factors released by 
fibroblasts in the connective tissue affect keratinocyte differentiation and proliferation 
(Mackenzie and Fusenig 1983; Costea et al., 2003; MacNeil 2007). Culturing the model at an 
air-liquid interface (ALI) increases expression of differentiation markers and encourages the 
epithelial cells to stratify and organise themselves to imitate natural oral mucosa (Bhargava et 
al., 2004; Feinberg et al., 2005).  Therefore models comprised of keratinocytes, fibroblasts and 
connective tissue grown in three dimensions at ALI are the most clinically relevant when 
looking at the response of tissue to substances and stimuli. 
Alaminos et al., used a tissue engineered oral mucosa to study the gene expression over time in 
the maturation of the epithelium (Alaminos et al., 2007).  Their model comprised of oral 
keratinocytes and fibroblasts grown on a fibrin-agarose scaffold.  This model formed a mature 
epithelium with intracellular junctions and a basement membrane.  Looking at gene expression 
alongside morphological analysis enabled them to understand more regarding the genes 
involved in epithelial differentiation and maturation (Alaminos et al., 2007).  Other 
applications include the work of Chai et al., which used a tissue engineered model of oral 
mucosa to test the interaction between dental implants and soft tissue (Chai et al., 2010) and 
Moharamzadeh et al., who used 3D tissue engineered oral mucosa to assess the safety of 
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antiseptic mouthwashes (Moharamzadeh et al., 2009) and dental composite resins 
(Moharamzadeh et al., 2008).  
 Scaffolds 
Several materials are being developed for connective tissue substitutes to mimic as closely as 
possible naturally occurring oral mucosa when cells are grown on them.  Scaffold materials 
include natural substances such as acellular skin (Bhargava et al., 2004) and amniotic 
membranes as well as synthetic polymer scaffolds (Moharamzadeh et al., 2007; Blackwood et 
al., 2008; Selim et al., 2010).  Some models include gels into which fibroblasts are seeded to 
form a substitute connective tissue component (Duong et al., 2005; Klausner et al., 2007).  
Materials used for these gels include collagen (Klausner et al., 2007), gelatine and fibrin 
(Hsieh et al., 2010), reviewed extensively in (Moharamzadeh et al., 2007).  
Klausener et al. describe a full thickness oral mucosa model in which keratinocytes were 
cultured on top of a collagen matrix mixed with gingival fibroblasts (Klausner et al., 2007).  
The histology showed detachment between the epithelial and connective tissue components 
with limited fibroblasts in the collagen gel (Klausner et al., 2007).   
Kinikoglu et al., have developed a model of oral mucosa which is para-keratinised and 
resembles human native tissue histologically (Kinikoglu et al., 2009).  The connective tissue 
component of their models used a porous cavity collagen glycosaminoglycan-chitosan scaffold 
into which fibroblasts could be seeded.  Transmission electron microscopy analysis of the 
model demonstrated there was a continuous, well-organised basement membrane onto which 
the epithelium was strongly attached and the presence of desmosomes (Kinikoglu et al., 2009).  
The immunohistochemistry profile, of this tissue engineered non-keratinised oral mucosa, 
closely matches that of naturally occurring para-keratinised oral mucosa. There was strong 
expression of keratin 3 and 13, with no expression of keratin 10.  Laminin V could be seen 
continuously along the basement membrane of the tissue engineered oral mucosa model 
demonstrating that the cells in the model were capable of producing basement membrane 
proteins in a well organised manner which resembled naturally occurring oral mucosa 
(Kinikoglu et al., 2009).    
Acellular skin can be processed in a way that retains the naturally occurring basement 
membrane proteins aiding cell attachment in the model (Chakrabarty et al., 1999).  Acellular 
skin is durable with good structural properties and shows reduced antigenic reactions 
compared to other materials when implanted (Moharamzadeh et al., 2007). Histologically, 
models grown on acellular skin closely resemble natural oral mucosa.  Immunohistochemical 
analysis showed similar cytokeratin 16 profiles in the cultured models and the natural oral 
mucosa, while maintaining differences such as a lack of cytokeratin 10 expression (Ophof et 
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al., 2002).  Heparin sulphate was present in the basement membrane of normal oral mucosa 
and in the models after 14 days culture (Ophof et al., 2002).  
 Tissue Engineered Models of Oral Squamous Cell 
Carcinoma 
Monolayer cell culture studies are often the primary tool used for the evaluation of cancer 
therapies before their investigation in animal models.  Although simple, well established and 
versatile the 2D monolayer method has several limitations.  In order for a cancer treatment to 
be effective the bio-distribution within a tumour as well as its action on different stages of 
cancer progression and in different microenvironments within solid tumours are all important 
considerations.  These factors cannot be tested in monolayer studies, therefore 3D models, 
which model stages of cancer progression and which posses a genetic expression profile which 
is similar to naturally occurring tumours, are an important tool (Hirschhaeuser et al., 2010).  
Often drugs tested in 2D and 3D produce different results (Knuchel et al., 1989) possibly 
explaining why many compounds which appear promising in 2D fail to show the same results 
in animal studies.  Testing more novel drug compounds in 3D models could increase our 
ability to predict a drug‟s efficacy in in vivo studies, reducing the number of failed animal 
studies and preventing potentially useful drugs being eliminated at the in vitro testing stage. 
OSCCs are epithelial in origin, progressing from a dysplastic, disordered epithelium to a 
carcinoma in situ where the whole epithelium is abnormal and displays the properties 
described previously (page 22).  The next stage of disease progression is invasive OSCC, 
where cancer cells invade into the connective tissue underlying the oral epithelium.  Once 
these cells have invaded they form tumour islands, solid expanding masses of cancer cells.    
Here we describe two types of OSCC models: (i) a 3D model of epithelial OSCC comprised of 
cancer cell lines and a connective tissue component and (ii) a 3D model of a solid expanding 
OSCC tumour. 
 3D epithelial models of OSCC 
Being able to model the different degrees of OSCC progression from dysplasia to carcinoma in 
situ would provide a useful tool for in vitro studies investigating the mechanisms of lesion 
progression and OSCC invasion as well as being a tool for testing treatment and diagnostic 
technologies for pre-cancerous and cancerous lesions.   The stromal portion underlying the oral 
epithelium is known to play an important role in cancer progression (Mueller and Fusenig 
2004; Gaballah et al., 2008) and invasion (Figure 1.9) (Costea et al., 2006). Therefore a model 
which incorporates epithelial and connective tissue portions is important in order to study 
tumour progression and potential treatments.  
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Figure 1.9  Effect of human fibroblasts on invasion of dysplastic oral keratinocytes (DOK) 
cells.  A = DOK cells grown on collagen matrix, B = DOK cells grown on collagen matrix with 
human fibroblasts incorporated.  (Costea et al., 2006) 
 
 
Currently just a few models of this type have been developed for oral cancer.  Gaballah et al., 
have developed models of mild, moderate and severe dysplasia using keratinocytes and 
fibroblasts isolated from clinical lesions on collagen scaffolds (Gaballah et al., 2008).  Using 
various different strains of keratinocytes and fibroblasts derived from different lesions with 
different characteristics they used a scoring system, which included changes in stratification, 
polarity, intraepithelial keratinisation, nuclear size, nuclear pleomorphism and proliferation 
index (measured by Ki67) to determine the severity of dysplasia resulting from different 
culture conditions and different cell types. 
As well as cancer progression these organotypic models can be used to study the mechanisms 
of invasion, determine the invasiveness of certain cells and to assess the effect of different 
conditions on the invasiveness of OSCC in vitro.  For example, the model created by Duong et 
al. used OSCC cell lines cultured on a collagen gel with fibroblasts incorporated into it to 
model cancer cell invasion into the connective tissue (Duong et al., 2005).  A gel containing 
basement membrane proteins including laminin and collagen IV was added to the top of the 
collagen gel prior to seeding the squamous cell carcinoma cell lines onto the top of this.  The 
effects of hypoxia and cell migration factors on the invasion of the cancer cells were able to be 
imaged over time using an Opticell™ chamber (Duong et al., 2005).   Nyström et al., devised a 
method to quantify the invasion of cancer cell lines into a collagen gel embedded with 
fibroblasts using a computer-assisted digital analysis system (Nyström et al., 2005).   
 Fibroblasts and stromal component 
The relationship between the stromal compartment, including fibroblasts, and their effect on 
carcinomas has long been investigated in animal models.  Reviewed in (Elenbaas and 
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Weinberg 2001) it is clear that elements within the stroma of tumours are important in 
tumourigenesis. However, this relationship is complicated and is most likely a combination of 
effects from fibroblasts, immune cells and endothelial cells involving growth factors, 
extracellular matrix proteins, proteases and protease inhibitors (Elenbaas and Weinberg 2001).   
The effect of fibroblasts on the invasiveness of DOK cells, a dysplastic non-tumourigenic cell 
line, was determined in (Costea et al., 2006).  DOK cells were cultured on collagen gels 
containing no cells, human fibroblasts or mouse fibroblasts (Costea et al., 2006).  Local 
invasion of DOK cells into the connective tissue was seen with the presence of human 
fibroblasts but little or no invasion was seen in models cultured without fibroblasts or with 
fibroblasts from mice.  Local invasion was also seen when the models were cultured in the 
presence of conditioned medium from a DOK and human fibroblast model, but not with the 
conditioned medium from human fibroblast monolayer culture (Costea et al., 2006).  This 
result suggests that for fibroblasts to initiate invasion they require co-culture with the epithelial 
cell type, and the co-culture encourages different factors to be released compared to 
monoculture.  Collagen IV production was seen in those models which invaded but was not 
seen in the models which were non- invasive (or minimally invasive) suggesting fibroblast and 
keratinocyte co-culture encourages collagen IV production.  
Fibroblasts found in the stroma of carcinomas are sometimes called myofibroblasts.  These 
cells are similar to the fibroblasts found in wound healing and behave differently to fibroblasts 
found in healthy tissues.  Myofibroblasts are more proliferative, express different extra-cellular 
matrix proteins and produce more growth factors compared to normal fibroblasts.   
Culturing normal keratinocytes with fibroblasts extracted from dysplastic clinical lesions, 
resulted in dysplastic epithelium, demonstrating the effect fibroblasts can have in the 
development of dysplastic epithelia (Gaballah et al., 2008). In xenograph models of 
carcinomas the addition of myofibroblasts, as opposed to normal fibroblasts, enhanced the 
tumour promoting activity (Elenbaas and Weinberg 2001).  It is thought that by returning the 
stroma and its constituents to a normal state, tumour progression could be slowed or even 
reversed (Mueller and Fusenig 2004), a theory which could be tested simply in tissue 
engineered models that incorporate dysplasia associated  myofibroblasts.   
 Growth factors 
Gaballah et al., tested the effect of culturing models with media supplemented with 
keratinocyte growth factor (KGF) or epidermal growth factor (EGF) and found KGF 
encouraged polarisation of the epithelium, reduced the thickness of the epithelium and 
increased the Ki67 score (Ki67 is an immunohistochemistry stain which detects proliferating 
cells) in basal cells.  In contrast EGF, a growth factor important in wound healing, increased 
the Ki67 score of suprabasal cells (a characteristic of dysplasia) and increased the architectural 
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and cytological changes in the resulting epithelia, leading to higher dysplasia scores compared 
to models cultured with KGF (Gaballah et al., 2008).     
 Model of solid expanding cancer: Multi-Cellular 
Tumour Spheroids 
In the 1970s, Sutherland et al., developed a method to study cancer cell lines in a way which 
more accurately models the in vivo tumour microenvironment (Sutherland et al., 1971). These 
multi-cellular tumour spheroids (MCTS) are solid cell aggregates comprised of cancer cell 
lines which behave in a way that mimic avascular areas of solid tumours.    
The tumour islands modelled by the MCTS model are those which have grown to a size where 
cells at the centre of the tumour are sufficiently distant from nutrient blood vessels to be at the 
limits of nutrient, oxygen and waste product diffusion. These tumour islands have central areas 
of necrosis and hypoxia further away from the blood supply and are often resistant to anti-
cancer treatments. MCTS models are able to expand beyond the natural diffusion range for 
nutrients, oxygen and waste products and this leads to pathophysiological diffusion gradients 
being established that replicate many of the classical features seen within tumours in vivo.  
There are many different versions of the MCTS model which have been employed for a variety 
of different applications, some of which are reviewed here along with a rationale for the 
development of these models.   
 Properties of MCTS 
Multi-cellular tumour spheroids closely resemble tumour nodules, tumour islands and 
avascular areas of solid tumours.  The extent of these characteristics depends on the size of the 
MCTS, the cell line used to culture them and the speed at which they form and grow.  Figure 
1.10 shows the characteristics typically seen in MCTS including nutrient distribution and 
apoptosis.   
The outermost cells behave in a similar way to those cells seen near the vascular supply in 
vivo, receiving plenty of nutrients and discarding waste products into the cell culture medium.  
These cells, seen in all MCTS, are highly proliferative and have high metabolic activity.  The 
oxygen, nutrient and catabolite gradients only become apparent in MCTS larger than 150µm, 
while the necrotic and apoptotic core only become apparent in MCTS above 500µm in 
diameter (Hirschhaeuser et al., 2010).  The necrosis in the core of MCTS is caused by several 
factors including accumulation of waste products, low pH, deficiency of nutrients and 
deficiency of oxygen, a phenomenon also seen in tumour cells in vivo over 100µm away from 
a blood supply (Kunz-Schughart and Knuechel 1998; Cottin et al., 2010).   
Poor oxygen perfusion into the central region of the MCTS causes the core to become hypoxic, 
similar to the hypoxia found in naturally occurring tumours.  This is of particular interest as 
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intra-tumoural hypoxic regions are often resistant to anti-cancer treatments and are an indicator 
of poor patient prognosis (Subarsky and Hill 2003; Duong et al., 2005).  Prolonged hypoxia 
can lead to genomic instability and this may contribute to the progression of metastases 
(Subarsky and Hill 2003).   Hypoxic tissues in vivo are known to release pro-angiogenic 
factors which enable the tumour to continue its growth as new blood vessels grow and supply 
the tissue with nutrients needed for proliferation and tumour growth (Timmins et al., 2004). 
The cells which surround the necrotic and hypoxic core adapt their behaviour to maintain 
homeostasis despite changes in the microenvironment.  These cells alter their proliferative 
behaviour, protein expression and react in different ways to drugs and drug candidates.  
Penetration barriers, cell-cell and cell-matrix interactions, signalling pathways, cellular targets 
and changes in the cell cycle distribution all contribute to the altered response of these cells to 
drugs and therapeutic compounds (Hirschhaeuser et al., 2010).  These changes, as well as 
changes to metabolic activity, collagen production and genetic expression are accounted for in 
this 3D model demonstrating a clear advantage of the MCTS model over monolayer studies 
(Horning et al., 2008).  
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Figure 1.10 Characteristics of spheroids determined by autoradiography, TUNEL assay, 
bioluminescence imaging, probing with oxygen microelectrodes and 
immunohistochemistry. 
Image from (Hirschhaeuser et al., 2010) 
 
 
 Methods to produce MCTS 
There are several ways to culture MCTS including the liquid overlay method developed by 
Carlsson and Yuhas (Carlsson and Yuhas 1984), hanging drop method (Kelm et al., 2003), 
spinner flasks, roller tubes and gyratory flasks (Figure 1.11) (Friedrich et al., 2007).  All these 
methods work by inhibiting cell attachment and therefore encouraging the cells to adhere to 
one another.   
For the liquid overlay method (Carlsson and Yuhas 1984) cancer cell lines are cultured in 96 
well plates coated with agarose or agar or in non-adherent round bottomed plates, all of which 
encourage cells to collect in the centre of the well and inhibit attachment to the plate 
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encouraging cells to adhere to one another. This method enables reproducible MCTS to be 
produced (dependant on the cell line), relatively simply, in large numbers and enables single 
MCTS monitoring over time.  For drug candidate testing this method does not require large 
quantities of drugs to be used, a benefit in commercial applications.  A robust method for the 
production of MCTS for high-throughput drug screening applications utilising the liquid 
overlay method has been developed by Friedrich et al., (Friedrich et al., 2009).  The main 
problem with stationary culture methods, such as the liquid overlay method, is the nutrient 
gradients experienced in the cell culture medium within the 96 well plates. This method can 
also produce irregular shaped, fragile MCTS (Kelm et al., 2003) therefore selection of 
appropriate cell lines in important. 
More recently the hanging drop technique, commonly used for culturing embryoid bodies, has 
been employed to produce MCTS (Friedrich et al., 2007) and has proved useful for MCTS 
initiation in cell lines that fail to form MCTS by the more conventional methods  (Kelm et al., 
2003). However, producing MCTS using this technique is technically harder and changing the 
medium is difficult.  Despite these challenges it is possible to produce reproducible spheroids 
using the hanging drop method and its use has been demonstrated for the screening of 
numerous chemotherapeutic compounds (Herrmann et al., 2008).  
Spinner flasks, roller tubes and gyratory flasks all work by inhibiting cell attachment to the 
culture flask; in this case through continuous movement.  The spinner flask method produces 
large numbers of MCTS with reproducible size up to 1-2mm in diameter (Kunz-Schughart and 
Knuechel 1998). The disadvantages of these rotating cultures include the effects caused by the 
sheer stress seen in the culture flask and the large volumes of cell culture medium required.  
The NASA bioreactor overcomes the problem of sheer stress as the wall rotates while the 
MCTS are in suspension in cell culture medium.  The bioreactor incorporates continuous 
media and oxygen perfusion and waste removal.  This system however, is very expensive, uses 
large volumes of cell culture medium and is cumbersome limiting its use.    
When choosing a method for MCTS production reproducibility in size and volume of MCTS, 
the numbers of MCTS required, volume of culture medium (and therefore test drug) needed 
and ease of production must all be considered. 
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Figure 1.11 Methods of producing MCTS in vitro 
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 Promoting MCTS formation 
The tumour models described above all rely on the inherent ability of cancer cells to adhere to 
one another and create MCTS.  Ivascu et al., tested the addition of reconstituted basement 
membrane (rBM), collagen type I and IV, fibronectin, laminin, heparin sulphate proteoglycane 
and chondronitin on a breast cancer cell line to initiate MCTS formation (Ivascu and Kubbies 
2006). Only rBM (a mixture of laminin, collagen type IV and entactin) was able to 
successfully induce MCTS formation. 
Other groups have used scaffolds into and onto which cancer cells can grow; enabling the 
formation of solid tumour models from cell lines which are usually unable to form MCTS.  
Horning et al., used poly(lactic acid) (PLA) microparticles (diameter 160-180µm diameter) 
with internal interconnecting pores to culture a 3D model of breast cancer using the cell line 
MCF-7 (Horning et al., 2008).   
Fragment spheroids (also called F-spheroids) are in vitro models in which a piece of excised 
cancerous tissue is cultured for diagnostic and research purposes.  This method requires tissue 
from patients to be donated and is less reproducible, or amenable to large scale testing 
compared to the models described previously.  However, F-spheroids do have the advantage 
that they include a mixed population of cells which is comparable to naturally occurring 
tumours.  The cell population includes fibroblasts, macrophages, endothelial cells and 
epithelial cells which are in both differentiated and progenitor forms (Hirschhaeuser et al., 
2010).   
 Applications of MCTS 
MCTS can be used to study (i) responses to drugs and cancer treatments such as radiotherapy, 
(ii) basic cell biology in tumours e.g. angiogenesis and cell invasion and (iii) epigenetic 
mechanisms involved in regulation of differentiation, proliferation and cell death (Kunz-
Schughart and Knuechel 1998).  
One of the most studied applications for MCTS is drug screening.  Many in the field hope 
screening in 3D models such as these will be commonplace in the future to improve drug 
candidate screening before testing in vivo.  Herrmann et al., screened a number of different 
drugs in MCTS produced from different cell lines using the hanging drop method (Herrmann 
et al., 2008).  The level of apoptosis induced by the drugs and cell viability was measured in 
MCTS and compared to cells grown as monolayers.  The viability and apoptosis levels 
between the two was markedly different for almost all drugs tested highlighting the value of 
this technique for the screening of large numbers of drugs in a more physiologically relevant 
way compared to monolayers (Herrmann et al., 2008).   
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The penetration of chemotherapeutics into avascular regions of tumours dictates the efficiency 
of the drug and its ability to treat solid tumours effectively.  Cottin et al., used MCTS models 
of glioblastoma and osteocarcinoma to test the hypothesis that gemcitabine, a 
chemotherapeutic drug commonly used in the treatment of pancreatic, ovarian and lung 
cancers, exerts its anti-cancer effects via a gap junction mediated “by-stander” effect (Cottin et 
al., 2010).  They found gemcitabine was able to inhibit growth and reduce the viability of cells 
within MCTS models within 2 hours of treatment.  This effect was not seen when a gap 
junction inhibitor was added, implying the anti-cancer effects of gemcitabine are achieved via 
the diffusion of gemcitabine and its metabolites via gap junctions into the central region of the 
MCTS.  This highlights the potential of gemcitabine for the treatment of solid tumours with 
regions of poor vasculature in vivo (Cottin et al., 2010).  
Other groups have also utilised MCTS models to evaluate the penetration and delivery of 
nanoparticle drug delivery systems.  For example, Waite et al., demonstrated the delivery of 
active siRNA into MCTS, comprised of malignant glioma cells (Waite and Roth 2009).  The 
delivery of dendrimers associated with siRNA was enhanced by the attachment of RGD 
ligands which enhanced the interaction between integrin ECM contacts in the MCTS and the 
dendrimer SiRNA complex (Waite and Roth 2009).  Novel therapies including 
radioimmunotherapy (Essand et al., 1995), cell- and antibody based immunotherapy 
(Ballangrud et al., 2001), hyperthermia and photodynamic treatment (Dubessy et al., 2000) 
have all been studied using 3D models of MCTS.  
The genetic expression of cells within MCTS can be evaluated. When combined with data on 
the efficacy of chemo- and radio-therapy, these MCTS can help us to understand the genetic 
factors involved in chemo and radio-resistance (Hirschhaeuser et al., 2010) potentially 
improving the treatment of resistant tumours.   
 Co-culture MCTS 
Monoculture MCTS, comprised of one cell type, do not take into account other cells which 
affect tumour behaviour in vivo.  MCTS incorporating other cell types such as fibroblasts, 
endothelial cells and immunocompetant cells have been developed (Kunz-Schughart and 
Knuechel 1998; Hirschhaeuser et al., 2010). 
Incorporation of immune cells into the MCTS has been achieved by adding a suspension of 
immune cells to preformed spheroids in culture.  These models are of great benefit to 
understand the role of immune cells in the development of tumours, as their role is currently 
unclear.  Some cells of the immune system are capable of recognising and destroying 
malignant cells, whereas other immune cells may be responsible for releasing growth factors 
and other signals that encourage tumour growth (Kunz-Schughart and Knuechel 1998). 
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Hauptmann et al,. used a MCTS model of colon cancer to test the effect of three different types 
of macrophage on tumour proliferation and migration (Hauptmann et al., 1993).  Konur et al., 
used MCTS comprised from different cancer cell lines to investigate the maturation of 
monocytes into tumour associated macrophages and found the maturation was different for 
different tumour tissues (Konur et al., 1998). 
Angiogenesis, the formation of new blood vessels from existing vascular beds, is essential for 
the continual growth of solid tumours as the blood supply delivers nutrients and oxygen, 
essential for growth and proliferation, as well as being important in the removal of waste 
products.  The blood supply to tumours is also responsible for transporting malignant cells to 
metastatic sites.  For this reason anti-angiogenic treatments are gaining popularity as an 
alternative method to halt, or slow, the growth of tumours.   
In order to test novel anti-angiogenic therapies in vitro, solid tumour models, which 
incorporate an endothelial component are essential.   Models incorporating endothelial 
components are also a valuable tool to study the mechanisms involved in angiogenesis and 
tumour growth.  Studies in monolayers, involving the co-culture of endothelial cells and cancer 
cells, have limited value as blood vessel formation is a complex 3D process.    
Timmins et al., created micro-vascularised MCTS by introducing isolated endothelial cells to 
pre-formed solid tumour spheroids using the hanging drop technique.  They demonstrated it 
was possible to incorporate an endothelial component without the addition of angiogenic 
factors or a need for endogenous supplements (Timmins et al., 2004). Vascular endothelial 
growth factor (VEGF) was up-regulated in MCTS, compared to the same cell lines cultured as 
monolayers (Timmins et al., 2004). 
1.6 Imaging and Diagnostic Techniques 
 Visual Diagnosis of OSCC and potentially 
malignant lesions 
Diagnosis of OSCC and potentially malignant lesions currently relies on histological analysis 
of surgically removed biopsies.  This is an accurate and well established method for the 
diagnosis of oral cancers and other mucosal diseases however, there are drawbacks.  The 
procedure of surgical biopsies is invasive, causing pain and discomfort for the patient. There is 
a delay before the patient can be presented with a diagnosis causing anxiety and delaying 
treatment where needed.  A non-invasive and instant method for diagnosing potentially 
malignant lesions would overcome these problems and could enable more widespread and 
regular screening of at risk patients.  This would be particularly beneficial in the treatment of 
oral cancer where low survival rates are often due to late diagnosis when the cancer is already 
at an advanced stage.   
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 Real time imaging could also help the surgeon define the margins of the lesions, helping them 
to completely remove diseased areas while maintaining as much healthy tissue as possible. 
Being able to take an “optical biopsy” non-invasively and without the need for ionising 
radiation would mean larger areas of tissue could be investigated compared to the areas of 
tissue examined in a surgical biopsy.  One technology which is proving to be promising for 
this application is optical coherence tomography (OCT).  
General dentists do not often see oral cancer cases and are therefore not as experienced at 
diagnosing and referring these patients when the cancer is still in the early stages (Keller 
2010).  Technology which is simple to use, affordable and gives reliable results could provide 
general dentists with a great aid to spot oral cancer earlier and therefore improve survival rates.  
Two thirds of oral cancers are not diagnosed until they have spread from their original 
location.  Pre-malignant lesions are often invisible to the naked eye and can have an 
appearance which is indistinguishable from other mucosal conditions including non-specific 
ulcers, frictional keratosis and lichen planus (Keller 2010). 
 Commercially available detection systems 
 Photosensitisers 
Photosensitisers are topically applied materials which create a strong fluorescent signal in the 
oral cavity.  This fluorescent signal is higher and appears more quickly in areas of pathology 
and can therefore be used to locate potential areas of oral cancer.  Photosensitisers have the 
advantage of being non-invasive, quick to perform and the only special equipment required is 
an inexpensive red diode type laser to detect the fluorescence.  A drawback to this technology 
is the fact that the dye is non-specific and often stains not only areas of oral cancer but also 
other oral pathologies such as non-specific ulcers, frictional keratosis and oral lichen plaus.  
The exposure of tissue to the red-diode type laser can also be damaging so this exposure needs 
to be minimized.   
 Toludene blue 
Toludene blue is a metachromatic vital dye (Zila Tolonium Chloride) which has been used for 
many years in dental practices.  The stain is rinsed around the oral cavity and is taken up by 
live cells.  Those cells which have higher metabolic activity will accumulate more dye than 
those with a lower metabolic activity.  The accuracy of this technique depends on the 
experience of the clinician.  Those who use the stain regularly can achieve 90% sensitivity 
however, specificity is low (Wilder-Smith et al., 2009) and less experienced clinicians are not 
able to obtain such high sensitivity.  This poor specificity often results in false positive results.  
 ViziLite 
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ViziLite is a system which is often used in conjunction with Toludene blue.  The patient is 
required to wash their mouth with acetic acid, to dehydrate the cytoplasm of cells.  This 
enhances the difference in retractile properties caused by the higher nuclear: cytoplasmic ratio 
of cancerous cells compared to healthy cells.  The ViziLite stick then uses chemo-
luminescence to show areas of potentially malignant and malignant lesions as white patches.  
This method is not very sensitive and many in the field believe a trained eye is more reliable.   
The advantages of Toludene blue and ViziLite are that they are fast, cheap and relatively 
simple to use. The limitations of Toludene blue and ViziLite are that they cannot distinguish 
between the different degrees of dysplasia and carcinoma and also provide a high proportion of 
false positive results.   
 VELscope 
VELscope is a spectroscopy device which does not require any prior tissue staining or 
treatment to image lesions in the oral cavity.  It works using the inherent optical properties of 
dysplastic or malignant tissue compared to healthy tissue.  A blue light (wavelength 400-
460nm) is shone onto the tissue being examined and the appearance of autofluorescence is 
different in areas of pathology.  It is believed this system uses auto-fluorescence from 
nicotinamide adenine dinucleotides (NADH) and flavin adenine dinucleotides (FAD) to 
distinguish between healthy tissues and potentially malignant lesions which lose this 
autofluorescence as a result of increased metabolism (Poh et al., 2007; Schwarz et al., 2008).  
Healthy tissue appears apple green while suspicious lesions appear dark with a loss of 
fluorescence (VELscope 2009).  In a pilot study VELscope showed 98% sensitivity and 100% 
specificity identifying severe dysplasia/ carcinoma in situ or invasive carcinoma from healthy 
tissue (Poh et al., 2007). However, other types of lesion such as non-specific ulcers, frictional 
keratosis and oral lichen planus were not included in the study which may artificially raise the 
specificity of the methodology.  Anecdotally its specificity is thought to be similar to that of 
Toludene Blue and ViziLite. Its ability to diagnose dysplasia and earlier stages of pre-
malignancy has yet to be shown in a randomised control trial of at risk patient groups.  It has 
however, been demonstrated in a case study of a patient with a case of recurring moderate 
dysplasia (Poh et al., 2007) that was not visible to the naked eye. VELscope is not an 
alternative to biopsies but is used as a adjunctive device to help clinicians know where to take 
biopsies (VELscope 2009).    
 Trimira Identafi 3000 
The Trimira Identafi® 3000 is a multi-spectral oral cancer screening system.  Approved by the 
FDA for clinical use in 2008, this device uses three different light sources to distinguish 
abnormalities in tissues more clearly.  The first is a regular white light which can highlight 
some suspicious lesions, but not all.  The second light is a violet light which enhances the 
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tissue‟s natural fluorescence.  This is the same method by which the VELscope works.  In 
addition to the violet light there is a green-amber wavelength light which enables easier 
visualisation of vasculature.  In normal tissues the vasculature is well defined and organised 
but in dysplastic and malignant tissues the vasculature is more diffuse and distinguishable from 
normal tissue.  By combining these three different imaging modalities it is hoped that the 
number of false positives can be reduced.   
 Impedance Spectroscopy 
Impedance spectroscopy is a non-invasive, real time type of spectroscopy which measures the 
bioimpedance of a tissue.  A sinusoidal current is applied to the tissue at a variety of 
frequencies.  The voltage drop caused by impedance in the tissue is referred to as 
bioimpedance and varies between different types of tissues and physiological changes within 
tissues. The electrical properties of the tissue give rise to different impedance signals at 
different frequencies.  Low frequencies (10Hz-10kHz) relate to differences in the ionic 
environment surrounding cells whereas higher frequencies (10kHz-10MHz) measure changes 
in structure relaxation (Sun et al., 2010).    Changes in the levels of water and salts within cells 
as well as orientation of cells and membrane permeability can all result in changes to the 
electrical impedance.  These factors change during the transformation of tissue from healthy to 
malignant tissue and therefore make impedance spectroscopy a feasible method for screening 
cancer.   
Impedance spectroscopy has been shown to be able to detect the degree of cervical 
intraepithelial neoplasia (CIN) with sensitivities of 74% and specificities of 53% (Abdul et al., 
2006).  The use of impedance spectroscopy for detecting breast cancer has been reviewed in 
(Zou and Guo 2003).  Differentiation between malignant breast tissue and surrounding tissue 
has been shown to be possible and positive trials of one device for impedance spectroscopy, 
the TS2000, led to its approval by the FDA for it to be used in association with mammography 
for the diagnosis of breast cancer (Zou and Guo 2003).  There has been some evidence in vitro 
and in vivo that impedance spectroscopy is able to distinguish between benign and malignant 
breast tissue (Sun et al., 2010) although, this has yet to be proved in patients (Zou and Guo 
2003).  Although commercially available the TS2000 is not without problems, the depth of 
penetration (3-3.5cm) is only able to detect breast cancers near the surface of the body, false 
positive results are common due to interference from other tissue types and skin lesions (Zou 
and Guo 2003). The accuracy of detection must be improved before this technique can have a 
real impact on the detection of cancerous breast tissue.  
Impedance spectroscopy has the advantage that it is relatively low cost, quick to do and 
requires little training compared to traditional histology and pathological analysis of suspicious 
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lesions.  The immediate results and ease of use also makes it suitable for use in resource poor 
settings and primary care.  
The first study of impedance spectroscopy for the investigation of oral lesions was published 
by Sun et al,. (Sun et al., 2010).  In their study, bioimpedance of cancerous tissue on the 
tongue of twelve patients with tongue cancer was measured and compared to healthy tissue on 
the patient‟s tongue, at least 10mm away from the cancerous region of the tongue, and 
measurements from the tongues of healthy volunteers.  The bioimpedance for the healthy 
tissue was compared to cancerous regions at six different frequencies (20Hz, 50 kHz, 1.3 
MHz, 2.5 MHz, 3.7 MHz and 5 MHz).   
Measurements of impedance, phase angle, real part of impedance and imaginary part of 
impedance were taken.  At 20Hz and 50 kHz the difference in all four of the parameters 
measured was statistically significant between the cancerous region of the tongue, the healthy 
region of the patients‟ tongues and the measurements taken from healthy volunteers.  At 
frequencies below 1MHz the current is unable to pass through the cells, therefore the current 
flows around the cells and impedance is affected by the intracellular space. In healthy tissues 
the cells are tightly packed with strong intracellular connections making the resistance high as 
the current must take an arduous route around the cells.  In cancerous tissues the extracellular 
space widens and intracellular connections are lost, resulting in lower resistance and therefore 
lower bioimpedance values.  
Higher frequencies detect changes to the electrical properties inside cells as well as 
intracellular spaces as the higher frequency current is able to pass through cells.  Impedance 
measurements at higher frequencies were not significantly different between healthy and 
malignant tissues. 
This paper demonstrates the potential of this technology in diagnosing changes to the oral 
epithelium in a quick and non-invasive way.  Further studies looking into various degrees of 
dysplasia and metastatic progression in different regions of the oral cavity will be interesting.   
 Fourier Transform Infra-Red spectroscopy 
Spectroscopy enables the detection of specific chemical compounds within a sample by 
measuring the absorption, emission or scattering of electromagnetic radiation.  In the case of 
Fourier Transform Infrared (FTIR) the radiation used is broad spectrum infrared (IR) light 
which includes many wavelengths.  IR radiation is aimed at the sample and different 
wavelengths are absorbed depending on the bonds present.  The absorption results in less 
radiation returning to the detector.  The Fourier Transform algorithm is used to convert raw 
data into information regarding the absorption at each specific wavelength.   
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Each wavelength corresponds to different bond types, enabling a molecular “finger-print” of 
the bonds present in a sample to be identified (including information on the functional groups, 
bonding types and molecular configurations present).   
Mid-FTIR measures between 400 and 4000 cm
-1 
wavenumbers.  This method is highly 
sensitive to strong polar bonds such as C=O, C-O, O-H, and C-H.  These bonds are commonly 
found in lipids, carbohydrates and proteins.  FTIR has therefore been able to detect changes in 
cell proliferation and distinguish cells in different stages of their life cycle and between 
malignant and healthy cells (Kendall et al., 2009).  
Unfortunately, the strong absorption of IR light by O-H bonds means that the presence of 
water can limit the use of mid IR FTIR for in vivo applications.    
 Raman Spectroscopy 
Raman spectroscopy (RS) is commonly used in conjunction with FTIR as the spectroscopic 
method detects differences in C=C bonds and carbon triple bonds found in aromatic amino 
acids (Kendall et al., 2009). RS detects subtle changes in wavelengths (called a Raman shift) 
which results from inelastic collisions of photons from incident light with molecules in the 
sample. Raman is not affected by water so is currently being developed for in vivo probes as 
well as histopathology diagnosis aids.  
 Optical Coherence Tomography 
 Introduction 
Optical coherence tomography (OCT) is a non-invasive method of imaging which utilizes the 
high penetration capacity of long wavelength light to image tissues beneath the surface.  OCT, 
often referred to as “optical ultrasound”, measures light back scattered and reflected from 
different tissue structures beneath the surface of a sample. Differences in the optical properties 
and reflectivity of tissue components create distinguishable signals from different depths of the 
sample.  These signals can be processed to produce a 2D cross section of a region of tissue 
(and in some systems a complete 3D reconstruction).  OCT imaging systems comprise of two 
interferometer arms.  Light from the low coherence light source is split using a beam splitter 
(usually a Michelson interferometer).  The first of these arms focuses the light onto the sample, 
scans the area being visualised and collects the backscattered light.  The second interferometer 
arm provides the reference light beam.  The speed of light means the method for calculating 
the depth corresponding to a particular signal is more complicated than in ultrasound.   In 
ultrasound the time taken for a sound wave to be reflected back to the detector is measured.  In 
OCT there are two different methods for working out the depth of a signal, time domain OCT 
and Fourier domain OCT (Illustrated in Figure 1.12 and Figure 1.13). 
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 TD OCT 
In time domain OCT (TD-OCT), also called temporal domain OCT, there is a moving 
reference mirror in the reference arm (Figure 1.12).  The reference mirror scans in the z 
direction as the sample is exposed to the light from the sample arm.  When light from the two 
arms have travelled the same distance the two light paths optically interfere with one another. 
The interference between the two light paths creates interference fringes which are detected 
and analysed.  This analysis provides information on the magnitude and echo time delay of the 
sample beam and a grey-scale cross-sectional image of the tissue can be created.   
 FD-OCT 
In Fourier domain OCT (FD- OCT), also known as spectral domain OCT, there is a stationary 
mirror in the reference arm (Figure 1.13).  In order to calculate the depth of a signal‟s source 
the phase shift of the backscattered or reflected light is compared with the phase of the signal 
from the stationary mirror.  The spectra of back scattered light from the sample can be 
measured over the entire optical bandwidth simultaneously enabling fast imaging without the 
need for a moving mirror. Signal depth information can be extracted from this spectral 
measurement using digital signal processing (Fourier transform).  The advantage of FD-OCT 
over TD-OCT is the speed at which an image can be obtained.  Eliminating the need for the 
moving mirror means that images can be obtained much faster, an obvious benefit when 
imaging live moving patients.   
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Figure 1.12 Simplified schematic diagram of Time domain OCT configuration 
Blue = reference beam, Red = sample beam 
Collimation lens = to align light beams into a parallel configuration 
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Figure 1.13 Simplified schematic diagram of Fourier domain OCT configuration.  Blue = 
reference beam, Red = sample beam.  Collimation lens = to align light rays into a parallel 
configuration. 
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 Light source 
The light source is the most expensive and important component of the OCT device. The light 
source must be broadband, low coherence light.  This can be femto-second mode lock pulsed 
lasers, super-luminescent diodes or fibre amplifiers.  The light source is important in 
determining the depth of imaging and the resolution.  Near IR light is used because these long 
wavelengths penetrate well into tissues, are not absorbed by haemoglobin and are scattered 
less than light of shorter wavelengths.   
 Resolution 
The coherence length of the light source determines the axial resolution of the resulting image.  
The coherence length of a light source is determined by how long the phase of a beam of light 
remains correlated (Figure 1.14). Light has a finite length of coherence as light travels in wave 
trains (Olsen 1996).  Each wave train has a finite length which determines the length of the 
light phase which is correlated.  Coherence is inversely proportional to the bandwidth of a light 
source, meaning light sources which simultaneously produce a wide range of wavelengths (or 
frequencies as one is inversely proportional to the other) have lower coherence than a single 
wavelength light source (with a narrow bandwidth) (Chen et al., 2007).  Signals from the 
reference arm and the sample arm only interfere when the path length difference is smaller 
than the coherence length.  This means, by using a low coherence length light source, signals 
from different depths of a sample can be distinguished when they occur a few microns apart. 
Standard OCT systems give axial resolution of approximately 10µm however, novel OCT 
systems with laser light sources have achieved resolutions down to 1µm (Morgner et al., 
2000).  This axial resolution is up to 100 times better than ultrasound making it more suitable 
for imaging morphological changes to smaller biological structures such as epithelia. The 
transverse resolution is dependant of the optical properties on the sample arm, for example the 
numerical aperture of the lens and the size of the focus spot on the sample.   
 Depth of penetration 
The maximum imaging depths of OCT depend on the light scattering and attenuation 
properties of the tissue being imaged as well as the wavelength of light used. Light of longer 
wavelengths (750- 1400nm) is used as it is able to penetrate further into tissues as it 
experiences less scattering effects compared to shorter wavelength light.  Transparent tissues 
such as those in the eye give the greatest depth of imaging.  Depths of 2-3mm have been 
achieved in tissue engineered structures (Georgakoudi et al., 2008) which is the limit in many 
tissues (Fujimoto 2003). This depth of imaging is low compared to other imaging techniques 
such as x-ray, ultrasound, magnetic resonance imaging (MRI) and computed tomography (CT) 
but OCT has the advantage of not requiring ionizing radiation (used in x-rays) and has a 
greater resolution compared to these methods.  
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The thickness of healthy oral mucosa epithelia vary between 75µm - 550µm in different 
regions (Ridgeway et al., 2006).  Many mucosal diseases are associated with considerable 
epithelial thickening however, a depth of 2mm is adequate to gain information in the majority 
of mucosal diseases, which often manifest in the boundary region between the epithelium and 
connective tissue.  This depth of penetration is considerably better compared to other imaging 
modalities such as contact endoscopy, methylene blue, acetic acid and indigo carmine.  These 
technologies provide transverse resolution of between 10 – 71 µm and enable signals from 
100µm deep to be seen (Ridgeway et al., 2006).  This information is however, visible as a 
plane view rather than the more informative (and histologically comparative) cross section 
which is achievable with OCT. 
 
 
 
 
Figure 1.14 An illustration of coherent light source interference 
 Applications  
OCT is currently widely used in ophthalmology as the optical properties of the eye make it 
relatively easy to image compared to other tissues which have higher light scattering 
properties.  OCT for retinal applications was first demonstrated in vivo in 1993 (Fujimoto 
2003).  Its ability to produce real time images of defects and morphological differences on the 
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retina non-invasively has changed the way ophthalmologists image and treat retinal conditions.  
OCT has now been applied to many areas of ophthalmology and is used for imaging and 
diagnosing macular holes, macular oedema, choroidal neovascularization, vitreomacular 
traction, epiretinal membranes, glaucoma, age-related macular degeneration, uveitis and 
cataract (Sakata et al., 2009; Bechtel 2010). Dr Walsh, of the Doheny Eye Institute, sees the 
potential for OCT to be used as a diagnostic tool in the developing world for the diagnosis of 
global blindness.  The simplicity of the system and the falling costs of light sources make it 
plausible that in the future diseases leading to global blindness could be diagnosed in a simpler 
way that is accessible to patients without the need for on-site ophthalmologists (Bechtel 2010).   
It is hoped that the technical advances which have been born from OCT‟s use in 
ophthalmology may enable it to be used in a number of other areas of diagnostics and imaging.  
The technology has progressed rapidly since 1991 and continues to improve with a large 
amount of research into OCT taking place.  Other applications under investigation include 
cancer diagnosis in several areas of the body (Jeres et al., 2010), intracoronary imaging to 
evaluate stent dissolution and lumen architecture (Bezerra et al., 2009) and Doppler OCT for 
functional imaging of blood flow in vascular disease and post photodynamic therapy in 
carcinoma (Standish et al., 2008).    
  OCT and OSCC 
Rdigeway et al., examined various locations of the oral cavity and oropharynx in 41 patients 
using time domain OCT (Ridgeway et al., 2006).  Patients were under general anaesthetic to 
reduce movement artefacts experienced when using time domain OCT systems.  The speed of 
scanning used here was 500 A-scans (axial direction scans) per second however, more recently 
scan speeds of 40,000 scans/second have been achieved with Fourier domain OCT (Sakata et 
al., 2009), removing the need to anaesthetise patients prior to imaging.  Many different 
anatomical features of the oral mucosa in various locations could be seen using OCT in healthy 
patients (Figure 1.15).  These included the epithelial connective tissue junction, stratified 
squamous epithelium and lamina propria (connective tissue) in all areas of healthy tissue. 
More location specific features could also be determined including the filiform papillae on the 
dorsum of the tongue, seromucous glands on the mucosal side of the lower lip, glandular duct 
architecture in the floor of the mouth and blood vessels in the floor of the mouth (Ridgeway et 
al., 2006).  Blood vessels containing blood and ducts containing clear fluid both appeared as 
black regions on the cross-sectional images however, the blood vessels produced an “optical 
shadow”; as light was absorbed by haemoglobin (and other components of the blood), images 
could not be obtained underneath the blood vessels.  This optical shadow was not seen with the 
ducts containing clear fluids.   
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The appearance of healthy buccal mucosa, dysplastic oral mucosa and OSCC of the alveolar 
ridge when imaged using OCT could be detected (Figure 1.16).  The dysplastic buccal mucosa 
has a different appearance around the epithelial connective tissue border and there is less 
difference between the brightness of the epithelium and the connective tissue in this image 
compared to the healthy buccal mucosa.  The squamous cell carcinoma shows a complete 
disruption to the image.  There in banding throughout the image (vertical white bands) and the 
definition between the epithelium and the connective tissue is lost.  
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Figure 1.15 OCT of different regions of healthy oral mucosa. 
 (A) Healthy buccal mucosa, (B) Mucosal side of lower lip, (C) Dorsum of the tongue, (D) 
Surface of healthy tongue, E) Floor of the mouth, (F) Floor of the mouth.  
Scale bar 500µm 
SS = stratified squamous epithelium, BM= basement membrane, LP = lamina propria 
SD = seromucocinous duct, SG = seromucinous glands, FP = Filiform papillae, KL = keratin 
layer, GD= Gland duct, BV= blood vessel 
 Images reproduced from (Ridgeway et al., 2006) 
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Figure 1.16 OCT image of pathological lesions in the oral cavity.  
Images adapted from (Wilder-Smith et al., 2009). (1) Stratified squamous epithelium, 
(2) keratinized epithelial surface layer, (3) basement membrane, (4) submucosal. 
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Wilder-Smith et al., tested the ability of clinicians to diagnose different stages of oral cancer 
progression in three different regions of the oral cavity (tongue, buccal and floor of mouth) 
from OCT images (Wilder-Smith et al., 2009). Observers were trained to score OCT images 
for severity of cancer progression in two hours. They were displayed 50 OCT images and the 
corresponding histology of those OCT images.   OCT from 50 patients was then scored by the 
trained observers and these scores were compared to scores (on the same scale) given by 
separate histo-pathological diagnosis.  The intra- and inter- observer diagnosis was established 
as well as the level of agreement with histo-pathological diagnosis of the same samples.  
Agreement between scores and histolpathology was calculated using Cohen‟s λ statistics.  
Inter- and intra-observer agreement was very good with λ values of 0.872 (intra) and 0.870 
(inter) for OCT diagnosis (inter- observer agreement for histo-pathological diagnosis was 
0.923).  The diagnosis from the OCT images was in good agreement with the diagnosis from 
histopathology, with a Cohen‟s λ of 0.896.  The specificity for detecting SCC versus all other 
modalities (healthy, dysplasia and carcinoma in situ) was 0.931 and the specificity was 0.973.  
This specificity and sensitivity was good and shows the value of OCT in diagnosing OSCC.  
The sensitivities and specificities for diagnosing stages of dysplasia were not stated so may not 
have been as high.  Despite this the agreement of OCT diagnosis with histopathology diagnosis 
was strong (0.896) and the time taken to train (2 hours) is far less compared to the experience 
required to gain high specificities using other techniques such as Toludene Blue (Wilder-Smith 
et al., 2009).   
Tsai et al., imaged patients with various stages of dysplasia and OSCC, using swept source 
OCT, in an attempt to produce a quantitative method to diagnosis between mild dysplasia, 
moderate dysplasia, early stage OSCC and well developed OSCC (Tsai et al., 2009).  Three 
markers, observable in OCT images, were used to determine the stage of dysplasia or OSCC.  
The first of these markers was the epithelial thickness as epithelial hyperplasia is often seen as 
a precursor to mild dysplasia and is observed in dysplasia.  An increase in epithelial thickness 
was observed from normal buccal mucosa < mild dysplasia < moderate dysplasia.  Once the 
lesion had progressed to OSCC the basement membrane could no longer be clearly seen in the 
OCT images, this same observation was also noted in (Ridgeway et al., 2006).   
The second marker for staging the level of cancer progression was to look at the variation in 
the intensity of the signal from different depths of the epithelial portion of OCT images. To 
calculate this, depth dependant lateral scan standard deviation was plotted.  Lines with a length 
of 2mm were drawn laterally across the epithelium at specific depths between 0 and 1.5mm.  
The standard deviation of intensity for each lateral line, calculated from the intensity profile, 
was plotted as a function of depth.  This was done for all 5 conditions (from normal epithelium 
to well developed OSCC) and the profiles of each condition were markedly different.  The 
graphs for OSCC were clearly distinguishable from the dysplastic and healthy profiles 
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(standard deviation decayed with time for OSCC).  For healthy mucosa, mild dysplasia and 
moderate dysplasia the highest standard deviation corresponded to the location of the basement 
membrane.  The profile of these three graphs had distinct differences.  To quantify this 
difference Tsai et al., calculated the axial distance for which the standard deviation was above 
70% of the maximum.  For the four mildly dysplastic and four moderately dysplastic samples 
they analysed there was a difference, the moderate dysplasia showed higher standard deviation 
over a greater depth compared to the mild dysplasia.   
The early stage and well developed OSCC, although easily distinguished from healthy and 
dysplastic tissue using the previous analysis could not be distinguished from one another.  
Therefore, a third method was employed to determine the difference between early stage 
OSCC and well developed OSCC.  In the early stage OSCC white and black vertical bands 
could be observed through the lamina propria.  Tsai et al., propose this image pattern was due 
to the connective tissue papillae observed in the histology from the early stage OSCC, which is 
not visible in the well developed OSCC.  Therefore, the lateral intensity of an area of banding 
was plotted and the standard deviation of this early stage OSCC was compared to the standard 
deviation of the lateral intensity profile of the same depth in well developed OSCC.  The 
standard deviation was higher for all 4 early stage OSCC compared to the 4 well developed 
OSCC samples examined.  A difference between early stage and well developed OSCC could 
also be observed in the decay profile of the intensity of the signal in the axial direction.  The 
intensity of the signal decayed as samples were imaged deeper.  More light was absorbed in 
the well developed OSCC compared to the early stage OSCC, therefore the exponential decay 
constant was greater in well developed OSCC.  This provides another quantifiable method to 
distinguish between the two stages of OSCC.  It is believed this increased absorption of light is 
due to the high density of cancer cells in well developed OSCC and the amount of capillaries, 
and therefore blood, which will absorb the light in greater quantities compared to the lamina 
propria (connective tissue) (Tsai et al., 2009).   
The sample size (four samples for each stage) is small so further work is needed in a larger 
sample size randomised control trial to test these parameters for their specificity and accuracy 
in staging oral cancer using OCT.  These results are encouraging and show that OCT may not 
just provide qualitative information of disease progression but may also provide a quantifiable 
standardised method for diagnosis (Tsai et al., 2009).   
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Aims and Objectives 
 
The aim of this project was to develop and utilise in vitro 3D tissue engineered models of oral 
mucosa and oral cancers to test novel therapeutic and diagnostic technologies.   
The three main objectives of this thesis were: 
1) To develop and characterise tissue engineered models which model all stages of oral cancer 
progression from normal oral mucosa through dysplastic oral lesions and carcinoma in situ to 
early invasive oral squamous cell carcinoma and ultimately to solid expanding tumour islands 
of squamous cell carcinoma.   
2) To investigate the behaviour of polymersomes as future vehicles for delivering agents into 
oral tissue. This involved looking at the distribution and penetration capacity of this novel drug 
delivery system in 3D models of healthy oral mucosa and solid expanding tumours.   
3) To use the tissue engineered models of oral cancer to test the ability of novel diagnostic 
technologies to distinguish dysplastic and malignant lesions from healthy tissue.  These 
technologies included: a metabolic cell marker (Vybrant™ cell metabolic activity kit with C12- 
resazurin), impedance spectroscopy, Fourier tansform infra-red and optical coherence 
tomography.   
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Chapter 2: Developing Tissue 
Engineering Models of Oral 
Cancer 
 
2.1 Aim 
To develop and characterise tissue engineered models which have characteristics of all stages 
of oral cancer development from a healthy oral mucosa to a dysplastic epithelium right through 
to a solid expanding tumour mass.   
2.2 Introduction 
Tissue engineered models of healthy human tissue have been developed for the replacement 
and repair of tissues in the body.  These models along with models of diseases, such as cancer, 
provide important in vitro tools for the study of disease development, therapeutics and 
diagnostic technologies.   
In this chapter three types of models are presented.  The first is a 3D model of healthy human 
oral mucosa which comprises of an epithelium with underlying connective tissue component. 
This tissue model has been developed in the MacNeil laboratory and has been developed for 
clinical applications (Bhargava et al., 2004). This tissue engineered oral mucosa (TEOM) has 
been successfully used in the clinic to replace scarred tissue in the urethra (Bhargava et al., 
2008) with three year follow up. 
The second group of models developed here are models of dysplasia and carcinoma in situ.  
Oral cancer most often originates in the epithelium as epithelial cells transform from healthy 
cells to dysplastic and finally become malignant cells.  This method of transformation is 
widely accepted however, it is not proven that all malignant cells go through the transition of 
being dysplastic before become malignant.  Here we produce models using a variety of 
different oral cancer and dysplastic oral cell lines to look at the morphology of epithelia 
produced when these cell lines are cultured on a connective tissue scaffold along with healthy 
fibroblasts. It is our aim to produce models for all stages of oral cancer progression from mild 
dysplasia to carcinoma in situ, and subsequently invasive OSCC.     
The third model is the multi-cellular tumour spheroid (MCTS) model. MCTS model solid 
expanding tumour masses, found deep in tissues once OSCC has invaded.  MCTS have 
previously been developed to model several different types of cancer from cell lines 
originating from cancers in different regions of the body.  MCTS have shown real potential as 
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a more accurate method for high through-put screening of novel drug compounds 
(Hirschhaeuser et al., 2010).  Here we characterise the MCTS currently used in our laboratory 
and look at the oral cell types which are able to spontaneously form MCTS under the right in 
vitro conditions.  
 
2.3 Materials and Methods 
 Cell culture basics 
All cell culture work was carried out in Class II laminar flow hoods (Walker Safety Cabinets, 
Glossop, Derbyshire, UK).  Laminar flow hoods and equipment used within them were 
sterilised prior to use using 70% (v/v) industrial methylated spirits (IMS) (Fisher Scientific UK 
Ltd, Loughborough, UK) or by autoclave sterilisation.  Laboratory plastic wear for cell culture 
was purchased from Costar, High Wycombe, Buckinghamshire, UK and Greiner Bio-one, 
Gloucestershire, UK.   Liquid materials were either purchased sterile from the supplier or were 
filter sterilised prior to use.  All cells were incubated at 37°C in humidified incubators 
containing 5% CO2. 
 Cell culture medium  
 Materials 
 
Dulbecco’s modified Eagle’s Medium (DMEM) 
DMEM was purchased from Gibco, Paisley, UK and came supplemented with 4500mg/l 
glucose GlutaMAX™ I and sodium pyruvate. 
Nutrient Mixture F12 (Ham’s F12) 
From Biosera, East Sussex, UK, supplemented with L-glutamine and sodium bicarbonate. 
Fetal Calf Serum (FCS) 
FCS (heat inactivated) from Biosera, East Sussex, UK was stored frozen.  New batches were 
tested prior to use to ensure comparable cell growth and behaviour from the previous batch.  
Penicillin/Streptomycin 
From Sigma Aldrich, Dorset, UK. 
 Amphotericin B 
Amphotericin B from Sigma Aldrich, Dorset, UK.  Store protected from light. 
Adenine 
0.5g Adenine powder (Sigma Aldrich, Dorset, UK) was mixed with 70ml distilled water.  1M 
Hydrochloric acid (HCl) was added to the mixture until the powder dissolved completely.  The 
solution was filter sterilised and made up to 80ml with distilled water to give a final 
concentration of 6.25µg/ml.  
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 Insulin 
10mg Bovine Insulin powder (Sigma Aldrich, Dorset, UK) was added to 1ml of 0.01M HCl.  
Once dissolved 9ml of distilled water was added to give a final concentration of 1mg/ml. 
3, 3, 5- Tri-iodothyronine/Apo-Transferrin 
13.6mg T3 (Sigma Aldrich, Dorset, UK) was dissolved in the minimum volume of 0.02M 
sodium hydroxide (NaOH).  Once dissolved the solution was made up to 100ml with distilled 
water.   250mg apo-transferrin (Sigma Aldrich, Dorset, UK) was dissolved in 30ml of PBS.  
0.5ml of the T3 solution was added to 30ml of the apo-transferrin solution and the volume was 
made up to 50ml with PBS.    
Hydrocortisone 
25mg of hydrocortisone powder (Sigma Aldrich, Dorset, UK) was added to 1ml distilled 
water.  The volume was then made up to 10ml with PBS.   
Epidermal Growth Factor (Human Recombinant from E. Coli) 
Epidermal growth factor (EGF) was purchased from Sigma Aldrich, Dorset, UK.  100µg was 
dissolved into 1ml of distilled water.  
Cholera Toxin 
Cholera toxin (extracted from Vibrio cholera), was purchased from Sigma Aldrich, Dorset, 
UK.   A 1mg aliquot was dissolved into 1.18ml distilled water, this was stored as stock at 4°C.  
100µl of stock was diluted into 10ml of media with serum.   
RPMI 1640 AQ media 
From Sigma Aldrich, Dorset, UK, RPMI contained sodium bicarbonate and L-glutamine.  
IMEM 
Iscove‟s Modification of DMEM from Gibco, Paisley, UK was supplemented with L-
glutamine.  
 Preparation of Cell culture medium 
Normal Oral Keratinocytes 
Normal Oral Keratinocytes were cultured in Green‟s Medium.  Media was made 500ml at a 
time, stored at 4°C and used for up to one month.  Sterility of cell culture medium was checked 
by incubating 10ml of cell culture medium at 37°C for 24 hours prior to use.  The composition 
of Green‟s medium is outlined below: 
Component Volume and stock 
solution 
Final concentration Storage 
Dulbecco’s modified 
Eagle’s Medium  
330ml 66% 4°C 
Nutrient Mixture F12 108ml 21.6%  4°C 
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(Ham’s F12) 
Fetal Calf Serum 50ml 10%  -20°C 
Penicillin/Streptomycin 5ml of 10,000i.u./ml 
penicillin and 
10,000µg/ml 
streptomycin 
100i.u./ml penicillin and 
100µg/ml streptomycin 
-20°C 
Amphotericin B 1.25ml of 250µg/ml  0.625µg/ml -20°C 
Adenine 2ml of 6.25µg/ml 0.025µg/ml  -20°C 
Insulin 2.5ml of 1mg/ml 5µg/ml 4°C 
3, 3, 5- Tri-iodothyronine/ 
Apo-Transferrin 
0.5ml of 1.36µg/ml T3 
and 5mg/ml apo-
transferrin 
1.36ng/ml T3 and 5µg/ml 
apo-transferrin 
-20°C 
Hydrocortisone 80µl of 2.5mg/ml  4µg/ml 4°C 
Epidermal Growth Factor  25µl of 100µg/ml 5ng/ml -20°C 
Cholera Toxin 500µl of 8.47µg/ml 8.47ng/ml 4°C 
Table 2.1 Green’s medium 
 
Normal Oral Fibroblasts  
Normal Oral Fibroblasts (NOF) were cultured in supplemented DMEM (see Table 2.2).  Media 
was made 500ml at a time, stored at 4°C and used for up to one month.  Sterility of cell culture 
medium was checked by incubating 10ml of cell culture medium at 37°C for 24 hours prior to 
use.  The composition of 10% DMEM is described below: 
Component Volume and stock 
solution 
Final concentration Storage 
Dulbecco’s modified 
Eagle’s Medium  
443.75ml 89% 4°C 
Fetal Calf Serum 50ml 10%  -20°C 
Penicillin/Streptomycin 5ml of 10,000i.u./ml 
penicillin and 
10,000µg/ml 
streptomycin 
100i.u./ml penicillin and 
100µg/ml streptomycin 
-20°C 
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Amphotericin B 1.25ml of 250µg/ml  0.625µg/ml -20°C 
Table 2.2 10% DMEM medium 
 
FaDu (ATCC HTB-43) 
FaDu cells were obtained from ATCC (HTB-43), Manassas, VA, USA.  FaDu are a squamous 
cell carcinoma human cell line from a male patient‟s pharynx. FaDu cells were cultured in 
10% RPMI (Table 2.3). 
Component Volume and stock 
solution 
Final concentration Storage 
RPMI 1640  443.75ml 89% 4°C 
Fetal Calf Serum 50ml 10%  -20°C 
Penicillin/Streptomycin 5ml of 10,000i.u./ml 
penicillin and 
10,000µg/ml 
streptomycin 
100i.u./ml penicillin and 
100µg/ml streptomycin 
-20°C 
Amphotericin B 1.25ml of 250µg/ml  0.625µg/ml -20°C 
Table 2.3 FaDu cell culture medium 
 
SCC4 (ATCC CRL-1624), SCC9 (ATCC CRL-1629), SCC25 (ATCC CRL-1628) 
SCC4, SCC9 and SCC25 are squamous cell carcinoma human cell lines originally isolated 
from the tongues of different patients.  All these cell lines were obtained from ATCC 
(Manassas, VA, USA).  Cells were cultured in the following cell culture medium (Table 2.4). 
Component Volume and stock 
solution 
Final concentration Storage 
Dulbecco’s Modified 
Eagle’s Medium  
225ml 45% 4°C 
Nutrient Mix F12 (Ham’s 
F12) 
225ml 45% 4°C 
Fetal Calf Serum 50ml 10%  -20°C 
Penicillin/Streptomycin 5ml of 10,000i.u./ml 
penicillin and 
10,000µg/ml 
100i.u./ml penicillin and 
100µg/ml streptomycin 
-20°C 
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streptomycin 
Amphotericin B 1.25ml of 250µg/ml  0.625µg/ml -20°C 
Hydrocortisone 80µl of 2.5mg/ml  0.4µg/ml 4°C 
Table 2.4 SCC cell culture medium 
 
Cal27 (ATCC CRL-2095)  
A squamous cell carcinoma human cell line isolated from the tongue was purchased from 
ATCC (Manassas, VA, USA). This cell line established as a squamous cell carcinoma has 
recently been found to show behaviour and morphology more like an adenosquamous cell 
carcinoma (Jiang et al., 2009).  Cal27 cells are culture in 10% DMEM (Table 2.2) 
DOK (ECACC 94122104)  
A dysplastic oral keratinocyte cell line isolated from the tongue of a 57 year old man.  The 
patient had a squamous cell carcinoma and the remaining dysplasia was removed and used to 
establish this cell line. The dysplasia was described as mild to moderate. DOK cells were 
obtained from the European Collection of Cell Culture (ECACC) via Sigma Aldrich (Dorset, 
UK).  Cells were cultured in 10% DMEM supplemented with hydrocortisone to promote cell 
growth (Table 2.5). 
Component Volume and stock 
solution 
Final concentration Storage 
Dulbecco’s modified 
Eagle’s Medium  
443.75ml 89% 4°C 
Fetal Calf Serum 50ml 10%  -20°C 
Penicillin/Streptomycin 5ml of 10,000i.u./ml 
penicillin and 
10,000µg/ml 
streptomycin 
100i.u./ml penicillin and 
100µg/ml streptomycin 
-20°C 
Amphotericin B 1.25ml of 250µg/ml  0.625µg/ml -20°C 
Hydrocortisone 1ml of 2.5mg/ml 5µg/ml 4°C 
Table 2.5 DOK cell culture medium 
 
PE/CA-PJ34 (Clone C12), (ECACC 97062513)  
A human basaloid squamous cell carcinoma cell line established from cells removed from a 60 
year old male patient.  PE/CA-PJ34 cells were obtained from the European Collection of Cell 
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Culture (ECACC) via Sigma Aldrich, Dorset, UK and cultured in IMEM medium 
supplemented with 10% FCS (Table 2.6).  
Component Volume and stock 
solution 
Final concentration Storage 
Iscove’s Modification of 
DMEM (IMEM)  
443.75ml 89% 4°C 
Fetal Calf Serum 50ml 10%  -20°C 
Penicillin/Streptomycin 5ml of 10,000i.u./ml 
penicillin and 
10,000µg/ml 
streptomycin 
100i.u./ml penicillin and 
100µg/ml streptomycin 
-20°C 
Amphotericin B 1.25ml of 250µg/ml  0.625µg/ml -20°C 
Table 2.6 PE/CA-PJ34 cell culture medium 
 
D19 and D20 
The D19 and D20 cells are dysplastic cell lines which were kindly donated by Dr Keith Hunter 
at School of Clinical Dentistry, University of Sheffield (McGregor et al., 1997; McGregor et 
al., 2002).  D19 and D20 cells were cultured in Green‟s medium (see Table 2.1).   
  
 Passaging, counting and storage of cells 
 Materials 
Phosphate buffered saline (PBS)  
PBS tablets (Dulbecco A) were purchased from Oxoid Ltd, Basingstoke, Hampshire, UK.  One 
PBS tablet was added to every 100ml of distilled water in a bottle able to withstand 
autoclaving to give a PBS concentration of 100mM.  PBS was autoclaved for 10 mins at 
115°C and stored at room temperature.   
Trypsin EDTA 
Trypsin/EDTA (0.05% trypsin/ 0.02% EDTA w/v) was purchased from Sigma Aldrich 
(Dorset, UK) and stored at -20 °C.   
Cryopreservation Medium 
Cryopreservation medium was made using  90% fetal calf serum (Biosera, East Sussex, UK) 
and 10% dimethyl sulphoxide (DMSO) (Sigma Aldrich, Dorset, UK) (v/v).  
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 Passaging of cells 
When cells reached 80% confluency they were transferred into a new cell culture flask with 
lower cell numbers to enable cell proliferation to continue.  To passage cells the cell culture 
medium was removed and cells were washed with 10ml of PBS to remove any serum proteins 
in the residual cell culture medium.  Cells were incubated with 5ml 0.05% trypsin/0.02% 
EDTA (w/v) for 5 minutes or until all cells had detached.  The trypsin EDTA was neutralised 
using cell culture medium containing FCS at a 1:1 (v/v) ratio.  Cells were next centrifuged at 
1200 revolutions per minute (rpm) for 5 minutes using a bench top centrifuge.  The 
supernatant was discarded in bleach and the cellular pellet re-suspended in the desired volume 
of cell culture medium.   
 Counting cells 
Cell counts were performed using a modified Neubauer haemocytometer (Weber Scientific 
International, Middlesex, UK).    At least two 1mm
2
 squares (volume 1 x 10
-4 
ml) were counted 
and their average taken.  Cell number was calculated as follows: 
average number of cells counted per 1mm
2 
square x dilution factor  =  Cells/ml 
volume counted (1x 10
-4
ml)           
 
e.g. average cell count of 100 with no dilution = 1 million cells per ml 
 Freezing cells for cryo-preservation 
For cryopreservation cells were treated as for passaging (described above).  However, rather 
than re-suspending the cellular pellet in media, cells were re-suspended into cryopreservation 
media (90% FCS, 10% DMSO).  The pellet was re-suspended to give a concentration of 
between 0.5 million and 3 million cells per ml of cryopreservation medium, depending on the 
cell type.  1ml of this cell suspension was pipetted into each cryovial (Cellstar cryovials from 
Greiner bio-one, Gloustershire, UK) and cryovials were placed in a Nalgene™ Cryo 1°C 
freezing container (Nalgene Co., New York, USA).  This freezing container, which contained 
250ml of iso-propanol, controlled the rate of cooling to be 1°C per minute in a -80 °C freezer.  
After a minimum of 4 hours the vials were then transferred into a liquid nitrogen dewar 
(temperature of -196 °C).     
 Thawing cells 
Cryovials were removed from liquid nitrogen using appropriate safety precautions and the 
cells in the DMSO mixture were quickly thawed in a 37 °C water bath.  Once thawed, the cell 
solution was diluted in cell culture medium and centrifuged for 5 mins at 1200 rpm.  The 
supernatant was discarded and the cellular pellet re-suspended in cell culture medium.    
 Cancer cell line culture 
Chapter 2:Developing Tissue Engineering Models of Oral Cancer 
 
79 
 
Cells were cultured in T75 tissue culture flasks until 80% confluent.  Cell culture medium was 
replenished ever 2-3 days. Cells were used up to 15 passages after the passage they were 
purchased, or until their behaviour (eg. speed of growth) changed.  Stocks of low passage 
number were kept in liquid nitrogen.  Cells were periodically tested for mycoplasma infection 
and any infected cells were discarded.    
 Primary Cell Extraction from Oral Biopsies 
 Materials and preparation 
 “Difco trypsin”  
Difco trypsin was prepared at a concentration of 0.1% (w/v).  0.5g of Difco Trypsin powder 
from Difco, West Molesey, Surrey, UK was dissolved in 500ml of PBS with 0.5g of D-
glucose.  The pH of the solution was adjusted to pH 7.4 with 2M NaOH.  The solution was 
filtered sterilised using a filter with 0.22µm pores, divided into 10ml aliquots and stored at -
20°C.   Difco trypsin solution was supplemented with 100 IU ml
-1 
penicillin, 100 mg ml 
-
1 
streptomycin and 0.625 µg ml 
-1
 amphotericin B prior to use. 
Syringes and filters 
Sterile syringes and filters for sterilisation were purchased from BD Biosciences, Oxford, UK.  
The pore size of these filters was 0.22µm enabling them to remove contaminating bacteria or 
fungi.  
Collagenase A  
Collagenase A extracted from Chlostridium histolyticum (Sigma Aldrich, Dorset, UK) was 
dissolved in Dulbecco‟s Modified Eagle‟s Medium (DMEM) supplemented with 10% Fetal 
Calf Serum (FCS) and stored at -20°C.  The final concentration of collagenase was 0.05% 
(w/v). 
Scalpel blades 
Scalpel handles and blades, size 22, were purchased from Swann-Morton, Sheffield, UK.  
 Surgical removal of biopsy 
Buccal or gingival tissue was obtained from consenting patients during routine dental surgeries 
(Sheffield Research Ethics Committee approval (Ref: 07/H1309/105)) or from willing 
volunteers by a dentist.  Once removed the biopsy, typically around 5-10mm
2
, was collected in 
a sterile tube containing PBS supplemented with 100 IU ml
-1 
penicillin, 100 mg ml 
-
1 
streptomycin and 0.625 µg ml 
-1
 amphotericin B and stored at 4°C before processing. 
 Preparation of Irradiated Feeder Layer 
XCELLentis 3T3 murine fibroblast cells (XCELLentis, Gent, Belgium) were used as a feeder 
layer for proliferating keratinocytes.  These mouse cells were expanded first in regular cell 
culture flasks and subsequently using a CellSTACK® (Corning Life Sciences Inc, New York, 
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USA).  The CellSTACK® was used to obtain large numbers of cells as this had a surface area 
of 6,360cm
2
. Once the cell stack was 80% confluent cells were passaged as described in the 
previous section and put into a sterile sealed 25ml universal tube (in fresh cell culture 
medium).  The cells were exposed to 60 Grays using a cobalt-60 source irradiator to arrest the 
3T3 cell growth.  Once irradiated the cells, referred to as irradiated 3T3s (i3T3) were 
cryopreserved as described on page 78.  Cells were resurrected immediately prior to use.  
 Isolation of primary normal oral keratinocytes 
Oral biopsies were incubated overnight at 4°C in 0.1% w/v Difco trypsin. The epithelium was 
then peeled from the connective tissue component.  Keratinocytes were gently scraped from 
the underside of the epithelium and the top side of the connective tissue layer using a scalpel in 
a Petri dish containing the Difco trypsin solution. The large lumps of tissue remaining were 
removed and stored in PBS supplemented with 100 i.u./ml
 
penicillin, 100 mg/ml 
 
streptomycin 
and 0.625 µg/ml amphotericin B for subsequent fibroblast extraction. The scraped cells and 
trypsin solution was centrifuged at 1200 rpm for 5 minutes.  The cellular pellet was 
resuspended in Green‟s medium (Table 2.1 Green‟s medium on page 74) and seeded onto an 
irradiated mouse fibroblast (i3T3) feeder layer in a T75 cell culture flask.    
 Normal Oral Keratinocyte Culture 
NOKs were cultured according to the method of Rheinwald and Green (Rheinwald and Green 
1975).   Briefly, cells were cultured on an irradiated mouse fibroblast (i3T3) feeder layer in 
Green‟s media.   Cells were cultured until 80% confluent and cell culture medium was 
replenished every 2-3 days.   NOK cells could be used up to and including passage 3 however, 
after this the cells lost their ability to adhere to cell culture surfaces and could no longer be 
cultured. 
For NOK cell culture the i3T3 feeder layer of cells was detached using 0.02% EDTA solution 
before passaging NOK cells.  NOK were seeded with a fresh i3T3 feeder layer in the new cell 
culture flask. 
 Isolation of primary normal oral fibroblasts 
Normal oral fibroblasts (NOF) were isolated from the connective tissue of the biopsy.  The 
connective tissue, remaining after NOK isolation, was finely minced using a surgical scalpel 
and incubated at 37 °C in a 5% CO2 humidified incubator for 14-18 hours in 10 mL of 0.5% 
collagenase A.  After incubation the collagenase A containing minced connective tissue was 
centrifuged at 2000 rpm for 10 minutes.  The supernatant was carefully removed using a 
pipette and the cellular pellet (including undigested tissue) was re-suspended in 10% DMEM 
(Table 2.2 10% DMEM medium).   The cell suspension was seeded into a T25 cell culture 
flask with vented lid.   
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 Normal Oral Fibroblast Culture 
NOF cells could be cultured up to and including passage 8.  After passage 8 the cell behaviour 
changed and were no longer used for experiments.  
 Culturing tissue engineered oral mucosa 
 Preparation of De-epidermised dermis (DED) 
Glycerol treated cadaveric skin was obtained from the Euro Skin Bank (Beverwijk 
Netherlands) and was stored at 4°C until in required.   Skin was washed thoroughly in pre-
warmed PBS for two days until all the glycerol had been removed and the skin cells were 
removed by dehydrating the skin in 1 M sodium chloride for 24 hours at 37 °C. The epithelium 
was then gently scraped from the surface of the skin and the skin then washed 3 times in PBS.  
This method removes the epidermis but retained basal membrane proteins such as collagen IV 
and laminin which aided the subsequent attachment of NOK in the 3D culture.  The processed 
Euroskin, here referred to as de-epidermised dermis (DED), was stored at 4°C in Green‟s 
media.  This process was very effective at removing cellular material from the skin but 
retaining structural integrity and basement membrane antigens.  Figure 2.1 shows the 
appearance of the DED post processing demonstrating the extent of the de-cellularisation.  
 
 
Figure 2.1 H&E stained section of Euroskin post processing.  
Scale bar 200µm. 
 Culturing tissue engineered oral mucosa (TEOM) 
Processed DED was cut into 2cm x 2cm squares and placed into 6 well plates submerged in 
Green‟s media.  Chamfered surgical stainless steel rings with an internal diameter of 8mm 
were pushed onto the DED to provide a liquid tight seal. 1mL of cell suspension containing 5 
x10
5
 NOKs and 5x10
5
 NOFs in Green‟s media was added into the ring.  Green‟s media was 
also added outside the ring to stop the cell solution leaking out. Half the media inside the ring 
was changed each day.  On day 3 the DED with cells attached was brought to an air liquid 
interface using a stainless steel grid.  The underside of the model was in contact with Green‟s 
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media while the top was exposed to the air to encourage epithelial stratification. Models were 
cultured for 10-14 days at the air-liquid interface (ALI) (Figure 2.2). 
 
 
Figure 2.2 Method of culturing 3D TEOM 
 Culturing 3D models with OSCC cell lines 
Eight different cell lines were cultured in 3D tissue engineered models to investigate the 
pathological appearance of different cell lines when cultured in three dimensions.  These 
models were cultured using a very similar method to that described for TEOM.  The Euroskin 
was processed in the same way as described previously.  NOF (5 x 10
5
) and oral cancer cells 
(2.5 x 10
5
) were seeded onto processed Euroskin (DED) inside a surgical steel ring for 3 days 
before the models were raised to an ALI.  Models were cultured in the cell culture medium 
corresponding to the cell line used.  For details of the cell culture medium used for each cell 
line see page 72.  Models were cultured for 7, 14 and 21 days before being fixed and processed 
for histological analysis.    
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 Analysis of tissue engineered oral mucosa and 3D 
models of OSCC 
 Materials and preparation 
3.7 % formaldehyde 
37% paraformaldehyde was purchased from (Sigma Aldrich, Dorset, UK) and was diluted 1 in 
10 in PBS.   
3% hydrogen peroxide in PSB 
A 3% hydrogen peroxide solution was made by adding 3ml of hydrogen peroxide to 97ml of 
PBS. 
1M Tri sodium citrate buffer (pH6) 
2.94g of tri-sodium citrate (dehydrate) was added to 1 litre of distilled water and mixed to 
dissolve. The pH was the adjusted to pH 6.0 using 1M HCl.  0.5ml of Tween20 was then 
added to the mixture which could be stored for up to 3 months at room temperature.   
Monoclonal primary antibodies  
 
Primary antibody Clone Supplier Dilution in PBS 
Collagen IV 94 Sigma Aldrich, Dorset, UK 1:500 
AE1/AE3 AE1/AE3 Dako, Copenhagen, Denmark 1:100 
Ki67 MM1 Dako, Copenhagen, Denmark 1:50 
Table 2.7 
Primary antibodies, suppliers and dilutions. 
 
Secondary antibody 
Vectastain® Elite ABC kit (Vector labs, Peterborough, UK) was made up as per the 
manufacturer‟s instructions. First a blocking serum was produced with serum from horse.  
Three drops of horse serum was added to 10ml of buffer in the mixing bottle provided. Next 
the Biotinylated secondary antibody was made up.  Three drops of normal blocking serum 
stock was added to 10ml of buffer in another mixing bottle with 1 drop of biotinylated 
secondary antibody stock.   
Avidin and Biotinylated horseradish peroxidase macromolecular Complex (ABC) 
The Vectastain® Elite ABC solution was made up by adding 2 drops of reagent A to 5ml of 
buffer in a large mixing bottle. Next 2 drops of reagent B were added to the same bottle and 
this was mixed before being left to stand for 30 minutes.    
3, 3’-diaminobenzidine   
3, 3‟-diaminobenzidine (DAB) kit (Vector labs, Peterborough, UK) was prepared immediately 
prior to use according to the manufacturers instructions.  Two drops of buffer stock solution 
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were added to 5ml of distilled water and mixed well.  Next 4 drops of DAB stock solution was 
added and mixed followed by 2 drops of hydrogen peroxide solution.   
 Fixing Tissue Engineered Models 
Samples were washed in PBS and placed directly into 3.7% formaldehyde for at least 24 hours 
at room temperature prior to histological processing. 
 Histological analysis of tissue engineered oral 
mucosa 
Samples were processed overnight using a Leica TP1020 benchtop tissue processor (Leica 
microsystems, Milton Keynes, UK). Samples were processed through the following solutions 
(Table 2.8 Histological processing schedule). 
Solution Time exposed to solution 
10% neutral buffered formalin 1 hour 
70% alcohol 1 hour 
70% alcohol 1 hour 
90% alcohol 1 hour 
90% alcohol 1 hour 
Absolute alcohol 1 hour 
Absolute alcohol 1 hour 
Absolute alcohol 1 hour 
Xylene 1 hour 30 mins 
Xylene 1 hour 30 mins 
Paraffin Wax I 2 hours 
Paraffin Wax II 2 hours 
Table 2.8 Histological processing schedule 
 
Samples were then bisected and embedded in molten paraffin wax using a Leica EG1160 
embedding center, dispenser + hot plate (Leica microsystems, Milton Keynes, UK).  Samples 
were embedded perpendicular to the bottom surface of the mould so the samples could be cut 
in the right orientation.   Samples embedded in wax blocks were next cooled on ice blocks for 
at least 1 hour prior to sectioning using a Leica RM2235 microtome (Leica microsystems, 
Chapter 2:Developing Tissue Engineering Models of Oral Cancer 
 
85 
 
Milton Keynes, UK) with microtome blades, S35 type (Feather, Japan).  Blocks were trimmed 
using initial slices of 10µm thickness until the sample was fully exposed on the surface of the 
wax block.  Next sections of 5µm thickness were cut and immediately transferred to a water 
bath set at 38 °C. This allowed the sample to flatten out before samples were mounted onto 
SuperFrost® Plus slides (VWR International, Lutterworth, UK) and dried under a desk lamp.   
Samples were stained with hematoxylin and eosin using a Shandon linear staining machine 
(Department of Pathology, School of Clinical Dentistry, Sheffield, UK) Table 2.9).   
 
Solution Purpose 
Heat  To remove any water from the slide and ensure the 
section is fully adhered to the slide 
Xylene (times 3) To remove the wax from the section (leaving the 
tissue section adhered to the slide) 
Absolute alcohol  
 
To gradually rehydrate the section 
Absolute alcohol 
70% alcohol 
Running tap water 
Harris’s Haematoxylin (Shandon) 
(times 5) 
To stain basophilic parts of the section (cell nuclei) 
Running tap water (times 2) To wash off excess Haematoxylin 
0.1% HCl in 70 % alcohol To differentiate the sample helping the sample to 
take up the red eosin stain 
Running tap water To wash off acidic alcohol 
Scott’s tap water substitute To increase the “blueing up” of the heaomtoxylin 
stain 
Running tap water To wash salt from Scott‟s tap water substitute off 
Eosin Y-aqueous stain (Shandon) To stain eosinophilic parts of the section (inc. 
cytoplasmic proteins, collagen and keratin)  
Eosin Y-aqueous stain (Shandon) 
Running tap water To wash off excess eosin stain 
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95 % alcohol  
 
To gradually dehydrate the sample  
Absolute alcohol (times 4) 
50:50 absolute alcohol: xylene 
Xylene (times 2) 
Table 2.9 Staining procedure 
 
Slides were mounted with DPX (Dibutyl phthalate, Polystyrene, Xylene) and coverslips placed 
on the top of the sample.  The DPX on the slides were left to set before being imaged using an 
Olympus BX51 microscope and Colour view IIIu camera with associated Cell^D software 
(Olympus soft imaging solutions, GmbH, Münster, Germany). 
 Immuno histochemistry  
Immunohistochemistry was performed on 5µm sections of paraffin embedded samples 
mounted on SuperFrost® Plus slides (VWR International, Lutterworth, UK).  The same 
method was used for all three antibodies except the dilutions of the three different antibodies 
(see Table 2.7). Slides were de-waxed in xylene and rehydrated through a series of ethanol 
dilutions. Endogenous peroxidise activity was next neutralised with 3% hydrogen peroxide in 
PBS for 20 mins.  Slides were then washed in stirring PBS for 5 minutes.   
Antigen retrieval was achieved using a sodium citrate buffer.  Slides were submerged in pre 
warmed 0.01 M Tri sodium citrate buffer (pH 6) and the slides in sodium citrate buffer were 
microwaved on medium heat for 8 minutes and then washed in stirring tap water for 5 minutes.  
Sections were blocked for non-specific binding using the blocking serum mixture from the 
Vectastain® elite ABC kit, for 20 minutes at room temperature.   
The primary antibody, prepared as described in table Table 2.7, was dropped onto the slides, 
ensuring the whole section was covered and the slides were incubated for 1 hour at room 
temperature.  Slides were washed for 5 minutes in stirring PBS before the diluted biotinylated 
secondary antibody solution was added to the slide.  Slides were incubated in humidified 37°C 
5% CO2 incubator for 30 minutes with the secondary antibody.  Slides were again washed in 
stirring PBS for 5 minutes.  Slides were then incubated with the Vectastain® Elite ABC 
reagent mixture, made up as described above, for 30 minutes and washed for 5 minutes in 
stirring PBS. The DAB solution, was mixed well before being added to slides for between 2 
and 10 minutes.  Colour development was observed under a light microscope to ensure a good 
staining intensity was obtained.    Slides were washed and counter-stained with haematoxylin 
using the Shandon automatic stainer described in (Table 2.9).  Slides were added to the stainer 
at the water step immediately prior to the haemotoxylin stain.  The eosin staining 
compartments were blocked and slides subject to immunohistochemistry staining were not 
Chapter 2:Developing Tissue Engineering Models of Oral Cancer 
 
87 
 
stained with eosin. Slides were mounted with coverslips using DPX mount and imaged using 
an Olympus BX51 microscope and Colour view IIIu camera with associated Cell^D software 
(Olympus soft imaging solutions, GmbH, Münster, Germany). 
 Culturing multi-cellular tumour spheroids  
 Coating of agarose plates 
An agarose mixture of 1.5% agarose (type V) in RPMI (for FaDu cells) or DMEM (for other 
cell lines) (w/v) was autoclaved to sterilise.  The autoclaved media and agarose mix was stored 
at room temperature for up to 3 months before use.  The agarose mixture was warmed prior to 
use using a microwave until it had completely melted.  Agarose was poured into a Petri dish 
and 100µl of agarose and media was pipetted into 96 well plates (Costar, Corning Life 
sciences, MA, USA) using a multichannel pipette.  Care was taken not to get bubbles in the 
wells as this affected MCTS formation and growth.   Agarose was allowed to cool and set 
before storing upside down in the fridge for up to 6 months.  Before culturing spheroids excess 
condensation on the lid of the 96 well plate was removed using Azo™ sterilising wipes 
(Synergy Health, Swindon, UK).   
 Culture of multi-cellular tumour spheroids (MCTS) 
The MCTS were grown using the liquid over-lay method first described in (Carlsson and 
Yuhas 1984).  Cancer cells were cultured in cell culture flasks until 80% confluence.  Cells 
were enzymatically detached from the flasks as described on page 78.  Cells were then re-
suspended in cell culture medium (specific for cell type) and counted.  The volume of the cell 
suspension was adjusted with cell culture media to give a concentration of 1.2 x10
5
 cells/ml.  
100µl of the cell suspension was pipetted into each well using a multi-channel pipette resulting 
in 1.2 x 10
4
 cell per well of the 96 well plate.  This procedure was the same for all cell types as 
they were tested for MCTS forming behaviour, except different media for each cell type was 
used (all media and cell types listed on pages 73-77).   Unless otherwise stated all MCTS used 
in subsequent chapters were created from the FaDu cell line.   
Cell culture media was replenished every 3-4 days when in culture by adding 100µl of fresh 
media and then removing and discarding 100µl of media per well.  Care was taken not to 
aspirate spheroids up into the pipette tip during this process.   
 Culture of MCTS with Fibroblasts 
Normal oral fibroblasts were added to MCTS cultures to test if they could promote spheroid 
formation.  10 ml of cancer cell suspension (1.2 x10
5
 cells/ml) was mixed with 2.5 ml of NOF 
cells (1.2 x10
5
 cells/ml).  125µl of this solution was added to each well of an agarose coated 96 
well plate to give a final concentration of 1.2x 10
4
 cancer cells and 3x10
3
 NOFs per well.   
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 Methods for characterising MCTS 
 Materials 
Formalin agarose (0.02g/ml) 
2g of Agarose (Sigma Aldrich, Dorset, UK) was dissolved in 90 ml of distilled water and 
mixed with 10 ml of 40% formaldehyde (Sigma Aldrich, Dorset, UK). 
Hypoxyprobe ™-1 
Hypoxyprobe™-1 (Chemicon, Nuevo León, Mexico) contains pimonidazole hydrochloride 
which binds selectively to oxygen starved cells. 100mg of Hypoxyprobe™-1 was dissolved in 
1ml PBS (to give a 340mM stock solution) and was stored at -20°C in 30μl aliquots.  
Immediately prior to use the stock solution was diluted 1 in 200 in pre-warmed serum free 
medium.  
Dako blocking solution  
Used as purchased from Dako UK Ltd., Cambridgeshire, UK.  Stored at 4°C. 
Anti-hypoxyprobe monoclonal primary anti-body 
Stored at 4°C. 
Bovine Serum Albumin (BSA) 
From Sigma Aldrich, Dorset, UK and stored at room temperature. 
Brij 35 
A surfactant powder purchased from Sigma Aldrich, Dorset, UK.  Dissolved in PBS to give 
final concentration of 0.2%.  
Texas red labelled secondary anti-body 
Stored at 4°C. 
VECTASHIELD Mounting Medium with DAPI  
From Vector Laboratories, Peterborough, UK. Stored at 4°C.  
 Characterisation of FaDu MCTS 
Images of MCTS were taken on a Zeiss Axiovert 200M light microscope (Carl Zeiss Inc., 
Germany) under bright field and images were taken using in integrated high resolution digital 
camera (AxioCam MRm, Carl Zeiss Inc. Germany) and Axiovision Rel. 4.6 software (Carl 
Zeiss Inc. Germany).  The size of MCTS over time in culture was measured using the 
Axiovision Rel. 4.6 software.  The diameter of at least 5 MCTS per time point was averaged 
and the standard deviation calculated.   
 Histological analysis of MCTS 
MCTS were washed in PBS and fixed in 3.7% formalin for at least 24 hours at room 
temperature.  MCTS in fixative were placed into the bottom of a cryovial.  The fixative was 
removed being careful not to lose MCTS.  100µl of formalin agarose was added to the MCTS 
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in the cryovial.  The agarose was allowed to set before the MCTS in agarose were placed in 
histology cassettes and processed as described on page 84.  Once processed and embedded 
MCTS were sectioned and stained as described on page 84.   
 Biopsies of solid oral cancers 
Many thanks to Dr Adam Jones and Dr Helen Colley for allowing me to use their images of in 
vivo tumours stained for Ki67 and hypoxia.   
 Ki67 
Staining for proliferative cells using Ki67 was performed as described for TEOM models on 
page 86.   
 Hypoxia staining on wax section 
Hypoxia staining on the wax section of tumours was achieved using anti carbonic anhydrase 
IX (Novis Biologicals, Cambridge, UK) used at a 1:1000 dilution.  Immunohistochemistry 
staining was performed as described on page 86. 
 Hypoxia staining on frozen section 
For visualisation of hypoxia within MCTS the MCTS were incubated with Hypoxyprobe™-1 
for 3-4 hours at 37 °C.  10µl of the diluted stock solution was added to each well (which 
contained 100µl).  MCTS were washed in PBS and fixed in 4% paraformaldehyde overnight.  
MCTS were next frozen in OCT freezing medium (VWR, Lutterworth, UK) at -20 °C in 
disposable base moulds (Surgipath, Peterborough, UK) and stored at -80 °C.  8µm sections 
were cut with a Leica Cryostat CM 3050 S (Leica Microsystems, Nussloch, Germany) and 
transferred onto Superfrost slides (VWR, Lutterworth, UK).   Non-specific binding was 
blocked using DAKO blocking serum for 20 minutes at room temperature.  The primary 
antibody was diluted 1 in 50 in PBS with 0.1% BSA.  Slides were incubated with the antibody 
for 1 hour at room temperature.  Slides were then washed twice for 5 minutes with cold PBS 
with 0.2% Brij 35. Next slides were incubated with the secondary antibody for 30-45 minutes 
again at room temperature.  Another washing step (two washes each for 5 minutes in PBS + 
0.2% Brij 35) followed before the slides were mounted using VECTASHIELD Mounting 
Medium with DAPI.  Slides were imaged using a Zeiss Axioplan 2 fluorescent microscope 
(Carl Zeiss Inc. Germany) with a Q-imaging Retiga 1300R camera (QI Imaging, Arizona, 
USA) and Image Pro Plus image software (Media Cybernetics, Inc., MD, USA).  
 Screening of other cells lines for MCTS formation 
It was determined whether a cell aggregate or true MCTS had formed from 5 representative 
images from each plate at each time point over a period of 14 days.  Images were taken 1, 2, 6, 
8 and 14 days after seeding the cells.  Representative images were taken using a Zeiss Axiovert 
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200M light microscope (Carl Zeiss Inc., Germany) with an integrated high resolution digital 
camera (AxioCam MRm, Carl Zeiss Inc. Germany) and Axiovision Rel. 4.6 software (Carl 
Zeiss Inc. Germany). 
2.4 Results 
 Tissue Engineered Oral Mucosa  
 Production of tissue engineered oral mucosa on 
DED 
The tissue engineered oral mucosa (TEOM) used in this project has built on work previously 
done in the MacNeil laboratory by Dr. A. Bullock and Dr S. Bhargava.  The model used 
throughout this project has been modified to improve the model‟s reproducibility and to 
overcome problems with material availability.   The TEOM used here were cultured on an 
acellular skin scaffold processed from glycerol treated cadaveric skin purchased from Euroskin 
Bank (Beverwijk, the Netherlands).  This was used instead of fresh dermis obtained from 
surgery as the supply was more reliable and large pieces of skin from the same patient could be 
obtained improving reproducibility in the thickness and behaviour of the scaffold.  No 
significant difference was seen in models produced on glycerol treated skin compared to fresh 
dermis obtained from surgery.   Cell seeding densities were also increased (compared to the 
original protocol set out in (Bhargava et al., 2004)) in order to improve the reliability of 
models.   
 Epithelium of tissue engineered oral mucosa 
matures over time 
Tissue engineered oral mucosa (TEOM) was cultured using primary human keratinocytes and 
primary human fibroblasts on a acellular skin scaffold.  The length of time the models were 
cultured at air liquid interface affected the thickness of the epithelium and degree of 
stratification (Figure 2.3).  The length of time a model could be kept in culture was very 
dependent on the batch of cells which were used.  The models shown in Figure 2.3 continued 
to grow after 14 days and the epithelium continued to thicken.  However, models cultured with 
cells extracted from other biopsies had lost their epithelium after 21 days in culture.     
 Formation of a differentiated epithelium 
Culturing the TEOM at an ALI produced a stratified epithelium after 7 days in culture (Figure 
2.3).  By 21 days in culture the epithelium was up to 10 cells thick and showed clear signs of 
organisation and differentiation.  Over time in culture the model became more organised and 
the epithelium became thicker.  When the heamotoxylin and eosin (H&E) stained histology 
sections are compared against healthy oral mucosa biopsy (Figure 2.4), similarities between 
the tissue engineered model and the human biopsy are apparent.  Although the TEOM model 
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has a thinner epithelium compared to the biopsy the differentiation pattern which is observed 
in vivo can also be seen in our tissue engineered model (Figure 2.4).  The basal cells are 
densely packed with a high number of nuclei in the basal region of the epithelium. 
Superficially the basal and the supra-basal cells are larger and the nuclei are more dispersed as 
the cells are beginning to differentiate. The most superficial layer contains cells which are 
flattened with very few nuclei.  These cells are terminally differentiated and have produced a 
smooth flat surface to the epithelium.  Both the human biopsy and the TEOM have rete ridges, 
the characteristic rounded appearance of the epithelial connective tissue junction.  The cells of 
the epithelium have differentiated in strata (rather than individual cells), a sign that intra-
cellular signalling has been involved in the evolution of the epithelium.   
 
 
 
Figure 2.3  TEOM cultured from NOK and NOF cells on DED were exposed to ALI for 7, 14 or 
21 days.  Representative images n=5 
Scale bar = 200µm 
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 Immunohistochemical analysis of TEOM compared 
to normal human oral mucosa biopsies 
The TEOM was compared to a healthy oral mucosa biopsy using immunohistochemistry stains 
for collagen IV (a protein found in the basement membrane of oral epithelia), AE1/AE3 (a 
broad spectrum cytokeratin marker) and Ki67 (a cell proliferation marker) (Figure 2.4).   
Staining for collagen IV was used to confirm the presence of the basement membrane protein.   
These proteins are essential for the epithelium to obtain and maintain a strong connection with 
the connective tissue.  The collagen IV staining (brown) on the TEOM was along the 
epithelial-connective tissue junction, as is seen in the human biopsy (Figure 2.4).  The brown 
collagen IV stain showed continuous staining along the junction as well as staining residual 
blood vessel structures in the connective tissue.   
AE1/AE3 is a broad spectrum cytokeratin stain which stains both high molecular weight 
cytokeratins and low molecular weight cytokeratins.  The broad spectrum stain used here 
stained throughout the epithelium with staining in both the TEOM and the human biopsy more 
intense in the basal portion of the epithelium and the most superficial cells (Figure 2.4).  
Therefore, the presence and distribution of cytokeratins between the two samples appears to be 
consistent.   
Ki67 is an immunohistochemistry stain used to detect the protein which is expressed in the 
nucleus of cells during the active part of the cell cycle, during cell proliferation.  The nuclei of 
cells undergoing proliferation stain brown.  In both the TEOM and the human biopsy those 
cells which are most proliferative, according to the Ki67 staining pattern are the basal cells 
(Figure 2.4).  This is what would be expected as cells become less proliferative as they 
differentiate and move superficially in the epithelium.  A high level of staining for Ki67 in 
suprabasal cells would be an indication of the presence of a potentially malignant disorder.  
More cells stained positive for Ki67 in the human biopsy however, this is most likely due to 
the greater number of cells in the human biopsy compared to the TEOM.   
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Figure 2.4 Immunohistochemisty analysis of TEOM and a human oral mucosa biopsy.   
Scale bar = 200µm 
Image adapted from (Colley et al., 2010). 
Histology of models cultured from different OSCC 
cell lines 
All the cell lines tested here produced models with distinct architectural and cytological 
morphology.  The following section presents the appearance of each model and compare the 
features of the models to features seen clinically to determine the ability of our models to 
recreate different stages of cancer and pre-malignancy.  In all of these models normal oral 
fibroblasts were added.  Table 1.1 on page 23 has been used to grade the pathological features.  
Chapter 2:Developing Tissue Engineering Models of Oral Cancer 
94 
 
Particular thanks to Dr. Keith Hunter, consultant oral pathologist at the University of Sheffield 
for his expert opinion and guidance on this part of the project.   
 
 
Figure 2.5  Haematoxylin and Eosin stained histological sections of the DOK cell line 
cultured in three dimensions on DED.  Models were grown at an air liquid interface for 7 
days (A x10 magnification and B x20 magnification), 14 days (C x10 magnification and D x20 
magnification) or 21 days (E x10 magnification and F x20 magnification). Highlighted circle 
in D shows invading cells.  Arrows in E show invaded tumour islands. Scale bar 200µm. n=3 
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Figure 2.6 Haematoxylin and Eosin stained histological sections of the D20 cell line cultured 
in three dimensions on DED.  Models were grown at an air liquid interface for 7 days (A x10 
magnification and B x20 magnification), 14 days (C x10 magnification and D x20 
magnification) or 21 days (E x10 magnification and F x20 magnification). Scale bar 200µm. G 
shows abnormal mitotic figures in model cultured for 14 days (x60 magnification). n=2 
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Figure 2.7 Haematoxylin and Eosin stained histological sections of the D19 cell line cultured 
in three dimensions on DED.  Models were grown at an air liquid interface for 7 days (A x10 
magnification and B x20 magnification), 14 days (C x10 magnification and D x20 
magnification) or 21 days (E x10 magnification and F x20 magnification). Scale bar 200µm. 
n=2. 
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Figure 2.8 Haematoxylin and Eosin stained histological sections of the SCC4 cell line 
cultured in three dimensions on DED.  Models were grown at an air liquid interface for 7 
days (A x10 magnification and B x20 magnification) or 14 days (C x10 magnification and D 
x20 magnification). Arrows in C and D show areas of cell death. Scale bar 200µm. n=2 
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Figure 2.9 Haematoxylin and Eosin stained histological sections of the SCC9 cell line 
cultured in three dimensions on DED.  Models were grown at an air liquid interface for 7 
days (A x10 magnification and B x20 magnification), 14 days (C x10 magnification and D x20 
magnification) or 21 days (E x10 magnification and F x20 magnification). Scale bar 200µm. 
n=2 
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Figure 2.10 Haematoxylin and Eosin stained histological sections of the SCC25 cell line 
cultured in three dimensions on DED.  Models were grown at an air liquid interface for 7 
days (A x10 magnification and B x20 magnification), 14 days (C x10 magnification and D x20 
magnification) or 21 days (E x10 magnification and F x20 magnification). Arrows show 
invaded cell islands. Scale bar 200µm. n=2 
 
 
Chapter 2:Developing Tissue Engineering Models of Oral Cancer 
100 
 
 
Figure 2.11 Haematoxylin and Eosin stained histological sections of the Cal27 cell line 
cultured in three dimensions on DED.  Models were grown at an air liquid interface for 7 
days (A x10 magnification and B x20 magnification), 14 days (C x10 magnification and D x20 
magnification) or 21 days (E x10 magnification and F x20 magnification). Scale bar 200µm. 
n=3 
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Figure 2.12 Haematoxylin and Eosin stained histological sections of the PE/CA-PJ34 cell line 
cultured in three dimensions on DED.  Models were grown at an air liquid interface for 7 
days (A x10 magnification and B x20 magnification), 14 days (C x10 magnification and D x20 
magnification) or 21 days (E x10 magnification and F x20 magnification). Scale bar 200µm. 
n=3 
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Figure 2.13 Haematoxylin and Eosin stained histological sections of the FaDu cell line 
cultured in three dimensions on DED.  Models were grown at an air liquid interface for 7 
days (A x10 magnification and B x20 magnification), 14 days (C x10 magnification and D x20 
magnification) or 21 days (E x10 magnification and F x20 magnification). Arrow in E shows 
area of cell death. Scale bar 200µm. n=3 
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 DOK 
Figure 2.5 A-F show the development of the 3D tissue engineered models resulting from DOK 
cells cultured on an acellular skin scaffold.     After 7 days in culture at ALI the DOK cells had 
formed a multi-layer epithelium of between 2 – 10 cells thick.  There were areas which showed 
signs of cell death and the cells had not differentiated into distinct strata (as was seen with the 
normal cells).   
After 14 days in culture the epithelium was thicker than at 7 days and the strata of the 
epithelium were beginning to show signs of organising themselves. A few of the superficial 
cells were becoming flattened and the cells adjacent to the connective tissue were in some 
cases organising in a pattern seen in normal epithelia.  There were signs of individual cells 
producing keratin rather than strata of cells (a sign of dysplasia) along with nuclear 
pleomorphism throughout the epithelium (an indicator of severe dysplasia or carcinoma in 
situ). There was significant cytological atypia seen in the basal cell which is a feature 
commonly seen in carcinomas (highlighted region of Figure 2.5 D).   
By 21 days in culture the epithelium had a severely dysplastic, carcinoma in situ appearance 
with cytological and architectural abnormalities throughout the epithelium.  These included: 
drop shaped rete peg (bulbous projection into the connective tissue) and keratin pearls (circular 
formations of keratin, stained with haematoxylin pink) in the middle region of the epithelium.  
There are islands of cells within the epithelium which have the appearance of epithelial cell 
invasion.  These cells have a different appearance to fibroblasts in the connective tissue as 
fibroblasts did not cluster in group as the cells seen here did and there is haematoxylin staining 
around the cells (not seen for the fibroblasts).  This could be confirmed using 
immunohistochemistry staining.     
 D20 
The dysplastic D20 cell line was cultured on a skin scaffold and images of the resulting 
histological appearance are shown in Figure 2.6 A-F.  The D20 cells formed an epithelium 
after 7 days in culture at ALI which was between 2 and 6 cells thick.  The epithelium here had 
some signs of stratification and keratin was being produced on the surface of the epithelium. 
The epithelium however, did not appear healthy as there were features of dysplasia present 
including nuclear and cytological abnormalities.  In areas the epithelial connective tissue 
junction had an interesting appearance.  Rather than a smooth junction with an ordered 
arrangement of basal cells the junction had become rough in appearance with small groups of 
cells protruding further into the connective tissue than in other regions.  This is sometimes 
seen clinically and is an indicator of severe dysplasia and invading carcinomas.    
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After 14 days in culture there were drop shaped rete pegs and invaded tumour islands within 
the connective tissue.  The overall structure of the epithelium contained the strata of naturally 
occurring epithelia; basal cells, a prickle cell layer and flattened keratinised cells in the top 
layer.  However, the epithelium was disordered throughout and there was hyperkeratosis 
within the epithelium.  Nuclear pleomorphism and abnormal mitotic figures could be observed.  
Abnormal mitotic figures (such as those see in Figure 2.6 D, highlighted by the arrow) are one 
feature used to grade the severity of dysplasia clinically and are a sign of defects during 
mitosis.  In the case of cancer the rate of mitosis is increased, heightening the chance of 
abnormalities occurring.  These abnormal mitotic figures appear as fragmented multi-ploid 
nuclei.  There was a small amount of epithelial cell invasion with cells growing in islands in 
the connective tissue. 
By 21 days the epithelium had abnormal mitotic figures, signs of cell death and abnormal 
keratin production.  However, in some areas there were still signs of stratification.  The 
epithelial connective tissue junction was still abnormal with cells protruding into the 
connective tissue.  
 D19 
Figure 2.7 A-F show the models which result from culturing the dysplastic cell line D19 on an 
acellular skin scaffold for 7, 14 and 21 days.  After 7 days in culture at an ALI the D19 models 
have formed a multilayer epithelium.  The D19 cells were more mobile than other cells with 
cells growing on top and underneath the model.  The cells appeared to be unhealthy with poor 
cell-cell attachments and the cells did not differentiate.  Abnormal mitotic figures were seen in 
these models, a sign of increased proliferation, resulting in mistakes in the mitotic process.  
The cells seem to be invading into the connective tissue as spindle cells.  In Figure 2.7B there 
are a large number of cells in the connective tissue.  These cells have a spindled appearance 
and seem to have invaded as individual cells rather than forming tumour islands as was seen in 
some other models.  Immunohistochemistry staining would be required to see if these cells are 
have epithelial or mesenchymal markers.  
After 14 days the D19 cells of the epithelium still did not stratify however, there were further 
areas of invasion within the connective tissue.  In some areas the epithelium did not attach well 
to the connective tissue and some regions of epithelial tissue were lost during processing 
leaving fragments of cells on the surface adjacent to the basement membrane.  The epithelium 
has no order and there are signs of keratinisation within the epithelium.   
After 21 days in culture more of the epithelial cells had become detached however, the regions 
which did remain post histological processing, were in some cases, well differentiated with 
some areas appearing relatively normal (Figure 2.7 F). However, the nuclei in these regions 
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had abnormal morphology. The epithelial connective tissue junction was again disrupted and 
abnormal with cells protruding into the connective tissue.   
 SCC4 
The SCC4 cells line, when cultured on DED, grew into a multilayer mass of cells (Figure 2.8).  
There are no signs of stratification and all the cells have the same appearance, size and 
morphology.  In some areas (as seen in Figure 2.8 A) the cells proliferated extensively and 
produced large masses of cells.  There were poor intercellular connections and regions of 
atrophy (Figure 2.8 C and D) after 14 days.   After 21 days in culture the models became 
fragile and the epithelium became completely dissociated from the connective tissue during 
processing.  The appearance of these models is not one which is seen clinically.  
 SCC9 
SCC9 cells cultured for 7 days on acellular skin showed some signs of differentiation (Figure 
2.9).  The cells of the epithelium were keratinised towards the surface and the keratin formed 
in bands associated with many cells rather than single cell keratinisation as was seen in other 
models. Despite this the epithelium did still have signs of dysplasia with abnormal mitotic 
figures and irregular cell morphology throughout the epithelium.  
By 14 days in culture there were areas of clear differentiation however, other areas showed 
little or no differentiation.  The cells appear in two distinct layers the densely packed nucleated 
cells basally and the keratinised layer of cells superficially.  The basal cells had nuclear 
pleomorphism, the epithelial connective tissue junction was irregular and the epithelium 
protruded into the connective tissue in places.  The keratinised cells on the top of the 
epithelium had very small nuclei. These cells had not produced keratin bands and it appeared 
the keratinisation resulted from single cells rather than strata of cells (a sign of dysplasia).    
By 21 days the epithelium was less defined than before and the strata were more disorganised.  
There were signs of cell death and a cell layer growing on top of the keratinised region of the 
superficial epithelium (a feature not seen clinically).   
 SCC25 
Figure 2.10 shows the development of the SCC25 model cultured over time.  After 7 days in 
culture the SCC25 cells were starting to form a thin but dysplastic epithelium.  The basal cell 
layer was not well defined and there were some signs of basal cell keratinisation. The 
epithelium was between 2 and 6 cells thick with signs of abnormal mitotic figures.   
After 14 days in culture the cells were beginning to organise into the strata of epithelia.  The 
basal cells were well organised in some areas and a prickle cell layer could be observed 
superficial to the basal cell layer.  This differentiation was more normal looking than in some 
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models however, the pattern of dysplasia observed here is not one observed clinically.  There 
was individual cell keratinisation, rather than regions of cells forming keratin together. This 
unusual distribution of keratin exaggerated the abnormality of the tissue which was beginning 
to stratify and organise into distinct layers of an epithelium.  The SCC25 cells here appeared 
relatively large and the cells had large nuclei suggesting these cells were very active.  The 
models in Figure 2.10 C and E showed some signs of invasion (see arrows) with epithelial 
islands forming in the connective tissue.   
By 21 days in culture the basal cells remained fairly organised in areas while the rest of the 
epithelium became more abnormal with keratin pearls, keratinisation within the epithelium and 
significant nuclear pleomorphism.   
 Cal27 
The Cal27 cells produced models which were most comparable to the appearance of clinically 
occurring dysplasia and carcinoma in situ (Figure 2.11).   After 7 days in culture the 
epithelium was well differentiated with a well defined basal cell layer.  The differentiation 
occurred in regions and strata of the epithelium rather than in individual cells indicating some 
cell-cell interactions.  There were epithelial islands within the connective tissue suggesting 
invasion of the OSCC into the connective tissue.   
The models cultured for 14 days were highly keratinised on the surface.  This high level of 
keratinisation is commonly seen on the surface of dysplastic tissues clinically.  Figure 2.11 C 
shows the organised differentiation remaining in areas however, in other places this was 
disrupted by the extensive keratinisation.  
After 21 days in culture the appearance of the histology is less like dysplastic lesions seen 
clinically as cells had begun to grown over the top of the keratinised areas and the 
differentiation was mostly lost. This model has the appearance of a squamous cell carcinoma 
in situ with some signs of invasion as early as 7 days at ALI.   
 PE/CA-PJ34 
The models produced by culturing the PE/CA-PJ34 cell line showed little differentiation after 
7 days in culture (Figure 2.12).  The nuclei were a similar size throughout the epithelium and 
there was no difference in appearance between the top and bottom of the epithelium.  There 
was a small amount of keratin produced however, not superficially in bands as would be seen 
in naturally occurring healthy tissue. Hyperkeratisation such as this is a marker of dysplasia. 
After 14 days in culture the cells were beginning to organise into differentiated layers. The 
basal cells had formed an ordered basal cell layer and some keratin had been produced on the 
most superficial surface.  The epithelium was still disordered though, for example there were 
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keratin pearls which had become incorporated into the mid region of the epithelium in Figure 
2.12 D.   
After 21 days in culture the differentiation still did not have an appearance comparable to 
clinically occurring lesion.  In many areas the cell nuclei were of equal size throughout the 
epithelium and the keratin did not form in flattened bands but rather all around individual cells.  
The model showed signs of invasion with epithelial cells present in the connective tissue and 
protrusions from the epithelium into the connective tissue at points along the basement 
membrane.     
 FaDu 
When grown in 3D the FaDu cell line showed no signs of differentiating but instead formed a 
multilayer homogenous epithelium (Figure 2.13).  There are signs of cell death, apoptosis and 
necrosis, at all three time points.  The cells did not attach well to the connective tissue and in 
some cases the epithelium detached entirely from the connective tissue during processing for 
histological analysis.  After 14 and 21 days there was a large amount of cell death (see arrows 
on Figure 2.13 E and F).  If this level of cell death was seen clinically it would be indicative of 
a highly aggressive and invasive cancer however, this would not normally be observed in the 
epithelium but rather in deeply invaded regions of cancerous tissue.   
  
 Spheroid formation 
The definition for a spheroid or a MCTS is not consistent in the literature (Hirschhaeuser et al., 
2010) therefore I will define the term spheroid for use in this project.  A spheroid is a mass of 
cells which when cultured on a non-adherent surface form a spherical solid mass with a well 
defined border. Cells within the mass are indistinguishable from one another and some of these 
spheroids expand over time whereas others do not.  Spheroids have strong intracellular 
junctions and good integrity allowing them to be handled with a Pasteur pipette.  In contrast to 
spheroids some cells form aggregates when cultured using the liquid overlay method (Figure 
2.14).  These aggregates appear as a clump of cells, the border is not well defined and 
individual cells within the mass can be determined.  Aggregates usually fall apart when 
handled and are often surrounded by cells not incorporated into the aggregate.   
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Figure 2.14 Comparison of spheroids and aggregates imaged using light microscopy. 
Left hand image shows a spheroid (also called MCTS), image on the right shows an 
aggregate. Scale bar = 400µm 
 
FaDu MCTSFigure 2.15 shows the appearance of FaDu cells cultured on agarose coated plates 
over 21 days in culture.  These cells formed a solid mass of cells after 24 hours.  Very few 
cells could be seen outside the distinct border of the solid mass and individual cells within the 
spheroid could not be distinguished using light microscopy.  This mass of cells became denser 
over time and by day 6 the spheroid appeared black when imaged using phase contrast light 
microscopy.  The MCTS formed from FaDu cells continued to grow in culture over 21 days. 
After 1 day in culture the MCTS had an average diameter of 840 µm, this increased almost 
linearly over the subsequent 14 days and reached a diameter of over 1200 µm after 21 days 
(Figure 2.15).  As the spheroids became larger the size became more varied.  
 FaDu MCTS compared to in vivo tumours 
To validate the MCTS model of solid expanding tumours FaDu MCTS were compared to 
naturally occurring solid oral cancers (Figure 2.16).  Proliferation, hypoxia and cell death were 
compared using immunohistochemistry.  Ki67 staining showed the most proliferative cells 
(brown nuclei) were found in the peripheral cells.  The distribution of Ki67 positive cells was 
similar in our model and in the cancer biopsy.  Hypoxia is a common feature of solid tumours 
as oxygen diffusion is not sufficient to reach the central cell distant from the blood supply.  
The red staining highlights those cells which are oxygen starved.  In both in vivo and in vitro 
the cells in the central region are hypoxic.  Distance from the blood supply not only leads to 
hypoxia but also leads to cell death in vivo as there is an accumulation of waste products and a 
lack of cell nutrients.  The H&E images show the central region is necrotic, there is a much 
lower density of nuclei and reduced eosin staining in the centre, demonstrating a lack of 
cytoplasmic proteins.  
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Figure 2.15 Representative images of MCTS cultured from the FaDu cell line.   
Growth curve of MCTS cultured over 21 days.  Scale bar = 400µm.  Error bars = s.d. n=5 
 
 
Chapter 2:Developing Tissue Engineering Models of Oral Cancer 
110 
 
 
Figure 2.16 Comparing MCTS cultured from FaDu cells to clinical tumours seen in vivo.  
Proliferation measure using Ki67 immunohistochemistry marker. Pink region (in vivo), 
red region (in vitro) show areas of low oxygen tension. Necrosis shown using 
haematoxylin and eosin staining.  Scale bar = 200µm. 
 
 Which oral cancer cell lines are able to form MCTS 
in vitro? 
The FaDu MCTS model is now well established in our laboratory.  For drug screening and 
other applications it would be beneficial to have a larger catalogue of oral MCTS comprised 
from different OSCC cell lines.  Therefore, a number of different cells lines were tested for 
their ability to form solid expanding tumours in vitro including D19, D20, DOK, SCC4, SCC9, 
SCC25, Cal27, PE/CA-PJ34, and the primary NOK and NOF cells.  Cells were cultured using 
the liquid overlay method in cell culture media specific for that cell type.  Figure 2.17 shows 
the appearance of each of the spheroids formed from each cell line over time.  All images were 
taken using x5 magnification.   
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Figure 2.17  Screening of different cell types to test their ability to produce solid expanding 
MCTS after 14 days in culture.   
Scale bar =  400µm. n=3 
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 D19 
These cells formed aggregates which compacted over time and resulted in a small aggregate 
with a large amount of cells surrounding the aggregate after 14 days.  The cells within the 
aggregate were always distinguishable and the border of the aggregate was rough and 
irregular.  
 D20 
The D20 cells also formed aggregates with a large amount of cells surrounding the aggregate.  
These aggregates broke apart over the two weeks they were in culture and the aggregates were 
irregularly shaped.   
 DOK 
The dysplastic cell line DOK formed spheroids after 24 hours.  These spheroids had very few 
cells surrounding them and an average diameter of 610µm.  Over time these spheroids reduced 
in diameter and resulted in spheroids with a diameter of ~440µm after 14 days in culture.  
Over time the spheroids lost structural integrity, fell apart and resulted in individual cells and a 
large amount of cell debris surrounding the spheroids.  
 SCC4 
SCC4 cells did not form spheroids.  After 24 hours a monolayer could be seen growing on the 
agarose coated well.  Over time the cells proliferated and the monolayer started to clump and 
the cells appeared to grow on top of one another as they became over confluent.   
 SCC9 
These cells appeared to grow as a monolayer on the agarose for the first two days in culture.  
These cell monolayers had very small aggregates (of just a few cells) in the monolayer. After 6 
days in culture this monolayer appeared less healthy and there was a large amount of cell 
debris.  In the centre of the well there was a very small circular mass of cells however, this 
could not be classed as a spheroid.  
 SCC25 
The SCC25 behaved in a very similar way to the SCC9 cells.  They did not form spheroids 
initially; however, after 6 days in culture they did form a small spheroid with average diameter 
200µm but this reduced in size to just 120µm after 14 days in culture.  These spheroids were 
surrounded by a large amount of cells which were not incorporated into the spheroid and there 
was no well defined border of this spheroid.  
 Cal27 
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Cal27 cells formed spheroids after 24 hours when added as suspension to agarose coated wells.  
The diameter of these spheroids was ~ 480µm after 24 hours.  Some cells could be seen 
outside the spheroid and the border of the spheroid was almost as distinct as was seen for the 
FaDu MCTS.  Over time these spheroids reduced in diameter from ~480µm after 1 day to 
~300µm after 14 days in culture.  As time went on more cells could be seen surrounding the 
spheroid rather than within it.  The border also became more “fuzzy” over time when imaged 
using light microscopy.   
 PE/CA-PJ34 
The PE/CA-PJ34 cell line formed spheroids with a large amount of cells surrounding the 
central solid mass.  The diameter of these spheroids reduced from 405µm after 1 day to 300µm 
after 14 days in culture. The border was not well defined. 
 NOK  
The appearance of NOK cells cultured on agarose coated plates was very similar to that of the 
SCC cell lines.  The NOK cells grew as a monolayer on the agarose but over time the cells 
appeared to be dying and there was some cell debris in the well.   
 NOF 
The NOF cells formed spheroids with well defined borders after 24 hours in culture.  These 
MCTS shrank over time in culture.  The formation of spheroids by NOF was variable between 
different batches of NOF cells.  
 Spheroid Formation with Fibroblasts 
Next it was tested whether the addition of primary oral fibroblasts could promote spheroid 
formation.  The resulting appearance is shown in Figure 2.18. 
 D19 + NOF 
When cultured with NOF cells the dysplasic D19 cells formed spheroids with well defined 
borders.  There were very few cells outside the spheroid and the spheroid was dense with cells 
(appearing black under phase contrast light microscopy). These spheroids shrank over time in 
culture and by day 14 there were some cells surrounding the spheroid.  
 D20 + NOF 
The D20 cells initially behaved in a similar way to the D19 cells when cultured with NOF 
cells.  The cell mixture formed a large spheroid with a well defined border, no cells could be 
distinguished within the cell mass.  As the spheroids were cultured for longer in culture more 
and more cells became apparent outside the cell mass and the border of the spheroid appeared 
rough and irregular. 
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 DOK + NOF 
The DOK cells formed larger spheroids after 1 day in culture when they were also cultured 
with NOF cells (most likely due to the higher total cell number and therefore the greater cell 
mass per well).  These spheroids shrank rapidly over time in culture and the border became 
irregular and cells outside the spheroid became visible.  
 SCC4 + NOF 
The SCC4 cells were not greatly affected by the addition of NOF cells (compare Figure 2.18 to 
Figure 2.17).  The cell mass did appear denser on the images but the addition of NOF cells did 
not encourage spheroid formation and the cells still grew as an irregular aggregate. 
 SCC9 + NOF 
Adding NOF to the SCC9 cells caused the cells to form a compact aggregate, as opposed to 
growing as a monolayer.  Over time this aggregate compacted further and after 6 days in 
culture there was a spherical mass with a well defined border.  There was still a large amount 
of cells not contained within the mass of cells and the spheroid did not grow. 
 SCC25 + NOF 
The SCC25 cells, in contrast to the SCC9 cells, grew in a very similar way with or without 
NOF.   
 Cal27 + NOF 
The Cal27 cells also grew in a very similar way with or without the NOF cells.  The only 
difference being the Cal27 cells cultured with NOF cells formed slightly larger MCTS, 
probably due to the higher cell number. 
 PE/CA-PJ34 +NOF 
Culturing the PE/CA-PJ34 cell line with NOF created aggregates which included almost all 
cells in the well (as opposed to the aggregates created without NOF which had a large number 
of cells surrounding them).  The aggregates formed had irregular borders and reduced in size 
over time in culture. 
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Figure 2.18 Cell lines cultured with NOF cells to test their ability to produce solid expanding 
MCTS.  Cancer cells or NOKs were seeded at a density of 12x10 3 cells/ well plus 3x10 3 NOF 
cells/ well of a 96 well plate coated with agarose .  Scale bar =  400µm. n=3 
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 NOK + NOF 
The most dramatic effect from adding NOF cells was the effect these cells had on NOK 
cultured on agarose coated plates.  Instead of growing as a monolayer (NOK monoculture) the 
NOK cells cultured with NOF cells produced large dense aggregates.  These aggregates had an 
irregular border so could not be defined as a spheroid however, this demonstrates the effect 
NOF cells can have on the behaviour of NOK cells. Over time the aggregates reduced 
dramatically in size and many cells were lost from the aggregate.    
2.5 Discussion 
Currently the majority of new technologies and therapies which reach the patient will 
previously have been tested in in vitro cell monolayer experiments and subsequently in animal 
models.  There is a dramatic difference in the behaviour and response of cells in monolayers 
compared to the results seen in animal models.  Monolayer studies look at the way in which 
single cells respond to a compound; however, it is now well know that many cells behave 
differently in 3D culture conditions (Hirschhaeuser et al., 2010).   Three dimensional tissue 
cultures also provide a method by which drug delivery, penetration and distribution within a 
tissue can also be studied.  This is clearly important when investigating the bio-distribution and 
pharmacokinetics of a drug or drug delivery system.  
Animal studies provide a crucial step in the process of novel therapy development.  However, 
animal studies have many disadvantages and any developments which can reduce the need for 
animal studies or better predict results seen in vivo are welcomed by those inside and outside 
the field.   Testing in animals is strictly regulated making the process expensive, time 
consuming and the experiments which can be performed are limited.  It should also be 
remembered that animal models are not always the best predictor of outcome in humans as the 
biology of animals is vastly different to humans.    
 Tissue Engineered Oral Mucosa 
The factors mentioned previously have led to researchers to develop 3D tissue engineered 
models in vitro which can be used as a tool to test novel therapies and diagnostics.  A TEOM 
which can be produced in the laboratory from primary human cells provides researchers with 
an important in vitro tool as well as having uses in tissue regeneration (Bhargava et al., 2004; 
Bhargava et al., 2008).  The model presented here is a 3D model of a healthy human oral 
mucosa.  It has been cultured from normal human oral keratinocytes and normal oral 
fibroblasts from consenting volunteers.  As they originate from human tissue these cells are 
able to model the oral mucosa is a clinically relevant way.  When in culture the models are 
exposed to an air liquid interface which encourages epithelial differentiation and stratification.  
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These culture conditions resulted in stratified epithelium which thickened over time in culture 
(Figure 2.3). 
Some variation was found between models cultured from different cell batches from different 
patients.  This is the major drawback associated with using primary cells. However, the effects 
of this can be minimised by keeping good records of the behaviour of different cell batches.  
Factors including the age of the donor, donor site and condition of the donor site can all affect 
the behaviour of primary cells which are extracted. The alternative to primary cells would be 
to use cell lines which have either been transformed in the laboratory to be immortal (such as 
TURT2 OKF6) or have been isolated from squamous cell carcinomas (such as TR146).  
Although these cells are of oral epithelial origin their behaviour is different to healthy oral 
keratinocytes and this makes the model less physiologically relevant.  The cancer cell line 
TR146 is used in the commercially available Human Oral Epithelium (HOE) model from 
SkinEthic Laboratories.  It is clear from Figure 2.19 that this model does not show the 
stratification seen in the TEOM and does not demonstrate the differential layers of the oral 
epithelium seen in normal oral mucosa.  
 
Figure 2.19 Human Oral Epithelium (HOE) model from Skin Ethic Laboratories (Skin Ethic, 
Lyon, France).  Image reproduced from http://www.skinethic.com/HOE.asp 
 
 
 Fibroblasts 
Unlike the oral epithelium models discussed in chapter 1 the TEOM model produced here 
incorporates a mesenchymal element, primary human oral fibroblasts seeded into a connective 
tissue scaffold. Ralston et al., looked at culturing epidermal keratinocytes with and without 
fibroblasts and found that fibroblasts were required for epithelial cell attachment and 
differentiation (Ralston et al., 1999).  Both keratinocytes and fibroblasts were also required to 
maintain a continuous and well formed basement membrane (Ralston et al., 1999).  It has 
previously been shown in oral models that fibroblasts are essential to promote oral epithelial 
thickening, an effect which was also seen with the addition of KGF (Costea et al., 2003).  
Other features however, could not be induced with the addition of KGF alone.  For example 
co-culture with fibroblasts increased basal cell proliferation and produce a pattern of cell death 
similar to naturally occurring tissues, suggesting that further signals are released from 
fibroblasts which are responsible for these changes (Costea et al., 2003). Elsewhere is has been 
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observed that fibroblasts associated with non-keratinised regions of the oral cavity (such as 
alveolar mucosa) expressed higher levels of elastin compared to gingival fibroblasts, 
highlighting the importance of elastin in the keratinisation of tissues (Hsieh et al., 2010).   
 Connective tissue component 
The model presented here included a connective tissue component.  The acellular skin scaffold 
(EuroSkin Bank, Beverwijk, The Netherlands) provide a very physiologically relevant scaffold 
onto and into which the cells could grow.  Connective tissue from the oral mucosa would be 
optimum however, this tissue is not available in large amounts.  Fibroblasts were able to 
penetrate into the acellular dermal scaffold and keratinocytes adhered well to the upper 
surface, potentially due to the presence of residual basement membrane proteins after de-
cellularisation (Ralston et al., 1999). The protein composition of the acellular skin scaffold is 
similar to naturally occurring oral connective tissue. 
 Cell culture medium 
It has been noted in the literature that the cell culture medium in which models are cultured 
affects the resulting characteristics. For example, a medium low in serum and growth factors 
was used to produce a non-keratinised epithelium model  (Kinikoglu et al., 2009).  Effects of 
culture medium were also observed in (Costea et al., 2005) where three different medium 
types were tested to evaluate their effects on organotypic cultures.  The models developed in 
this project were all cultured in Green‟s medium (Rheinwald and Green 1975) as it is well 
established that this culture medium is optimal for keratinocyte growth and proliferation.  
However, research in this area opens up possible further developments of the model presented 
here.  For example, if non-keratinised areas of the oral cavity were to be modelled, reduced 
serum and growth factors may enable this.   
 Immunohistochemical characterisation 
Here immunohistochemistry was used to validate our model by demonstrating the similarities 
between the TEOM and a normal human oral biopsy.  The immunohistochemistry staining 
confirmed our models possessed key features of an oral epithelium including the presence of 
the basement membrane protein collagen IV, cytokeratin expression and proliferative basal 
cells.  
 3D models of OSCC 
The aim of this experiment was to screen a number of different cell lines to see which, if any, 
would make a good model of OSCC which could be used as a model to test novel cancer 
detection and therapeutic technologies as well as to investigate mechanisms of cancer 
development.  The ideal properties of a model for these applications are reproducibility and 
characteristics of naturally occurring cancers. If models for all stages of oral cancer from mild 
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dysplasia through to invading OSCC (Figure 1.4 on page 22) could be produced it would be an 
incredibly useful tool for in vitro studies into oral cancer progression and therapeutics.  Nine 
different models were cultured, each of which have different appearances and many of which 
show characteristics of naturally occurring tumours and pre-malignant lesions.  
Table 2.10 summarises the features seen in each model and if the appearance was comparable 
to naturally occurring tumours and the clinical grading was shown in the final column. Five 
out of the nine models had appearances which are not typically seen clinically so no clinical 
grading was given.    
 Cell type 
There are a number of factors which determine the morphology and behaviour of a tissue 
engineered model, most importantly the cell types used to culture the model.  Figure 2.5 to 
Figure 2.13 show the diversity of the models created from the oral cell lines tested here.  
Cell availability and a desire to improve the reproducibility of models led us to use cell lines, 
as opposed to primary cells extracted from dysplastic tissues and OSCCs.  It has been shown 
that primary dysplastic keratinocytes from clinical lesions have variable phenotypes when 
cultured in tissue engineered models due to the heterogeneous populations of cells extracted 
from lesions (Gaballah et al., 2008). The reproducibility of in vitro models is important for 
them to become a highly utilised model for testing novel technologies.  Unfortunately, there 
are a large number of factors which affect the behaviour of the model which are not all 
overcome using cancer cell lines.  For example, the passage number of the cells (Gaballah et 
al., 2008) and the exact level of the media in the air liquid interface can affect the resulting 
phenotype.   
It is well established that tumourigenesis is not a result of just epithelial cells but instead 
results from a combination of epithelial cells and the stromal compartment (Elenbaas and 
Weinberg 2001).  In addition to this, previous findings in our laboratories and others have 
shown that if models were cultured without fibroblasts, epithelial cells only formed weak 
attachments to the skin scaffold (Ralston et al., 1999).  Therefore, we cultured all of our 
models with primary oral fibroblasts from healthy patients. Variation between batches of 
fibroblasts from different donors was observed which is not surprising given fibroblasts and 
their released factors affect epithelial cells in many different way including cell adhesion, cell 
proliferation and cell behaviour (Costea et al., 2006).  There is now growing interest in the 
effect fibroblasts extracted from tissues around lesions, areas of dysplasia and carcinomas can 
have on model morphology.  Dysplasia associated fibroblasts have been shown to induce 
morphological changes in normal oral keratinocytes when co-cultured together, which was not 
seen with fibroblasts from healthy tissue (Gaballah et al., 2008).  Dysplasia associated 
fibroblasts also secreted higher levels of hepatocyte growth factor (HGF), expressed matrix 
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metallopeptidase 9 (MMP9) and increased the dysplasia scores of the models cultured with 
them.  
These models studied the level of invasion seen when epithelial dysplastic and cancer cell lines 
were cultured with fibroblasts and a stromal compartment (which retained basement membrane 
antigens from the de-epidermisation process (Ralston et al., 1999)).  Studies looking at the 
invasive behaviour of melanoma cell line (Eves et al., 2003) found the addition of 
keratinocytes and fibroblasts to models cultured with three different strains of melanoma 
altered the invasive behaviour of these cells.  It would therefore be interesting in the future to 
investigate what effect the addition of normal oral keratinocytes would have on these models 
and the invasion of these cell lines.   
Fibroblasts associated with areas of carcinoma in situ are often referred to as myofibroblasts.  
These myofibroblasts behave differently to normal fibroblasts and it is thought their 
transformation to myofibroblasts may be in part due to cytokines released by epithelial tumour 
cells (Elenbaas and Weinberg 2001).  Myofibroblasts release different levels of growth factors 
and ECM proteins aiding the initiation, growth and invasion of epithelial cancers (Elenbaas 
and Weinberg 2001).  It would be interesting to look at whether any of the fibroblasts in our 
models had myofibroblastic properties such as expression of α-smooth muscle actin, smooth 
muscle myosin heavy chain or vimentin. 
 Features of the OSCC models 
The majority of clinically familiar features modelled here are those associated with severe 
dysplasia and carcinoma in situ (see Table 2.10) because the abnormalities were present 
throughout the epithelium.  For some applications it would also be of benefit to be able to 
model mild and moderate dysplasia.  For this the epithelial changes associated with OSCC are 
only observed in the basal 1/3 or 2/3 of the epithelium respectively (see Table 1.1 on page 23).  
It may be possible to model this by culturing the cancer cells lines with healthy primary oral 
keratinocytes or by culturing a healthy oral epithelium and inducing dysplasia using external 
factors.  
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Clinical grade  
FaDu 
 
 
         
SCC4          
 
 
SCC9 
 
 
        Severe dysplasia 
PE/CA-
PJ34 
 
         
D19 
 
 
         
SCC25 
 
 
         
Cal 27 
 
 
        Invasive 
carcinoma 
DOK 
 
 
        Severe 
dysplasia/invasive 
carcinoma 
D20 
 
 
        Invasive 
carcinoma 
Table 2.10 
Features of OSCC models cultured with different cell types.  Shaded square shows features 
present.  Cell lines are arranged in order of increasing abnormalities. 
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Potentially malignant lesions (PML), including leukoplakia, erythroplakia, mild dysplasia and 
moderate dysplasia, are of particular interest to oral medicine specialists.  An ability to predict 
which of these PML was most likely to become malignant could enable earlier detection of 
carcinogenesis and could reduce unnecessary biopsies for those patients who have lesions with 
a very low chance of becoming malignant. Models of PML would have great value in testing 
agents able to prevent malignant transformation, understand the mechanisms which drive 
PMLs to become malignant and to test novel diagnosis technologies aimed to detect PMLs. 
Of the nine models produced here three had the appearance of invasive carcinoma, one had the 
appearance of severe dysplasia and the remaining five models had some features of dysplasia 
and carcinoma however, their overall appearance was not one that is seen clinically (Table 
2.10). Many of the cells cultured in the models appeared to behave as single cells rather than as 
a communicating group of cells.  This is not usually seen clinically and was apparent where 
there was single cell keratinisation and no polarity between the basal and superficial regions of 
the oral epithelium.   
Some models displayed different features as they were cultured for longer periods.  For 
example the SCC9 model cultured for 7 days showed relatively normal stratification however, 
after two weeks in culture the epithelium had a severely dysplastic appearance.  The D19 cells 
were particularly interesting.  The appearance of the model after 7 days in culture was 
significantly different to the model after 21 days in culture (Figure 2.7). This stark difference 
in morphology is most likely due to much of the epithelium becoming detached by 21 days and 
the areas which remained could have resulted from a different sub-population within the D19 
cell line as the D19 cells used here were at a low passage number. 
The D19 cells also showed an interesting feature after 7 days, many spindle like cells had 
invaded into the connective tissue.  The spindle like cell morphology of the D19 cells which 
invaded (Figure 2.7) suggests the cells may have undergone epithelial mesenchymal transition 
(EMT).  In EMT epithelial cells change their characteristics and become more like 
mesenchymal cells.  EMT has been proposed as a factor involved in oral submucous fibrosis as 
well as invasion and progression of OSCC (Yanjia and Xinchun 2007).  Epithelial cells 
undergoing EMT lose epithelial morphology and markers (including cell-cell adhesion and 
cytokeratins) in favour of mesenchymal phenotypes (including cell motility and α- smooth 
muscle actin) (Yanjia and Xinchun 2007).  Signs of EMT have been found to correlate with 
poor prognosis and tumour progression. The presence of EMT could be confirmed by 
immunohistochemistry staining for mesenchymal markers.  It is worth noting that in all of 
these studies normal oral fibroblasts were present.    If EMT could be confirmed this model 
could have value in studying inhibitors of EMT and as a model to study the process by which 
EMT occurs in dysplastic oral cells.   
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The origin of the Cal27 cell line has recently been put into question in (Jiang et al., 2009).  
However, in these experiments the Cal27 cells produced a model of carcinoma in situ which 
behaved in a similar way to a squamous cell carcinoma, suggesting the Cal27 cell line used in 
our laboratory is of squamous cell carcinoma origin rather than adeno-carcinoma as was 
proposed by Jiang et al., (Jiang et al., 2009).  The Cal27 models were the most representative 
of naturally occurring carcinomas.  Although the cells were invasive at all time points the 
severity of dysplasia increased over time as more keratin was produced and the nuclear and 
cytological pleomorphism became more pronounced.     
In some cases the models cultured in this project were also invasive which required the cancer 
cells to cross the basement membrane.  Eves et al., (2003) showed that the presence of a 
basement membrane affected melanoma cell pigmentation, location within the epithelium and 
invasive behaviour demonstrating the importance of including a basement membrane within a 
model of invasion (Eves et al., 2003). 
Eves et al., also demonstrated that there was a dynamic relationship between keratinocytes, 
fibroblasts and melanoma cells which together dictated the invasiveness of melanoma cells 
(Eves et al., 2000; Eves et al., 2003).  Matrix metalloproteinase (MMP) enzyme activity was 
not seen to increase in melanoma cells, however, MMP activity was activated in the adjacent 
epithelial and stromal cells (Eves et al., 2003). This data suggests melanoma cells were able to 
cross the basement membrane by utilising the collagenolytic enzyme activity of the 
surrounding cells.  
Work by Colley et al., has shown invading oral cancer models had disrupted collagen IV 
expression along the basement membrane (personal communication).  An ability to prevent 
tumour invasion clinically would be hugely advantageous to stop tumour metastasis and the 
formation of solid tumours deep within tissues. This model could provide a useful tool to study 
the mechanisms of invasion.  It also enables research to look at whether novel drug 
formulations are able to reach all cancer cells including those which have passed into the 
connective tissue.  
3D models of OSCC have great value in studying the mechanisms involved in tumourigenesis.  
Factors which contribute to the development of this disease can be examined in isolation to 
enable a complete picture of how the disease progresses and provides useful information which 
can be utilised in the development of future treatments and therapies.   
Gaballah et al., investigated the influence of factors in the cell culture medium (EGF and 
KGF) which affected the appearance of models (Gaballah et al., 2008).  They found culturing 
models with EGF increased the level of dysplasia (increasing suprabasal proliferation and 
increasing architectural and cytological features throughout the epithelium) (Gaballah et al., 
2008).  This finding is in agreement with high expression of EGF receptors (EGFR) being 
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linked to poor patient prognosis (Psyrri et al., 2005), indicating the important role of EGF in 
tumour progression. On the contrary, culturing with KGF resulted in models with features 
associated with a healthy epithelium including basal cell proliferation and no epithelial 
hyperplasia (Gaballah et al., 2008).   
 Spheroid formation 
To accurately model oral squamous cell carcinomas it is important to develop a model which 
incorporates as many features of a naturally occurring tumour as possible.  This model also 
needs to be reproducible and it would be advantageous to develop a model which can be 
produced in large quantities for high throughput experiments of novel agents.  The main 
characteristic of solid tumours which can be modelled in 3D tumour spheroid models are the 
distribution of proliferating and necrotic cells (periphery and core respectively), the diffusion 
gradients of nutrients and waste products and the intra-cellular connections (Ivascu and 
Kubbies 2007).   
The MCTS model cultured from the FaDu cell line, derived from a hypo-pharyngeal cancer, is 
a well established model in our laboratory as a model for solid expanding oral cancer tumours.  
The same FaDu MCTS have also recently been employed by Hirschhaeuser et al., to evaluate 
the efficacy of a novel anti-cancer antibody therapeutic (Catumaxomab) (Hirschhaeuser et al., 
2010).   
FaDu MCTS are reproducible and continue to expand over 21 days in culture. Figure 2.15 
shows FaDu spheroids expand from around 840µm in diameter after 24 hours to over 1mm in 
diameter after 21 days.  These MCTS have been compared against solid expanding oral 
cancers seen in vivo (Figure 2.16).  Characteristics of naturally occurring tumours including 
the proliferative outer cells, a hypoxic central region and necrotic cells in the centre were all 
comparable in vitro and in vivo (Figure 2.16). 
The proliferative cells on the periphery of these solid tumour regions are the cells responsible 
for tumour growth.  These cells are adjacent to blood supplies enabling them to obtain the 
nutrients required to proliferate. Therapies which are able to reduce the proliferative ability of 
these cells can slow tumour growth. 
The central regions of tumours above a certain size become hypoxic.  These cells are further 
from the blood supply and have poor oxygen diffusion resulting in a lower oxygen tension in 
this region. From a therapeutic point of view the hypoxic region presents a major challenge to 
treatment as it is this region which is most resistant to radiotherapy (Ljungkvist et al., 2000).  
The central region is not well served by vasculature meaning drugs administered systemically 
have to diffuse a long way though tissues in order to act on these cells.  This means 
chemotherapy is also less effective on these cells.  Regions of hypoxia are often an indicator of 
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poor patient prognosis clinically.  The presence of these features in the MCTS make it an 
especially useful model to study novel therapies which are able to treat these chemo- and 
radio-resistant cells.  
The cells in the very centre of the tumour undergo cell death as waste products accumulate and 
nutrient supply is limited.  The distance from the blood supply is the main driver for this cell 
death.  Both cell death and hypoxia can be seen in the FaDu MCTS model (Figure 2.15Figure 
2.16) making it a clinically relevant model.  This model can be produced quickly and cheaply 
in large numbers making it a useful tool for high throughput screening of novel drugs 
(Friedrich et al., 2009). 
The FaDu MCTS provide us with a very useful tool to study the behaviour of novel 
therapeutics on solid tumours.  A number of different oral cell types were investigated to 
determine if other oral MCTS models could be produced for testing therapeutic technologies.  
Extending the variety of MCTS which are able to be used in in vitro studies should improve 
the predictability of the behaviour of novel compounds in vivo and make testing on MCTS a 
more robust and commercially useful testing method.  
We tested 10 different cell types including dysplastic cell lines (D19, D20 and DOK), OSCC 
cell lines (SCC4, SCC9, SCC25, Cal27 and PE/CA-PJ34) and primary cells (NOK and NOF) 
to see if they were able to spontaneously form MCTS when cultured on a non-adherent agarose 
surface.  Anchorage dependant cells are usually cultured on surfaces on which they are able to 
adhere.  By culturing them on a non-adherent surface these cells are encouraged to adhere to 
one another to grow.  Four of the 10 cell types tested here were able to form spheroids.  The 
DOK, Cal27, PE-CA-PJ34 and NOF cells all produced spherical solid masses of cells with 
well defined borders (Figure 2.17).  In comparison to the FaDu cells (Figure 2.16) these MCTS 
did not expand over time and some of them fell apart in culture.  For a model to be useful in 
the screening of novel chemotherapeutic agents a predictable growth of MCTS is important to 
assess the ability of a compound to slow or retard growth of a tumour.    Other cell types, 
including the OSCC cells and NOK cells, did not show any sign of aggregating or forming 
spheroids when cultured in this way.   
It is well known that only some cell lines have the inherent ability to produce spheroids in 
culture using the liquid overlay method.  Friedrich et al., tested the 60 human epithelial cell 
lines included in the National Cancer Institute Developmental Therapeutics Programme (NCI-
DTP) human tumour cell line screen (Friedrich et al., 2009).  These cell lines make up the 
standardised catalogue of cells for testing novel anti-cancer treatments.  Of these 60 cells, 
which include cells derived from lung, colon, brain, ovary, breast, prostate, and kidney cancers 
as well as leukaemia and melanoma (DTP), only 26 formed MCTS.  Nine of the 26 MCTS did 
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not grow once formed but the maximum diameter of those which did grow was between 500-
1000 µm (Friedrich et al., 2009).  
A number of different techniques have been tested to encourage MCTS production from cell 
lines which do not spontaneously form these spheroids in culture.  The hanging drop method 
has been employed by Kelm et al., to form spheroids from cell lines which did not form MCTS 
using the liquid overlay method (Kelm et al., 2003).   
Here we tested the effect of adding NOF cells to the MCTS culture to test if NOF cells could 
aid MCTS formation.  As discussed previously, it is well known that tumourigenesis is a result 
of the interactions between epithelial and stromal cells.  Stromal cells, namely fibroblasts, also 
produce large amounts of ECM proteins.  Therefore we investigated whether adding NOF to 
the cancer cells would enable MCTS formation from the cell lines which did not form or 
expand previously.   
Some cells showed little or no difference when cultured with or without NOF cells.  These 
cells included SCC4, SCC25 and Cal27.  In other cases the addition of NOF initially 
encouraged spheroid formation however, none of these went on to expand in culture and many 
fell apart when cultured for longer times.  The NOK cells without NOF cells did not aggregate 
at all.  When NOF cells were added the NOK cells did aggregate but these aggregates were not 
spheroids and fell apart over time in culture.  The dysplastic cell lines (D19 and D20) formed 
spheroids when cultured with NOF rather than aggregates.  The other dysplastic cell line 
(DOK) formed larger spheroids when cultured with NOF but still did not expand.  
There are many different factors which influence whether or not cells form MCTS in culture.  
These include the components of the cell culture medium, the method used to initiate MCTS 
formation and various other factors.  These factors include the tissue type from which the cells 
originate, the age and differentiation of the cells as well as the cell density used (de Ridder et 
al., 2000).  Extrinsic factors including temperature, rotation speed (if used) and the ions 
present in the culture medium have all been shown to effect MCTS formation (de Ridder et al., 
2000). The method by which cells are detected from monolayer culture surfaces can effect the 
morphogenic capacity.  de Ridder et al., avoided the use of enzymes such as collagenase and 
trypsin as these alter the surface of the cells, but instead used mechanical detachment (de 
Ridder et al., 2000).   
Ivascu and Kubbies looked at the cell adhesion molecules involved in spheroid formation with 
eight different breast cancer cell lines (Ivascu and Kubbies 2007).  Different cell lines showed 
dependence on different adhesion molecules for spheroid formation and tight cell packing 
demonstrating the complex interactions between many different cell surface proteins which are 
involved in the establishment of 3D cell culture models in vitro.   
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Cell adhesion molecules which were seen to have a role in spheroid formation included E-
cadherin, N-cadherin and the interaction between collagen I and integrin β1. In cells from 
other cancers and fibroblasts, integrin β1-fibronectin interactions have also been identified as 
being important (Salmenpera et al., 2008).  It may be the relative expression of these cell-cell 
interaction proteins and cell-matrix interactions which contribute to whether or not cells 
spontaneously form solid MCTS.  It is well documented that cells behave differently in vitro 
compared to in vivo, therefore the expression of cadherins and integrins is likely to be different 
when cells are cultured in vitro affecting spheroid formation.   Further studies into the 
expression of these integrins and cadherins would be interesting in the cell lines tested here to 
establish whether these are responsible for the pattern of spontaneous MCTS formation. 
Cell-cell interactions and cell-matrix interactions have also been proposed to be involved in 
drug resistance clinically.  These features are seen in MCTS models enabling in vitro research 
into ways to overcome the drug resistance seen in tumours and MCTS (also called the “multi-
cellular resistance” effect) (Green et al., 2004).  This highlights a clear advantage of using 
MCTS over traditional two-dimensional cultures as only MCTS exhibit the “multi-cellular 
resistance” to cytotoxic agents (Green et al., 2004).  Green et al., have also demonstrated that 
by targeting these cell adhesions in multicellular tumours and MCTS it may be possible to 
sensitise them to respond better to anti-cancer agents (Green et al., 2004).    
A number of studies have looked at adding extrinsic and artificial additives and matrices to 
cancer cells to promote MCTS formation. For example Ivascu et al., tested the addition of 
reconstituted basement membrane (rBM) on breast cancer cells to induce MCTS formation 
(Ivascu and Kubbies 2006). However, it is important to remember the addition of external 
factors may alter the behaviour of cell lines, changing cell growth, protein expression and 
potentially altering responses to drugs (Friedrich et al., 2009). 
Some of the cells tested here were able to form MCTS (DOK, Cal27, PE-CA-PJ34 and NOF) 
but these did not expand over time in culture.  This could be due to a number of factors such as 
the effect spherical culture has on the proliferation of the outer most cells and the level of cell 
death experienced in the central core of the MCTS.   
 Correlation between MCTS formation and 
invasion 
All the cell lines tested in this study were genetically and phenotypically distinct from one 
another and this was apparent in the appearance of the 3D models cultured on DED with 
fibroblasts and the appearance of cells when cultured on a non-adherent surface.  
Table 2.11 shows the correlation between spheroid formation (with and without fibroblasts) 
and the invasive behaviour of the cells when cultured on DED with fibroblasts.  There is a 
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strong correlation between those cells which formed spheroids in the presence of fibroblasts 
and those which invaded into the 3D model.  All six cell lines which were tested for spheroid 
formation with fibroblasts and the FaDu cell lines invaded.  Interestingly, the correlation is not 
as strong when comparing those cell lines which formed spheroids without fibroblasts and 
those which invaded (as not all invading cell lines formed spheroids in monoculture). This data 
further supports the hypothesis that invasion and cancer progression are the result of a 
combination of factors from the epithelial and stromal compartments.  Used in combination 
these models could provide a useful tool to study factors which determine invasiveness of 
tumours and the relationship between epithelial cancer cells and fibroblasts.  
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Cell type 
Formed 
spheroid 
Formed 
spheroid in 
co-culture 
with 
fibroblasts 
Invasive in 
3D model 
DOK 
 
 
   
Cal27 
 
 
   
PE/CA-
PJ34 
 
 late  
SCC25 
 
 
late tiny  
D20 
 
 
   
D19 
 
 
   
FaDu 
 
 
 Not tested  
SCC4 
 
 
   
SCC9 
 
 
   
Table 2.11 
Correlation between invasion in 3D model and spheroid formation.  Shaded squares show 
positive result.  Cells listed in order of correlation. 
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Chapter 3: Novel therapeutic 
technologies 
3.1 Aims 
To produce nano-sized polymersomes using the polymers 2-(methacryloyloxy)ethyl 
phosphorylcholine)-poly(2-(diisopropylamino)ethyl methacrylate) (PMPC-PDPA) and 
poly(ethylene oxide)-poly(2-(diisopropylamino)ethyl methacrylate)  (PEO-PDPA) and to study 
the behaviour of these polymersomes in three dimensional tissue engineered models in vitro.  
3.2 Introduction 
In order for chemotherapy outcomes and patient tolerance to significantly improve, highly 
potent anti-cancer drugs need to be delivered with better specificity to sites of disease.  
Improving bio-availability of drugs in target areas and reducing drug delivery to other 
locations will reduce side effects, which are often dose limiting, and will therefore improve 
therapeutic outcomes. The bioavailability of drugs and control over their delivery can be 
achieved using drug delivery vectors, reviewed in chapter 1 on page 29. 
Delivery systems enable better delivery of drugs which exhibit poor tissue penetration and 
enable targeted drug delivery both passively, via the EPR effect, and actively via targeting 
moieties.  Drug delivery vectors can also have drug release profiles tailored to the application.  
In the most part these alterations can be achieved without altering the drug‟s structure or 
therapeutic action. 
This chapter evaluates the properties of the amphiphilic block co-polymers PMPC-PDPA and 
PEO-PDPA.   These self-assembling block co-polymers have previously been demonstrated to 
produce membrane-enclosed vesicle structures (polymersomes) in aqueous solutions (Du et 
al., 2005; Massignani et al., 2009).  The polymersomes are non-toxic and rapidly taken-up by 
a large selection of primary cells and cell lines (Massignani et al., 2009) (Figure 3.1).  Capable 
of encapsulating DNA, RNA, antibodies and proteins (Lomas et al., 2007; Massignani et al., 
2010) these polymersomes have huge potential in the field of drug delivery for many different 
diseases. 
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Figure 3.1 Viability and uptake of PMPC-PDPA after 24 hours exposure with many different 
cell types.  
Graph from (Massignani et al., 2009) 
 
 
The polymersomes investigated here are pH sensitive.  The PDPA block (poly(2-
(diisopropylamino)ethyl methacrylate) present in both polymers is pH sensitive.   At low pH 
(below pH 6.4) the PDPA polymer block is hydrophilic.  Raising the pH causes the PDPA 
block to become deprotonated and causes it to become hydrophobic (Figure 3.2). The PMPC 
and PEO blocks on the other hand are not pH sensitive so remain hydrophilic at low and high 
pH.  Therefore the change in pH causes the block co-polymer to shift from entirely hydrophilic 
(at low pH) to amphiphilic (part hydrophobic, part hydrophilic).  The hydrophobic effect 
causes the amphiphilic block co-polymers to self assemble into membrane-enclosed vesicles.  
This configuration is energetically favourable as the hydrophobic regions are shielded from the 
aqueous solution by the hydrophilic blocks of the polymer.  
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Figure 3.2 pH sensitive PMPC-PDPA.   
Below pH 6.4 the block co-polymer is hydrophilic.  Above pH 6.4 the polymer is amphiphilic.  
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Figure 3.3 Proposed mechanism for the escape of polymersomes from the endolysosomal 
pathway and the release of polymersome encapsulated cargo into the cell’s cytosol.  
Reproduced from (Massignani et al., 2010) 
 
 
This pH sensitivity is thought to have a role in the delivery of encapsulated cargo into the 
cytosol of cells (Massignani et al., 2010) (Figure 3.3).  The endosomal vesicles which deliver 
and traffic materials endocytosed by the cell into the endolysosomal pathway have a lower pH 
compared to the rest of the cell.  The pH in these endocytic vesicles is below pH 6.4 causing 
any polymersomes which enter these vesicles to disassemble as the PDPA block becomes 
hydrophilic.  This results in an osmotic shock as one particle (the polymersome) disperses into 
many thousands of polymer chains and the cargo is released.  This osmotic shock is sufficient 
to lyse the endocytic vesicle membrane and the material within the endocytic vesicle 
(including encapsulated polymersome cargo) is released into the cytosol thus escaping the 
endo-lysosomal pathway.    
Before polymersomes can be utilised clinically their behaviour in vitro and in vivo must be 
understood.  Here the behaviour of these polymersomes was studied, in a range of oral cancer 
cells and primary oral cells grown in monolayers.  The uptake of polymersomes by these cells 
and the toxicity profile associated with polymersome exposure was investigated.  Next the 
behaviour of polymersomes in three dimensional tissues in vitro was examined and their 
ability to penetrate into 3D tissues was evaluated.  This was tested using the tissue engineered 
models described in the previous chapter of solid oral cancer tumours (MCTS) and healthy 
oral mucosa (TEOM).  This information is clearly important in the development of 
polymersome mediated therapies for the treatment of oral cancer and for transmucosal 
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delivery.  Delivery to the basal epithelial cells and the central regions of solid tumours is 
particularly difficult due to the penetration barrier of the oral mucosa and the distance from a 
blood supply respectively.  These areas are particularly desirable to deliver to as the centres of 
solid tumours are often resistant to radiation and chemotherapy.   
If it can be demonstrated that polymersomes can cross the oral mucosa membrane intact and 
deliver their payload into the circulation then polymersome mediated therapy could provide an 
alternative to parenteral delivery.  For chronic diseases parenteral delivery by injection is not 
well accepted by the patient and requires administration by a healthcare professional (except in 
the case of diabetes).  Therefore, self-administered transmucosal therapy which is able to 
deliver treatment directly to the circulation could significantly improve treatment of a number 
of chronic conditions. On the other hand a technology which was able to deliver its payload 
across the penetration barrier and into the epithelium of the mucosa would be beneficial for a 
number of mucosal diseases including OSCC.  The MCTS models are used here to test if 
polymersomes could enable drug delivery into the avascular areas of tumours which are 
typically harder to treat because of poor drug penetration and radiotherapy resistance.   
The behaviours of these polymers in vivo has been tested in (Murdoch et al., 2010).  This 
paper demonstrated a good safety profile and acceptable bio-distribution of PEO-PDPA and 
PMPC-PDPA polymersomes.  
3.3 Materials and Methods 
 Production of polymersomes 
 Materials 
PMPC25-PDPA70, PEO23-PDPA15 block co-polymer and rhodamine 6G conjugates 
PMPC30-PDPA60 block co-polymers 
Block co-polymers were kindly synthesized by Paul Topham, Jeppe Madsen, Nick Warren and 
Adam Blanzas in Professor S Armes‟ laboratory in the Department of Chemistry, University of 
Sheffield. The synthesis of the polymers used in this work is described in (Hearnden et al., 
2009); (Massignani et al., 2009).  Chemical structures of both polymers and the PMPC-PDPA 
conjugated with rhodamine 6G are shown in Figure 3.4.  
Rhodamine B octadecyl ester perchlorate dye 
Purchased from Sigma Aldrich, Dorset, UK, dissolved in chloroform to give a concentration of 
1mg/ml, protected from the light and stored at -20°C in a spark-free freezer (Figure 3.4d).  
Sodium hydroxide(NaOH) 
Made up to a concentration of 1M using distilled water.  Filter sterilised prior to use and stored 
at room temperature.  
Hydrochloric acid (HCl) 
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Made up to a concentration of 1M using distilled water.  Filter sterilised prior to use and stored 
at room temperature.  
Sonicator 
From Sonicor Instruments Corporation, New York, USA. 
Sepharose 4B 
Purchased from Sigma Aldrich, Dorset, UK and stored in methanol at 4°C.  
 Preparation of block co-polymer film 
890nM of PMPC25- PDPA70 or PEO23-PDPA15 were dissolved in a glass vial in 2:1 chloroform: 
methanol solution.  For rhodamine labelled samples, 5% (molar %) rhodamine labelled 
polymer (rho-PMPC30PDPA60) was added to the polymer solution.   
For internalisation experiments on cell monolayers an amphiphilic rhodamine B octadecyl 
ester perchlorate dye (Sigma Aldrich, Dorset, UK) was encapsulated into polymersomes 
(Figure 3.4d).  100µl of the stock solution of the dye (1mg/ml rhodamine B octadecyl ester 
perchlorate dye) was added to 20mg of the PMPC-PDPA polymer dissolved in the solvents (or 
per 4mg of PEO-PDPA).  A co-polymer film was formed by evaporating the solvent in a 
vacuum oven at 40°C for 2-3 hours, or until all solvent was removed.   
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Figure 3.4 Chemical structures of PMPC25-PDPA70 (a), PEO23-PDPA15 (b),  Rho- PMPC30-
PDPA60 (c) and rhodamine B octadecyl ester perchlorate (d). 
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 Polymersome production: pH increase method 
The film was then rehydrated using 2 ml of pH 2 PBS (100mM) giving a co-polymer 
concentration of 0.2mM (10mg/ml for PMPC-PDPA and ~2mg/ml for PEO-PDPA) (Figure 
3.5).  Once the polymer had dissolved and the solution was completely clear the pH was raised 
very gradually using 1 M sodium hydroxide (NaOH).  The NaOH was added drop wise into 
the polymer solution while the solution was being mixed.  Vortexing and sonication were used 
throughout the pH increase to remove any precipitates which occurred.  Once the solution 
reached pH 7.4 the polymersome solution was sonicated for 20 minutes in icy water to create a 
more evenly dispersed solution of polymers with single membranes and of a similar size 
(Figure 3.5).   
 Preparation of gel permeation chromatography 
column 
Gel permeation chromatography (GPC) columns were prepared with Sepharose 4B.   
Sepharose was packed into a column, 300mm in length.  The column, containing sepharose, 
was shaken once packed to remove any bubbles which may have formed.  GPC columns were 
sterilised prior to use by autoclaving or with 70% IMS.  Once the IMS had run through the 
column the column was washed three times with sterile PBS to remove all the alcohol.  
Columns were stored at room temperature, upright and the sepharose was always kept 
submerged in PBS or IMS to prevent it from drying out and creating bubbles in the column.  
The sepharose was replaced monthly and resterilised periodically.   
 Purification of polymersome solution by GPC 
Once the polymersome solution had been brought to pH 7.4 using sodium hydroxide and the 
solution had been sonicated, the solution was passed through a GPC column to remove free 
rhodamine, micelles or polymer which was not incorporated into the polymersomes.  In GPC 
the largest molecules travel fastest as the sepharose allows them to travel around the sepharose 
particles.  Smaller materials are able to pass both around and through the sepharose, creating a 
slower more convoluted route which enables the separation of large macromolecules from 
smaller molecules.  The polymersome solution was added to the top of the column 2ml at a 
time.  Once the polymersome solution had entered the sepharose the column was washed 
through with PBS and fractions were collected (Figure 3.5).  Those fractions with the highest 
turbidity were retained while the rest were discarded.   
 Checking for removal of free rhodamine 
One ml fractions from the GPC column were collected, diluted 1 in 10 with PBS and the 
fluorescence of 1 ml of this solution measured using a fluorescence spectrophotometer (Varian 
Cary Eclipse, CA, USA) with excitation set at 540nm and emission at 560nm.      
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Figure 3.5 Method for making polymersomes   
(1) The co-polymer film is rehydrated at pH 2 making a solution of unimers. (2) The pH is 
increased and the block co-polymers become amphiphilic.  Macromolecular structures such 
as polymersomes and micelles form. (3) The solution is sonicated to encourage all polymer 
to form unilaminar vesicles as the membranes are broken and reform. (4) The solution is 
passed through the GPC column to extract large structures (polymersomes), from smaller 
structures (such as micelles and unimers).  
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 Characterisation of polymersomes 
 Transmission Electron Microscopy (TEM) 
For TEM analysis, samples of polymersome solution were mounted onto pre-carbon-coated 
copper grids. These grids were firstly glow discharged for 40 seconds, and then submerged 
into the polymersome solution for 60 seconds. The grids were then blotted dry and submerged 
into a phosphotungstic acid solution (0.75 w/v %, made up using distilled water) for 20 
seconds, before being blotted dry, and then briefly dried under vacuum. Imaging was 
performed on a Philips CM100 instrument operating at 80 kV equipped with a Gatan 1k CCD 
camera. 
 Cell monolayer and polymersomes 
 Materials and Preparation 
MTT Solution 
MTT (3-(4,5-dimethylthiazol-2-yl)-2,5 diphenyl tetrazolium bromide) powder was purchased 
from Sigma Aldrich, Dorset, UK.  MTT solution was made up in PBS at a concentration of 
0.5mg/ml.  MTT powder is mutagenic if inhaled and was therefore always weighed in a fume 
cupboard.  MTT solution, once prepared, was kept at 4°C for up to one week, protected from 
the light. 
Acidified isopropanol 
Isopropanol (Fisher Scientific, Leicestershire, UK) was acidified using 125µL of 10M HCl per 
100ml isopropanol. 
 Paraformaldehyde solution 
Paraformaldehyde powder (Sigma Aldrich, Dorset, UK) was weighed in a fume cupboard and 
dissolved into a 100mM PBS solution to give a final concentration of 3-4% (wt %).  The 
paraformaldehyde powder in PBS was stirred and gently heated to 37 °C on a stirring plate for 
several hours. 5M HCl was then added to the solution drop-wise until the paraformaldehyde 
powder had completely dissolved and the solution was clear.  The paraformaldehyde solution 
was then cooled and the pH was adjusted to pH 7.4 using sodium hydroxide.   
Paraformaldehyde was frozen in aliquots and thawed immediately prior to use.  
 Cell monolayer exposure to polymersomes 
Cells were seeded in 24 well plates (Costar, Buckinghamshire, UK) for toxicity and flow 
cytometry experiments.  Cells were seeded at a density of 30,000 cells per well and incubated 
for 24 hours prior to polymersome exposure in humidified incubators (37°C, 5% CO2). Prior to 
polymersome exposure an equal number of cells were seeded in each well and were checked 
under phase contrast microscopy to ensure cells had adhered well.  5mg/ml polymersome 
solutions were diluted in fresh cell culture medium to give the desired concentration.  For 
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toxicity studies polymersome concentrations of 0.1mg/ml, 1mg/ml and 2mg/ml were used.  For 
control wells fresh cell culture medium was diluted with PBS so the concentration of cell 
culture medium was equivalent for all samples.  For flow cytometry experiments a 
polymersome concentration of 1mg/ml was used.   
Existing cell culture medium was removed and discarded into bleach.  The polymersomes, or 
PBS, in cell culture medium were then added to the cells and cells were incubated for the 
desired length of time.  For toxicity experiments, cells were incubated for 24 or 48 hours. For 
flow cytometry experiments looking at the uptake of polymersomes, time points of 2,5, 10, 30, 
60, 180, 480, 1440 minutes were analysed.     
 MTT assay for metabolic activity 
The mitochondrial metabolic activity of cells was measured using MTT (3-(4,5-
dimethylthiazol-2-yl)-2,5 diphenyl tetrazolium bromide) and was used as an indicator for cell 
viability (Mosmann 1983).  Monolayers were washed 3 times in 100mM PBS and incubated 
for 40min, with MTT solution (0.5 mg/ml MTT in PBS, 0.5ml per well in 24 well plate) at 37 
°C with 5% CO2.  After 40 minutes, the unreacted MTT solution was removed and the purple 
intracellular formazan salt (produced by dehydrogenase reduction of MTT) was solubilised 
and released from cells using acidified isopropanol (125µl of 10M HCl in 100ml isopropanol).  
The eluted dye was transferred to a 96 well plate.  The optical density of the solution was 
measured at 540nm with a reference at 630nm, using a spectrophotometer (Tecan).  All optical 
densities were normalised to a control sample of untreated cells. 
 Flow Cytometry  
Cells monolayers were washed 3 times using PBS and detached using 0.5ml trypsin EDTA per 
24 well as previously described on page 78. Trypsin EDTA was neutralised using cell culture 
medium containing FCS and the cell suspension from each well was transferred into 1ml 
eppendorf tubes.  Eppendorfs containing samples were spun at 6000rpm for 2 minutes using a 
bench top centrifuge.  The supernatant was removed and cells were resuspended in 3% 
paraformaldehyde (w/v) to fix the cells.  Fixed cells were stored in the fridge for up to a week 
before flow cytometry analysis.  Fixed cell solutions were added to a 96 well plate and 
fluorescence at 543nm was measured using a BD FACSArray™ Bioanalyzer (BD Biosciences, 
California, USA).  Cell populations were gated using forward scatter (FSC) and side scatter 
(SCC) measurements.  Cell debris was excluded from the measurements (see Figure 3.6a).  A 
threshold for positively fluorescent cells was set using untreated control cells (see Figure 3.6).  
All samples were run in triplicate and the experiment was repeated twice. 
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Figure 3.6 Example of FACS dot plots.  
(a) Red dots indicate cells gated to be included in analysis (white dots indicate cell debris 
not included). (b) Untreated control sample used to determine non fluorescent population 
using dot plot and (c) Cells within white lines classed as positively fluorescent.    
  
 Statistics 
The standard deviation (error bars) and significance values were calculated from the 
normalised values of cell viability. Microsoft Excel 2007 was used to calculate mean, sum and 
standard deviation of data.  All measures of statistical significance were determined using  
Student‟s t-test.  To perform Student‟s t-test Microsoft Excel 2007 was used.  A parallel t-test 
on SigmaPlot v10 was also done to confirm the results.  An unpaired two tailed t-test was 
performed and homogeneity of variance was assumed.   
 Polymersomes + MCTS 
 Adding polymersomes to FaDu MCTS 
MCTS were cultured 7 days prior to polymersome exposure. PMPC-PDPA polymersomes 
were added to the MCTS to give a final concentration of 0.02mM in cell culture medium.  
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Polymersomes, labelled with conjugated Rho-PMPC-PDPA were mixed with cell culture 
media and administered when the cell culture media was replenished on the cells.  This cell 
culture media remained on the cells for the duration of the polymersome exposure.  
 Dissociation of multi-cellular tumour spheroids for 
flow cytometry analysis 
MCTS are clearly visible by eye once formed and can be removed from a 96 well plate using a 
Pasteur pipette.  MCTS were washed three times with PBS and placed in a clean 12 well plate.  
1ml Trypsin/0.02% EDTA solution was added to the MCTS and incubated for 10 minutes, or 
until all cells in the MCTS had dissociated.  The cell suspension was then centrifuged and re-
suspended in 3% para-formaldehyde for flow cytometry analysis and stored in the fridge for up 
to 5 days. FACS analysis was performed as described for cell monolayers on page 140.  One 
spheroid per 96 well was measured and all samples were measured in triplicate or more.  
 Frozen sections 
For visualisation of polymersomes within MCTS the MCTS were frozen in OCT freezing 
medium (VWR International, Lutterworth, UK) at – 20 °C in disposable base moulds 
(Surgipath, Peterborough, UK) and stored at – 80 °C (Figure 3.7).  8µm sections were cut with 
a Leica Cryostat CM 3050 S (Leica Microsystems, Nussloch, Germany) and transferred onto 
Superfrost slides (VWR, Lutterworth, UK).   The sections were labelled with DAPI mounting 
medium (Vectashield, Vector Laboratories Ltd., Peterborough, UK) and cover-slipped.  
 Fluorescence imaging 
Frozen sections were imaged using a fluorescent microscope (Zeiss Axioplan 2) with a Q-
imaging Retiga 1300R camera (QI Imaging, Arizona, USA) and Image Pro Plus image 
software (Media Cybernetics, Inc., MD, USA).  
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Figure 3.7 Analysis of MCTS using cryo-sectioning. 
  
  
 Polymersomes and TEOM 
 Exposure of TEOM to Polymersomes 
TEOM were cultured for 10 days at ALI prior to polymersome exposure. Polymersomes were 
added to the superficial surface of the TEOM at a concentration of 0.2mM (10mg/ml for 
PMPC-PDPA, 2mg/ml PEO-PDPA) inside a plastic ring pushed gently onto the top surface of 
the TEOM (Figure 3.8).  Cell culture medium remained under the TEOM for the duration of 
the experiment.   
 Freezing of samples for fluorescence histology 
Samples were washed thoroughly in PBS and fixed in 3% paraformaldehyde overnight at room 
temperature.  Samples were coated in OCT freezing medium and snap frozen by dipping the 
TEOM into liquid nitrogen.  Frozen samples were stored at -80°C, sectioned, stained and 
imaged as described above for MCTS frozen sections (page 142).  
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Figure 3.8 Application of polymersomes to surface of TEOM. 
 
Confocal laser scanning microscopy (CLSM) 
TEOM samples exposed to polymersomes were washed thoroughly in PBS and left submerged 
in PBS in a 6-well plate for CLSM imaging.  All CLSM images were obtained using Zeiss 
LSM 510 META Upright Laser Scanning Confocal Microscope (Carl Zeiss Inc., Germany) 
with corresponding LSM 510 META Software (Carl Zeiss Inc., Germany).  
 Determining autofluorescence from TEOM 
To successfully image polymersome penetration into the TEOM a fluorescent dye which was 
excited at a wavelength which did not result in a large amount of autofluorescence was 
required.  To assess the best wavelength to use, TEOM were exposed to 488nm and 543nm 
excitation and the emission spectra detected using lambda stack mode on the confocal.  The 
resulting emission spectra was detected between 500nm and 700nm, using a multi-channel 
detector consisting of 32 photo-multiplier elements enabling an emission fingerprint to be 
detected across a range of wavelengths.   
 Detecting fluorescently labelled polymersomes 
within TEOM 
Samples were washed 3 times in PBS prior to imaging and samples were submerged in PBS 
throughout imaging and then imaged using an Acroplan x40 dipping lens (Carl Zeiss Inc., 
Gemany).  All samples were imaged fresh and unfixed.  Three dimensional images of 200µm x 
200µm x 100-200µm were obtained using the z-stack function.  These images are made up of 
50-100 images 2µm apart.     
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Figure 3.9 Diagrammatic representation of CLSM 
 
 
3.4  Results 
 Characterisation of polymersomes 
 
Figure 3.10 Transmission electron microscopy (TEM) images of PEO23-PDPA15 (a) and 
PMPC25-PDPA70 (b). 
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 Imaging of polymersomes 
To confirm the presence of polymersomes we imaged polymersome samples using 
transmission electron microscopy.  Spherical polymersomes with diameters ~100nm can be 
observed in samples of both the PEO 23-PDPA 15 and PMPC 25-PDPA 70.  
 Removal of free rhodamine using gel permation 
chromatography (GPC) 
Two methods were used to fluorescently label the polymersomes.  In the first method PMPC-
PDPA conjugated to rhodamine 6G (Rho-PMPC-PDPA) was mixed with either PMPC-PDPA 
or PEO-PDPA polymer solutions before the film was produced.  5% of Rho-PMPC-PDPA was 
added to label the polymer (molar %).  A second method was implemented, which resulted in 
higher fluorescence intentisites.  An amphiphilic rhodamine dye (Rhodamine B octadecyl ester 
perchlorate dye) was encapsulated within the membrane of the polymer vesicles.   
The method used to conjugate or encapsulate these dyes into polymersomes always resulted in 
some free rhodamine being present in the sample. To remove any non-conjugated rhodamine 
or non-encapsualted amphiphilic rhodamine, polymersomes were passed through a GPC 
column.  Fractions were collected every 1ml and the fluorescence profile was measured using 
fluorescence spectroscopy.  Fractions 2ml-5ml after the first fraction were used for 
experiments as these showed the highest rhodamine fluorescence, were turbid and contained 
polymersomes.  Due to its small size the free rhodamine left the GPC column after 16ml 
(Figure 3.11), un-encapsulated rhodamine was also removed in this way. 
 
Figure 3.11 Removal of free rhodamine from polymersome solution using GPC column 
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 Effect of Polymersomes on Cell Viability 
 PMPC-PDPA 
 The mitochondrial activity of six different cell lines was tested and used as a method to 
determine relative viability of cells after 24 and 48 hours of polymersome exposure.  PMPC-
PDPA polymersomes were added to cell culture medium at concentrations of 0.1mg/ml, 
1mg/ml and 2mg/ml.  After 24 hours there was no significant reduction in viability in any of 
the cell types at 0.1mg/ml PMPC-PDPA (Figure 3.12).  Some cells types were affected after 
24 hours exposure to 1mg/ml PMPC-PDPA (oral and skin fibroblasts) and all cell types except 
the SCC4 cell line showed significant toxicity when exposed to 2mg/ml of PMPC-PDPA for 
24 hours.  After 48 hours exposure there was no significant reduction in viability when 
0.1mg/ml of polymersomes was added.  The longer exposure time however, caused significant 
toxicity to all cell types at 2mg/ml and all cell types except Cal27 and normal oral 
keratinocytes at 1mg/ml (Figure 3.12).   
 PEO-PDPA 
The viability of cells exposed to PEO23-PDPA15 was tested on 3 different cell types (Figure 
3.13).  Normal oral fibroblasts (NOF), normal oral keratinocytes (NOK) and the cancer cell 
line FaDu were exposed to 0.02mM or 0.01mM for 24 or 48 hours. The concentration 0.02mM 
is the molar equivalent to 1mg/ml of PMPC25-PDPA70.  
The PEO-PDPA was not tested at the equivalent of 2mg/ml concentration however, at 0.02mM 
the PEO-PDPA did not affect the viability of these cells as significantly as the PMPC-PDPA 
(Figure 3.13).  The NOK cells were affected at 0.02mM after 24 hours exposure.  After 48 
hours NOK cells were not significantly affected, likely due to the high variability in the control 
samples.  The FaDu cells were significantly affected after 48 hours, at the higher concentration 
(0.02mM).   
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Figure 3.12 Viability of cell monolayers exposed to PMPC-PDPA polymersomes at various 
concentrations. 
Error bars= s.d.  FaDu = OSCC cell line, NOF = normal oral fibroblasat, SCC4 = OSCC cell line, 
Cal 27= OSCC cell line, NOK = normal oral keratinocytes and HDF = human dermal 
fibroblasts. * p < 0.05, ** p < 0.01, *** p < 0.005 Representative of one experiment n=3 
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Figure 3.13 Viability of cells exposed to PEO23-PDPA15 polymersomes.  
 *=  p< 0.05, *** = p < 0.005. Representative of 1 experiment n=3. 
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 Kinetics of Polymersome Uptake 
 Effect of Cell types of PMPC-PDPA Polymersome 
Uptake 
Polymersomes containing the amphiphilic rhodamine dye, rhodamine B octadecyl ester 
perchlorate, were added to a variety of cell lines and the uptake of polymersomes by these cells 
was measured over time using flow cytometry.  The FaDu cells took up the PMPC-PDPA 
polymersomes very rapidly (Figure 3.14).  After 2 minutes exposure over 70% of FaDu cells 
contained detectable levels of polymersomes. The Cal27 cancer cell line showed the next 
fastest uptake with SCC4 cells showing a similar rate of uptake.  These cancer cell lines 
showed faster uptake when compared to the primary cells in terms of the percentage of cells 
which contained detectable levels of rhodamine.  The oral keratinocytes took up polymersomes 
faster than oral and dermal fibroblasts.  Virtually one hundred per cent of all cell types had 
taken up polymersomes after 3 hours exposure (Figure 3.14).   
The amount of polymersomes taken up by each cell type over time was measured using the 
fold increase of fluorescence compared to the control cells.  Fold increase was used as a 
measure of fluorescence to account for the differences in autofluorescence occurring from the 
different cell types before polymersome exposure (Figure 3.14). 
For all cell types this increased over time, and continued to increase for the whole time the 
cells were exposed to polymersomes (24hours).  After 100% of cells had taken up 
polymersomes the increase in intensity appears to be linear. 
The cells which took up the most polymersomes per cells (highest fold increase in 
fluorescence intensity) were the FaDu cell line; with the least polymersomes taken up by the 
oral fibroblasts.  
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Figure 3.14 Uptake of PMPC-PDPA Polymersomes by monolayers of various cell types.   
Percentage of population positive for polymersomes (detected by flow cytometry, see 
Figure 3.6) and fold increase in fluorescence compared to control. n=3 
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 PMPC-PDPA Polymersome Uptake is Concentration 
Dependant 
PMPC-PDPA polymersomes labelled with encapsulated amphiphilic rhodamine were added to 
FaDu cells at two different concentrations (0.1mg/ml and 1mg/ml) and analysed by flow 
cytometry. The percentage of cells which contained a detectable amount of polymersomes was 
significantly higher in the samples exposed to the higher concentration of polymersomes 
(1mg/ml) for 1 hour compared to 0.1mg/ml (Figure 3.15).  By 3 hours exposure over 90% of 
cells, in both the high concentration and low concentration samples, had taken up a detectable 
amount of polymersomes.  The intensity of fluorescence, and therefore amount of 
polymersomes per cell, increased at a similar rate in both samples once the uptake of 
polymersomes could be detected in the majority of cells (1-3 hours).  The reason for this is 
probably because before this point the samples exposed to lower concentrations were taking up 
polymersomes however, the fluorescence was below the detection limit until around 1 hour 
exposure.  After 1 hour the intensity of fluorescence and therefore amount of polymer was 10 
times higher in the cells exposed to the higher concentration (Figure 3.15) compared to the 
lower concentration.  This indicated the uptake of polymersomes is concentration dependant as 
the difference in concentration between the two samples was 10 times.   
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Figure 3.15 Concentration dependant uptake of PMPC-PDPA polymersomes encapsulated 
with amphiphilic rhodamine in FaDu cells.  n=3 
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 Penetration of Polymersomes into TEOM 
Delivery of drugs and therapeutic agents into and across the oral epithelium is desirable for the 
treatment of many conditions.  The penetration capacity of fluorescently labelled 
polymersomes (containing 5% rho-PMPC-PDPA) through the oral epithelium was assessed 
using the TEOM model, described in the previous chapter.  Initially TEOM models exposed to 
polymersomes were examined using frozen sections, counter stained with DAPI.  The control 
samples were exposed to PBS instead of polymersomes. Figure 3.16 shows the frozen sections 
of TEOM after 6 and 30 hours exposure to polymersomes. 
 
Figure 3.16 TEOM exposed to polymersomes with encapsulated amphiphilic rhodamine.  
Blue fluorescence is DAPI a marker for cell nuclei. Representative image, n=3. 
 
Chapter 3:Novel therapeutic technologies 
 
155 
 
The fragile nature of the models once they had been snap frozen and the autofluorescence 
signal from the tissue lead to confocal microscopy being used for future experiments.  
 Avoiding the autofluorescence of TEOM 
In order for the TEOM and polymersomes to be imaged effectively the autofluorescence from 
the tissue needed to be avoided. Figure 3.17 shows the emission spectra of the oral mucosa 
model when excited at 488nm and 543nm.  Both spectra were taken using the same settings 
and the same excitation intensity.  There is a broad fluorescent emission from TEOM 
autofluorescence when the TEOM was excited at 488nm (Figure 3.17a) but very little when 
excited at 543nm (Figure 3.17b).  The autofluorescence comes predominantly from the extra-
cellular matrix (ECM) proteins (Schenke-Layland et al., 2006). To avoid the autofluorescence 
as far as possible we used rhodamine 6G which is excited at 543nm, to label the 
polymersomes.   
 
Figure 3.17 Emission spectra of TEOM without polymersomes when excited with 488nm 
and 543nm lasers.   
z-x section of TEOM excited at 488nm (a), and at 543nm (b).  Scale bar 50µm. 
 
After the TEOM was exposed to rhodamine labelled polymersomes the emission spectra 
arising from 543nm excitation changed dramatically demonstrating the presence of 
polymersomes (Figure 3.18a). Figure 3.18b shows a confocal image of TEOM excited at 
488nm and 543nm after 48 hours exposure to polymersomes while Figure 3.18c shows the 
control model without polymersome exposure.  The 488nm channel (autofluorescence) was 
used to locate the model during CLSM imaging and was useful to orientate the epithelium.  
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Combining both excitation channels gives a composed image. A negative control of unlabelled 
polymersomes also showed no fluorescence in the 543nm channel.   
 
 
Figure 3.18 Emission spectra of tissue engineered oral mucosa after exposure to rhodamine 
labelled polymersomes excited at 543nm.   
(a) z-x section of TEOM exposed to PMPC25-PDPA70 polymersomes for 48 hours (b) z-x 
section of TEOM with no polymersome exposure.  Blue= 488nm excitation. Red= 543nm 
excitation. Scale bar 50µm.   
 
 
Figure 3.19 examined the location of the PMPC-PDPA and PEO-PDPA polymersomes over 48 
hours using CLSM.  The diffusion of both PEO-PDPA and PMPC-PDPA polymersomes into 
the TEOM was time-dependant.  In Figure 3.19 the z-x plane shows a cross section through the 
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full thickness model.  While the x-y plane shows a representative horizontal slice through the 
model and the image on the right shows a 3D reconstruction of the TEOM.  After 6 hours 
exposure to both formulations of rhodamine labelled polymersomes (PEO-PDPA and PMPC-
PDPA), rhodamine (red) fluorescence could be seen in the most superficial epithelial layers of 
the model (Figure 3.19b,e).  The position of the polymersomes in respect to the 
epithelial/connective tissue interface can be judged from the relative positions of the red 
fluorescence of the polymersomes and the blue autofluorescence of the connective tissue.  The 
basal region appears dark suggesting the polymersomes have not penetrated into the basal 
cells.  There was more wide spread uptake of polymersomes by the superficial epithelial cells 
for the PMPC-PDPA polymersomes than the PEO-PDPA (Figure 3.19c & f).  After 48 hours 
exposure to PMPC-PDPA it appears that all cells within the epithelium contain polymersomes 
(Figure 3.19d) and display high levels of fluorescence. There is no dark region between the 
upper epithelium and connective tissue component in Figure 3.19d suggesting polymersomes 
have diffused down to the epithelial/connective tissue interface and have been internalised by 
basal, as well as more superficial epithelial cells.  The TEOM exposed to PEO-PDPA for 48 
hours expressed high levels of polymersome uptake and fluorescence in the upper layers of the 
epithelium, but less uptake and fluorescence in the deeper layers of the epithelium compared to 
PMPC-PDPA polymersomes (Figure 3.19 g). The PEO-PDPA polymersome diffusion pattern 
is less uniform and appears in patches. However, this may be due to differences in 
fluorescence intensity between the two polymersome formulations rather than an inherent 
difference in polymersome behaviour of the two formulations (see appendix 2).   
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Figure 3.19 Tissue engineered models were exposed to rhodamine labelled PMPC25-PDPA70 
or PEO23-PDPA15 polymersomes for 6, 30 or 48 hours.  
(a) shows control sample, no exposure to polymersomes.  CLSM images of TEOM exposed 
to PMPC25-PDPA70 for 6 hours (b), 30 hours (c) or 48 hours (d).  TEOM exposed to PEO23-
PDPA15 polymersomes for 6 hours (e), 30 hours (f) or 48 hours (g).  Images on the left show 
x-y and x-z sections.  Images on the right are three-dimensional projections of these 
models.  Scale bar 50µm. n=2 
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Confocal images were also used to obtain quantitative information about the penetration of the 
two polymersome formulations into the TEOM.  Zmax was calculated by measuring the 
greatest depth of red fluorescence in the TEOM at different time points (Figure 3.20a).  The 
depth of penetration was greater for the PMPC-PDPA compared to the EPO-PDPA but not 
significantly different.  PMPC-PDPA reached a depth of over 50µm after 48 hours (Figure 
3.20b). 
 
 
Figure 3.20 Depth of penetration (zmaz) for PMPC25-PDPA70 polymersomes into the model as 
measured by analysing the x-z and y-z projections (a). Depth of penetration over time for 
the two different polymersome formulations (b). n=3 
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 Polymersomes and MCTS 
 Effect of polymersomes on viability and growth of 
MCTS 
FaDu MCTS were cultured for 7 days before being incubated with fluorescently labelled 
PMPC-PDPA polymersomes.  The effect of polymersomes on MCTS growth and viability was 
measured using the MTT viability assay (Figure 3.21) and microscopy (Figure 3.22).  No 
significant effect could be seen on the viability of MCTS when incubated with 0.1mg/ml 
PMPC-PDPA or 1mg/ml PMPC-PDPA for up to 11 days.  The growth curves of all spheroids, 
unexposed control spheroids, spheroids exposed to 0.1mg/ml and 1mg/ml of PMPC-PDPA 
were very similar (Figure 3.22).  This is in comparison to the FaDu cell monolayers which 
were affected by 48 hours exposure to 1mg/ml.  This demonstrates the difference in the 
behaviour of cells in 2D and 3D.  
 
 
Figure 3.21 Viability of cells exposed to PMPC-PDPA polymersomes for up to 11 days. n=5 
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Figure 3.22 Growth curve of MCTS exposed to PMPC-PDPA polymersomes.   
Day 0 indicates time of polymersome addition. n=5 
 
 Uptake of Polymersomes by MCTS 
MCTS were incubated with fluorescently labelled PMPC-PDPA polymersomes for 6, 24 or 48 
hours before being frozen, sectioned and stained with DAPI to show up the cell nuclei.  These 
frozen sections show that polymersomes penetrated into MCTS in a time dependent manner 
(Figure 3.23).  After 6 hours exposure the polymersomes had entered the most superficial cells 
of the MCTS. After 24 hours the outer most 2-3 cells contained polymersomes (labelled with 
Rho-PMPC-PDPA) and after 5 days (120 hours) the whole MCTS appeared to contain PMPC-
PDPA polymersomes as the whole MCTS was strongly fluorescent in the red channel.   
To quantify the uptake of polymersomes by cells, MCTS were dissociated and analysed by 
flow cytometry.  After 24 hours exposure polymersomes had been taken up by around 20% of 
cells within the MCTS (Figure 3.24).  By 120 hours exposure the polymersomes had been 
internalised by 80% of the cells and the intensity of fluorescence per cell increased over the 
120 hours of polymersome exposure (Figure 3.25).   
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Figure 3.23 Diffusion of rhodamine labelled PMPC-PDPA polymersomes over time.  
(a) control, no polymersomes, (b) 6 hour, (c) 24 hour and (d) 120 hour incubation with 
polymersomes.  Blue = DAPI stained cell nuclei Red= Rhodamine fluorescence.  NB the 
differences in size of MCTS are due to where the MCTS slice was taken. Scale bar = 100µm. 
Representative images n=3 
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Figure 3.24 Percentage of cells in MCTS which took up polymersomes as measured by flow 
cytometry on dissociated MCTS. n=3 
 
 
 
 
Figure 3.25 Median fluorescence of cells within MCTS exposed to polymersomes labelled 
with rho-PMPC-PDPA over time.  n=3 
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3.5 Discussion 
 Characterisation of Polymersomes 
Analysis of polymersomes using TEM indicated the presence of polymersomes in the turbid 
solutions for both polymers (PEO-PDPA and PMPC-PDPA).  This is in agreement with 
previous studies involving polymersomes made from these polymers (Massignani et al., 2009).  
To study polymersome location in cells and other in vitro settings requires a marker and 
fluorescence is one of the most common labelling techniques used in bioimaging.  
Polymersomes have been fluorescently labelled in two different ways, described on page 135.  
Figure 3.11  shows the removal of free rhodamine which remained after synthesis.  Using GPC 
the small free rhodamine molecules could be separated from the polymersomes.  The same 
method was also used for the removal of rhodamine B octadecyl ester perchlorate which had 
not been encapsulated.  This meant tracking of polymersome location could be achieved using 
these dyes, as the only dye remaining after GPC purification was associated with the 
polymersomes.  
 Effect of Polymersomes on Cell Viability 
For polymersomes to be utilised in a clinical setting they must be non-toxic and not stimulate 
an immune or inflammatory response when administered to a patient.  Despite previous studies 
showing minimal or no toxicity (Figure 3.1 (Massignani et al., 2009)) in this study it appears 
that for longer incubation times polymersomes can effect mitochondrial activity in some of the 
cell types looked at here.  MTT has been used as an indicator for cell viability because  MTT 
salts are only reduced by cells with active mitochondria (Mosmann 1983).   
The reduction in cell viability seen in this project is not desirable. However, it may not pose a 
problem for the applications proposed in this research.  Cells grown in vitro in monolayer 
culture are an artificial representation of cells which are present within the body.  It has been 
shown previously (Sun et al., 2006) that cells grown in two-dimensions behave differently 
compared to cells grown in three dimensions.  In the study by Sun et al., the same cells 
cultured in 3D were able to withstand much higher concentrations of silver and hydrogen 
peroxide than cells grown in monolayer.  It is also very likely that cells in 3D within the 
complex environment of the human body will be more able to withstand potential cytotoxic 
agents because of blood perfusion of the tissues which will rapidly reduce the concentrations 
of agents added.  In a clinical scenario it is very unlikely that a population of cells would be 
continuously exposed to such high concentrations of polymersomes for 48 hours due to the 
nature of drug delivery and clearance. It is more likely the cells will be exposed for a short 
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period of time, during the drug administration, but would then have the opportunity to excrete 
the polymer between administrations. 
The most significant toxicities were found after 48 hours of exposure which could be due to a 
number of factors.  The damage to the cells may not be caused instantly but instead may be a 
result of prolonged polymersome-cell interaction.  The cells may also be tolerant to a certain 
amount of polymer material within the cytosol but may become damaged when the 
concentration within the cell reaches a threshold.  As can be seen in Figure 3.14, the cells 
continued to take up polymersomes steadily over 24 hours.  
As a result of these findings subsequent monolayer studies were carried out for 24 hours and 
concentrations of 1mg/ml or less were used. 
 Internalisation of Polymersomes by Monolayers 
The uptake of polymersomes by a variety of primary cells and oral cancer cell lines was 
measured using PMPC-PDPA polymersomes with rhodamine B octadecyl ester perchlorate 
encapsulated within them.  Flow cytometry was used to determine how many cells had taken 
up polymersomes over 24 hours.  The cell population was classed as positive for 
polymersomes when it was above the detection threshold for the flow cytometry machine.  
Figure 3.6 shows how the control and fluorescent populations were set using a dot plot of 
fluorescence intensity vs. side scatter.    
The faster uptake of polymersomes by the cancer cells (Figure 3.14) may provide a method to 
passively target polymersomes to cancer. Interestingly, the cancer cell lines, in particular 
FaDu, took up the polymersomes more rapidly than the primary cells.  From a therapeutic 
point of view this is beneficial as higher uptake of cytotoxic agents by cancer cells with a 
relatively lower uptake by healthy cells could dramatically increase tumour killing and reduce 
unpleasant and dose limiting side effects.  There are a number of factors which may be 
responsible for this increased uptake including preferential binding of polymersomes to the 
surface of cancer cells, faster metabolic rate of cancer cells and higher levels of endocytosis.   
The quantity of polymersomes taken up by each cell type increased over 24 hours at a similar 
rate however, the quantity taken up by FaDu cells was the greatest throughout. There does 
appear to be some connection between the rate and quantity of uptake by cells and their 
viability post exposure.  The uptake of fluorescently labelled PMPC-PDPA polymersomes, as 
measured by flow cytometry showed that the FaDu cells took up the polymersomes fastest.  
After 10 minutes over 90% of the cell population contained some fluorescently labelled 
polymersomes and had more polymersomes per cell compared to other cell types.  It was the 
FaDu cell line, which showed the lowest viability after 48 hours exposure for the two highest 
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concentrations 1mg/ml and 2mg/ml (Figure 3.12).  This could be due to the quantity of 
polymer present in the cells or the response of FaDu cells to polymersomes.  
The uptake of polymersomes was concentration dependant, as shown in Figure 3.15.  This is 
important to know when taking polymersomes to the clinic and considering dosing of 
polymersome mediated therapy.   
 Penetration of Polymersomes across TEOM 
Developing drug delivery systems that can carry a wider array of therapeutic agents across the 
epithelial permeability barrier, in particular biological agents and genes, and deliver them with 
high efficiency either into basal keratinocytes or directly into the connective tissue where they 
can be taken up by the blood supply, would open up a broad spectrum of more effective 
therapeutic tools for treating many oral mucosal diseases.  
The aim of this study was to explore the use of TEOM as a convenient in vitro surrogate for 
normal oral mucosa to examine the penetration of two novel forms of polymersomes through 
healthy oral mucosa using CLSM. As these polymersomes are being developed to deliver 
drugs, proteins or genes into tissues for future clinical use, information on their penetration 
into tissues is clearly an important part of their development. 
Initial experiments showed that it was possible to track rhodamine labelled polymersomes 
using CLSM as the wavelength used to excite the rhodamine (543nm) did not result in 
autofluorescence from the TEOM.  The 488nm autofluorescence was used as a reference to 
orientate the oral mucosa.  Figure 3.19 shows time-dependent penetration of polymersomes 
comprised of PEO-PDPA or PMPC-PDPA into the epithelium of a TEOM model over 48 
hours. The TEOM used in this study closely resembled normal oral mucosa with epithelial cell 
differentiation and stratification, minimal keratinisation of superficial epithelial layers and a 
well attached epithelium on a collagenous connective tissue containing fibroblasts (Figure 2.4 
on page 93).  
The PMPC25-PDPA70 polymersomes appear to penetrate the epithelium faster and over a more 
widespread area than the PEO23-PDPA15 polymersomes.  By 48 hours the fluorescence 
generated by the PMPC25-PDPA70 polymersomes appeared to follow the contours of the basal 
epithelial cells which reside along the basement membrane, strongly suggesting that these 
polymersomes diffuse as far as the basal cells. The diffusion of the PEO-PDPA polymersomes 
compared to the PMPC-PDPA did not appear to be as widespread and penetration was higher 
for PMPC-PDPA polymersomes compared to PEO-PDPA polymersomes, but not significantly 
so (Figure 3.20).   
Unfortunately, whether or not the differences in cell membrane adhesion and polymer-cell 
interactions caused the distinct distribution profiles seen for each polymer cannot currently be 
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confirmed as there were significant differences in the fluorescence intensity between the two 
types of polymersomes (see appendix 2).  The difference may be due to the fluorescence 
detection limit of CLSM rather than the behaviour of the polymers.   
The penetration of both polymersome formulations was over 50µm which corresponds to at 
least 5 cell layers.  Models with a thicker epithelium, closer to naturally occurring oral 
epithelium (which can be over 500µm in thickness (Nanci 2003)) or an in vivo model would be 
needed to further test whether polymersomes can reach the basal cells of these thicker 
epithelia.   
The bilayer membranes of polymersomes are highly deformable enabling them to pass through 
gaps between cells in tissues, such as the oral epithelium, that are smaller than their own 
diameter (Discher et al., 1999).  For a bilayer membrane to be ultra-deformable there must be a 
certain level of flexibility within the membrane which enables the molecules to redistribute 
themselves within and between the bilayers (Cevc and Gebauer 2003).  Re-distribution within 
membranes reduces the volume-stress created by the deformation.  The deformation capability 
of polymersomes has been demonstrated (Discher et al., 1999) using micropipette aspiration of 
giant sized (20-50 µm) polymersomes.   
It is hoped this flexibility and the encapsulation potential of polymersomes may enable 
efficient trans-epithelial delivery of several therapeutic agents. The diffusion of polymersomes 
across the oral epithelium may not be driven by a concentration gradient as for other materials 
but rather via a hydration gradient across the different layers (Cevc and Gebauer 2003). In the 
epithelium the hydration gradient pulls the carriers through the relatively dehydrated 
keratinized layer until they reach the viable epithelium where there is a higher level of 
hydration. These rather bulky carriers are then pushed through the lower layers of the 
epithelium by more carriers which are drawn into the epithelium by the hydration gradient 
(Cevc and Gebauer 2003).  
For transmucosal applications, the ability to deliver intact polymersomes containing their 
therapeutic loads would be incredibly beneficial.  To test if polymersomes were able to cross 
the epithelium intact polymersomes encapsulating a cargo (usually impermeable to the oral 
epithelium) should be applied to the surface of the TEOM and detection of the cargo 
underneath can then be measured.  Whether or not polymersomes cross intact depends on the 
route by which they traverse the epithelium and its permeability barrier.  From the current data 
we are unable to determine which path is taken by either PMPC-PDPA or PEO-PDPA 
polymersomes. However, there are two possible routes: (i) the intercellular pathway where 
material passes through lipid rich domains around the cells and (ii) the trans-cellular pathway 
where material passes in and out of the cells in each layer (Sood et al., 2005).   
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As discussed in the previous chapter the permeability of TEOM could not be measured with 
the equipment available. A previous study of tissue engineered skin, with a similar 
composition to the TEOM, found trans-epithelial potential was comparable to a split thickness 
skin graft (Bullock et al., 2007). However, similar studies have not been undertaken for 
TEOM.  
Despite this, preliminary experiments did show the TEOM was less permeable to dextrans 
with molecular weights of 20kDa and 40kDa compared to dextrans with molecular weights of 
4 and 10 kDa.  Naturally occurring oral epithelia have been shown to be impermeable to 
dextrans of 20kDa and greater (Selvaratnam et al., 2001). 
The data presented here demonstrates the potential for polymersome mediated therapies to be 
delivered for topical delivery to the oral mucosa in the future.  There are still many aspects to 
consider including how to deliver high enough concentrations of therapeutic agents topically to 
the oral mucosa for long enough periods of time to obtain a therapeutic effect.  Polymersomes 
may need to be formulated into mucoadhesives or gels to enable sustained release.  These and 
other formulations for drug delivery to the oral mucosa are reviewed in (Hearnden et al., in 
preparation). 
 Penetration of Polymersomes into MCTS 
The viability and growth of FaDu MCTS were not affected by exposure to polymersomes for 
11 days (Figure 3.21 and Figure 3.22). The same FaDu cells were previously seen to be 
significantly less viable when grown as monolayers and exposed to the same concentration of 
PMPC-PDPA (1mg/ml) for 48 hours (Figure 3.12).  It has previously been shown that cells are 
more resilient when grown in 3D compared to monolayers and it is referred to as the 
“multicellular effect” in (Green et al., 2004).  Green et al., (2004) showed MCTS and solid 
tumours were less sensitive to cytotoxic anti-cancer agents compared to cell monolayers.  
Possible reasons for this include the proportion of cells exposed to the agent (peripheral cells 
in 3D compared to all cells in 2D), the difference in cell metabolism in 3D compared to 2D or 
the way in which cells respond to cyto-toxic agents when in contact with other cells.  The stark 
difference between viability in 2D and 3D highlights the value of using MCTS and other 3D 
models to test novel agents prior to further studies.  
The MCTS model here is a valuable model which enabled us to investigate the penetration of 
polymersomes through a solid tumour.  The model includes necrotic and hypoxic regions as 
well as the penetration barrier, created by the 3D arrangements of cells. The uptake of 
polymersomes by cells within the MCTS shows promise for delivering anti-cancer drugs to 
those cells not often reached by chemotherapeutic agents delivered in a conventional manner.  
By using polymersomes labelled with Rho-PMPC-PDPA we were able to see that 80% of calls 
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within the MCTS took up polymersomes over 5 days, which correlated well to the images of 
the frozen sections.  
Though this experiment shows the location of the polymer it does not allow us to determine 
whether or not the polymersomes were able to reach the central region intact.  To test this we 
would need to deliver an encapsulated agent (not able to penetrate alone), such as a DNA 
plasmid to see if the agent reached the central region of the MCTS or whether its delivery was 
restricted to the superficial cells.  As discussed previously for the penetration into the TEOM, 
whether or not the polymersomes are intact depends on the route by which the polymersomes 
penetrate (trans-cellular or intercellular).   
The uptake of polymersomes by the cells within the MCTS was dramatically slower compared 
to the FaDu cells grown as monolayers.  The increase in polymersomes per cell increased 
linearly over the 5 days of polymersome incubation (Figure 3.24).  Polymersomes were 
internalised by 80% of cells within the MCTS.  In the future it would be interesting to see if 
the remaining 20% of cells which did not internalise these polymersomes were non-viable, not 
metabolically active or if the remaining 20% of cells could be reached with longer exposure 
times.   
Preliminary work in vivo has shown polymersomes are able to penetrate throughout a tumour 
from the injection site (Murdoch et al., 2010).  Polymersomes were found within the cytosol of 
cancer cells throughout the tumour after intra-tumoural injection (Murdoch et al., 2010).  
Polymersomes were also found in the spleen and liver associated with macrophages.  It is well 
known that tumours in vivo are populated by immune cells such as macrophages which 
phagocytise cell debris and necrotic cells so it is not surprising that these cells came into 
contact with and took up polymersomes.  It would be interesting to see if the macrophages 
phagocytised polymer with or without encapsulated cargo.  This in vivo study examined 
polymersomes which were fluorescently labelled but delivered no cargo.  The effect this 
uptake by macrophages may have clinically (especially if delivering cytotoxic agents) will 
need to be considered before taking polymersome therapy to the clinic.  
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Chapter 4: Novel Diagnostic 
technologies 
4.1 Aim 
To test novel diagnostic technologies for diagnosis of potentially malignant lesions and oral 
cancer using tissue engineered models. 
4.2 Introduction 
A non-invasive oral cancer diagnostic technology could dramatically improve patient care and 
enable widespread screening of at risk patient groups. This could enable oral cancer to be 
detected earlier and thus improve survival rates. The current gold standard for oral cancer 
diagnosis is histopathological examination of surgical biopsies taken from lesions with a 
suspicious appearance.  Histopathlogy is a well established method which produces reliable 
diagnoses, in the hands of expert pathologists, for numerous diseases.  However, as with any 
technique, there are disadvantages associated with surgical biopsies and their subsequent 
analysis.  It is hoped new technology could reduce the amount of biopsies which need to be 
taken and help clinicians to biopsy those parts of a lesions that will provide the most valuable 
diagnostic and prognostic information.   
From biopsy to diagnosis is a time consuming process which requires the expertise of the 
dentist, histology staff and pathologists before a patient can be told the outcome.  In the case of 
cancer this delay can cause significant stress and anxiety for the patient.  The procedure for 
performing a biopsy on a patient can be painful and if longitudinal monitoring of a suspicious 
lesion is required sequential biopsies must be taken.  The continuous biopsying of suspicious 
lesions potentially has other consequences.  In an area of abnormal tissue taking repeated 
biopsies will cause considerable trauma, inflammation and damage in that area which could 
speed up disease progression or exacerbate problems faced by the patient.  Kinsukawa el al., 
showed the presence of cancer cells in the circulation after taking a biopsy of a squamous cell 
carcinoma increasing the risk of metastasis (Kinsukawa et al., 2000). 
Of the suspicious lesions which are biopsied just 5% require treatment.  In the interests of 
time, money and patient satisfaction a technique which could achieve real time non-invasive 
imaging and diagnosis of suspicious lesions would be hugely beneficial. Another problem 
faced by clinicians is choosing the best area to biopsy which will give the most reliable result 
as only a small section of tissue can be analysed at a time in this way (Oliver et al., 2004).  
Technologies which improve this and reduce sampling errors could help earlier more accurate 
diagnosis of oral cancer to be achieved.   
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Here four different techniques for detecting OSCC were investigated in vitro using the tissue 
engineered models, described in chapter 2.  The first technique used an exogenous marker for 
cell metabolism to determine whether cancer cells could be distinguished from normal cells 
using an inherent difference in metabolic activity (Skala et al., 2007).  The second technique 
was impedance spectroscopy (described on page 56) a method which measures changes in 
bioimpedance of different tissues when a current is applied to the tissue.  FTIR was the next 
diagnostic technique evaluated.  FTIR is a spectroscopy method which can detect specific 
bonds within a tissue by measuring IR radiation absorbed by bonds within a sample.  Finally, 
optical coherence tomography (OCT) was investigated.  OCT is a form of imaging which 
detects differences in the optical scattering and reflectance properties of tissues up to 2-3mm 
deep (described on page 58).   
4.3 Materials and Methods 
 Metabolic stain for cancer detection 
 Materials 
C12 resazurin cell metabolic assay  
A stock solution of Vybrant Cell metabolic assay kit with C12 resazurin (Molecular probes, 
Invitrogen, Paisley, UK) was made as per the manufacturer‟s instructions.  Kit components 
were allowed to warm to room temperature before a 10mM stock solution was prepared by 
dissolving 1 vial of C12 resazurin into 20µl of DMSO.  To ensure all the C12 resazurin was 
fully dissolved the solution was sonicated briefly in an ultrasonic water bath.  
CellTrace™ Far Red DDAO-SE 
One vial of CellTrace™ Far Red DDAO-SE (Molecular probes, Invitrogen, Paisley, UK) was 
dissolved in 20µl of pre-warmed DMSO (Sigma Aldrich, Poole, UK).  The solution was mixed 
gently with a Gilson pipette until fully dissolved.  Twenty µl of dissolved CellTrace™ in 
DMSO was next added to 5ml of pre-warmed serum-free DMEM media. 
DAPI (4',6-diamidino-2-phenylindole) Cell nuclear stain preparation 
Ten mg of DAPI powder was dissolved in 10ml of PBS to make a concentration of 1mg/ml.  
This was then stored in 10µl aliquots at -20°C and protected from the light. Immediately prior 
to use 10µl of the DAPI stock solution was defrosted and diluted in 10ml of PBS to give a 
final concentration of 1µg/ml and kept protected from the light until used. 
 Exposure of cell monolayers to C12 – Resazurin 
metabolic indicator 
Three x 10
4
 cells were seeded onto glass coverslips (19mm diameter) (Menzel Gläser, 
Braunschweig, Germany) in 12 well tissue culture plates.  Cells were cultured for 48 hours 
prior to being exposed to C12 resazurin.   The stock solution of Vybrant Cell metabolic assay 
Chapter 4:Novel Diagnostic technologies 
172 
 
kit with C12 resazurin (Molecular Probes , Paisley, UK) was diluted in DMEM cell culture 
medium (without serum) to give a concentration of 10µM.  Cells were incubated with 300µl of 
10µM C12 resazurin solution for 15 minutes in fresh 12 well plates.  Coverslips with cells on 
were washed three times in excess PBS and imaged submerged in PBS on the confocal 
microscope.   
 Confocal Laser Scanning Microscopy of cell 
monolayers exposed to C12 – Resazurin metabolic 
indicator 
Models were imaged on a Zeiss LSM 510 META Laser Scanning Confocal Microscope (Carl 
Zeiss Inc., Germany) with corresponding LSM 510 META Software (Carl Zeiss Inc., 
Germany) using the 543nm laser and an Achroplan x40 magnification, 0.8 numerical aperture, 
water dipping objective (Carl Zeiss Inc., Germany).   
 Image analysis 
Five fields of view were chosen at random from each sample and imaged using identical 
settings.  Images were quantified using the Image J software (version 1.43u, National Institute 
of Health, USA).  The median intensity of fluorescence from each image was measured by 
drawing around each cell or cell colony on each image.  The median intensity was chosen 
instead of the mean as some areas of the images were over exposed which would make the 
mean value unrepresentative (Figure 4.1).   
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Figure 4.1 Method to quantify fluorescence intensity of cells exposed to C12 resazurin.  
(a) Example where area of image was over exposed. Image re-coloured with LSM Image 
browser software (Carl Zeiss Inc., Germany) to show over exposed regions in red. 
(b) Diagram to show how cells were selected prior to quantification by Image J software.   
Area inside the white line border was measured for median fluorescence intensity.   
 
 Statistics  
The distribution of fluorescence intensity values was not normally distributed so the median of 
these values was calculated (rather than the mean).  The median values of each area measured 
from the 10 fields of view (from two experiments) were combined and the median value and 
inter-quartile ranges were calculated using SigmaPlot v10.  A Mann-Whitney Rank Sum Test 
was performed to determine the statistical significance of the variation in fluorescence 
intensity between different cell types using SigmaStat v2.03.  
 Culture of DOK + NOK 3D Model 
Models were cultured with a mixture of normal oral keratinocytes and the dysplastic cell line 
DOK.  Prior to seeding onto the 3D model the DOK cells were labelled with CellTrace™ Far 
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Red DDAO-SE (Molecular probes, Invitrogen, Paisley, UK).  5ml of CellTrace™ solution was 
added to a sub-confluent T75 flask of DOK cells and incubated for 45 minutes. Cells were then 
washed thoroughly with PBS before being enzymatically detached using trypsin-EDTA, 
counted and seeded onto the 3D model.  
To culture the model with DOK and NOK cells, models were first seeded with NOF and NOK 
cells as for TEOM described on page 81.  After 5 days at ALI 2.5 x 10
5
 labelled DOK cells 
were added to the model in a stainless steel ring.  The model was cultured submerged with 
DOK cells inside the ring for 48 hours during which time cell culture medium within the ring 
was half replenished after 24 hours.  After 48 hours the model now with NOK and DOK cells, 
was raised to ALI and cultured for a further 6 days at ALI before being imaged. 
Labelled DOK cells were seeded into a separate 6 well plate to observe the intensity of 
CellTrace™ in the DOK cells throughout the experiment (Figure 4.2a). 
 Culture of Spheroid model 
Models of carcinoma in situ were cultured as previously described in (Colley et al., 2010). 
Briefly, TEOM models were cultured as described on page 81.  Seven day old FaDu MCTS 
were added onto the upper surface of the TEOM after 6 days at ALI using a Pasteur pipette.  5-
6 spheroids were added onto each model and cultured at ALI for 6 days. 
 Exposure of 3D models to C12 – Resazurin metabolic 
indicator 
Models were placed onto a 6 well tissue culture plate and 1ml of C12 – resazurin solution at a 
concentration of 10µM (prepared as described on page 171) was added to each well to fully 
submerge the 3D model.  The tissue engineered models were then incubated for 15 minutes 
before being washed 3 times in 4ml of PBS and then submerged in DAPI nuclear stain solution 
for imaging.  DAPI was used to help orientate the models during confocal imaging.  
 Confocal Laser Scanning Microscopy of 3D models 
exposed to C12 – Resazurin metabolic indicator 
Models were imaged on a Zeiss LSM 510 META Laser Scanning Confocal Microscope (Carl 
Zeiss Inc., Germany) with corresponding LSM 510 META Software (Carl Zeiss Inc., 
Germany) and a Achroplan x40 magnification, 0.8 numerical aperture, water dipping objective 
(Carl Zeiss Inc., Germany).  Z-stacks of 20-40 slices with 2µm between slices were obtained.  
Models were imaged using the following excitation/emission filters. 
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Laser (excitation 
wavelength) 
Emission filter Stain imaged 
543nm  BP 565-615nm C12 – resorufin (Vybrant™ 
cell metabolism assay kit) 
Ti:Sa multi-photon laser 
(780nm) 
BP 390-465nm DAPI nuclear stain 
633nm BP 650-710nm CellTrace™ Far Red 
Table 4.1 
Confocal conditions used to image C12 experiment 
 
 Quantification of 3D models using Image J 
Four slices from each z stack were used to quantify the intensity of the fluorescence signal 
from resorufin (the fluorescent reduced product of C12 – resazurin) and therefore the metabolic 
activity of that area of tissue measured.   Z-stack slices were chosen at 4 distinct points 
throughout the thickness of the tissue (slices which had no cells in focus on that slice were 
ignored) (Figure 4.3).  For the DOK + TEOM model the areas measured were those which 
were fluorescent in the red (resorufin) and the far red (CellTrace™) channels.  The intensity of 
just the red channel was quantified and the far red channel was used as a guide to which areas 
contained DOK cells labelled with CellTrace™ (Figure 4.2b). For the MCTS + TEOM models 
it was clear which areas resembled the normal oral mucosa and which were the FaDu spheroid 
regions because of differences in cell morphology and nuclear to cytoplasmic ratios compared 
to the TEOM (Figure 4.2 c and d). Only regions which had the features of MCTS were used to 
quantify the intensity of fluorescence from the FaDu spheroid regions.  Intensity of resorufin 
fluorescence from TEOM was calculated from TEOM only models exposed to C12 – resazurin. 
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Figure 4.2 Method to quantify fluorescence of different cell types within 3Dmodels 
(a) Fluorescence of DOK cells labelled with CellTrace™ was confirmed by imaging cells in 
monolayer using CLSM.  (white= CellTrace™  far red DDAO-SE ). (b) Slice of CLSM z-stack 
showing DOK cells in white and all cells containing resorufin fluorescence (red). 
Representative images of FaDu spheroids on the MCTS + TEOM model (c), and of normal 
epithelium on TEOM (d).  Scale bar = 50µm.   
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Figure 4.3 Method for quantifying 3D models exposed to C12 – resazurin.   
Areas of slice which contain cells in focus were highlighted and the area within the line 
measured using Image J software.  
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The Image J software (version 1.43u, National Institute of Health, USA) was used to quantify 
fluorescence of the red channel, corresponding to the reduced product of C12-resazurin, 
resorufin.  The median intensity of fluorescence from each image was measured by drawing 
around the areas which contained cells in focus on that slice (Figure 4.3).  The median 
fluorescence intensity for the highlighted areas of the four slices over the three experiments 
were combined and the statistics were performed as described on page 173.  
 FTIR 
 Materials 
FTIR Spectroscopy Device 
The device used for this study was the Spectrum 2000 (Perkin Elmer, Cambridgeshire, UK). 
Slides 
Low „e‟ MirrIR slides (Kevley Technologies, Ohio, USA) were used.  These slides were 
coated with layers of silver so there was no absorption in the range of wavenumbers used (400-
4000cm
-1
).   
 FTIR on tissue engineered models 
Tissue engineered models produced as described on page 81 were used to test the ability of 
FTIR to distinguish between healthy oral mucosa (TEOM) and three different models of 
OSCC (FaDu, DOK and SCC9).   
Initially, it was attempted to measure the FTIR spectra from models fixed in formalin or fixed 
in formalin and subsequently dehydrated in ethanol.  Unfortunately, this technique was 
unsuccessful due to high noise levels in the spectra because of the presence of water which 
absorbs in the mid IR range and the thickness of the samples (samples above 15µm in 
thickness can cause spectral saturation).   
For these reasons further studies were performed on paraffin embedded samples sectioned and 
mounted onto MirrIR slides.  Sample processing and sectioning was performed as described on 
page 84. Instead of heamotoxylin and eosin staining the slides were dewaxed using xylene (2 
minutes immersed in xylene) and dried prior to FTIR analysis.   
The reflective nature of the slides meant the transflection mode on the FTIR device was used.  
Sixteen scans were taken per sample, spectra from at least three samples of each cell type from 
three separate experiments were measured, spectra from the same cell type were averaged and 
the data was analysed and graphed in MATLAB.  
There were significant differences in signal intensities from the different samples due to the 
differences in the size of the section on each slide.  To overcome this, the spectra were aligned 
based on points on commonality to enable comparison between spectra to be performed.  
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 Impedance spectroscopy 
 Materials  
An impedance spectroscopy device was kindly provided by Peter Highfield (Zilico Ltd, 
Sheffield, UK). The probe was an APX100, designed for the clinical investigation of cervical 
tissue.  Figure 4.4 shows the device and the tips used as well as the electrodes on the end of the 
disposable tips.  These tips were sterilised prior to use by submerging in 70% IMS and then 
washed twice in excess PBS.  The measurements were downloaded onto a personal computer 
(PC) using Cervical Probe Applications Software (CPAS), revision 1.03 (Triteq, Berkshire, 
UK).   
 Impedance spectroscopy on tissue engineered 
models 
The sterilised disposable probe tip was connected onto the device and the tip placed in contact 
with the epithelial surface of the tissue.  In built software within the probe was used to tell 
when the measurements were completed.  At least 5 measurements were taken per model and 
each individual measurement was an average of 8 measurements, averaged by the probe.  
Different regions of the model were measured and an average of the measurements from the 
whole model was calculated.  Photographs of the device and the tip are shown in Figure 4.4. 
OCT imaging 
Four different OCT imaging devices were used in this project.  The specification of each 
machine is shown in Table 4.2. 
All samples were imaged by OCT in the 6 well tissue culture plates in which the models had 
been cultured, with the exception of the Optovue® system.  Samples were kept sealed, sterile 
and at an ALI (on a stainless steel grid with cell culture medium in contact with the bottom of 
the sample) for imaging.  Care was taken to ensure that the level of media was low enough that 
no moisture remained on the top surface of the sample because liquid causes strong reflective 
signals when imaged using OCT.  Condensation which occurred on the inside of the lid of the 
sample was removed using a hairdryer on the warm setting.  The Optovue® system has been 
developed for ocular application so the samples were placed in a 9cm
2
 Iwaki petri dish 
(Sterilin Ltd., Caerphilly, UK) with no cell culture media and clamped perpendicular 
(vertically) to the lens using a bench top clamp and stand. For the Optovue® system, samples 
were not in contact with cell culture media; however, the imaging was very rapid (less than 3 
minutes for 4 images) avoiding substantial damage to the cells. Models were sacrificed for 
histological analysis and compared to the OCT images.    
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Figure 4.4 Impedance spectroscopy device.  
(a) Disposable tip, (b) end of disposable tip (electrodes), (c) the hand held impedance 
spectroscopy device.   
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Table 4.2  
Specifications for OCT devices used in this project. 
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4.4 Results 
 Using C12 –resazurin to detect areas of dysplasia 
and carcinoma in situ. 
 Can Cancer and dysplastic cell lines be 
distinguished from normal oral cells in cell 
monolayers using a metabolic activity marker? 
A Vybrant™ cell metabolic assay kit with C12 –resazurin (Molecular probes, Invitrogen, 
Paisley, UK) was used to measure the metabolic activity of a number of different cells 
(primary normal cells, dysplastic cells and cancer cell lines) in monolayer culture.  The active 
ingredient of Vybrant™ cell metabolic assay kit is resazurin, a non-fluorescent, non-toxic 
molecule which can be reduced by metabolically active cells.  The reduced product, resorufin, 
can be detected using fluorescence (excitation 530nm, emission 590nm).  The resazurin used 
here is a lipophilic C12 –resazurin which exhibits better cell retention and shorter exposure 
times compared to resazurin without the carbon chain, commonly known as alamarBlue® 
(AccuMed International, Inc.) (Probes 2001).  The different cell types were all exposed to C12 
–resazurin for 15 minutes and the intensity of resorufin fluorescence was imaged using CLSM.  
Figure 4.5 shows representative images of the different cell lines and primary cells post C12 –
resazurin exposure.  
Figure 4.6 shows the median intensity of fluorescence resulting from the different cell types 
cultured in monolayers.  Figure 4.6 (a) shows that the cell lines PE/CA-PJ34, SCC9, SCC25, 
D20 and D19 had a statistically higher median fluorescence compared to NOK cells.  The 
highest fluorescence was shown by the dysplastic cell lines D19 and D20 implying these cells 
were the most metabolically active.  The Cal27 cell line showed statistically lower median 
fluorescence compared to the NOK cells and the FaDu cells were similar to NOK.  When 
compared to NOF (Figure 4.6b) all cell lines except Cal27, FaDu, SCC4, PE/CA-PJ34 and 
DOK showed significantly higher fluorescence and therefore had an increased metabolic rate 
compared to NOF.   However, while these results achieved statistical significance (due to the 
high n number) the extent of the difference in fluorescence intensity between the different cell 
lines was small. 
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Figure 4.5 Representative images of cell lines and primary cells exposed to C12 -resazurin.  
Scale bar= 50µm. n=2 
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Figure 4.6 Median fluorescence of different cell types exposed to C12-resazurin compared 
to NOK (a) and compared to NOF (b). Box plot shows data between 25th and 75th 
percentiles. Error bars show 10th and 90th percentiles. * = p<0.05, **= p<0.01, ***= p<0.005. 
n=2  
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 Detecting regions of Carcinoma in situ and 
dysplasia in TEOM using a cell metabolic activity 
indicator 
Three different 3D tissue engineered models were used here as models to test if the C12 –
resazurin cell metabolic activity marker could be used to detect regions of carcinoma or 
dysplasia within an epithelia.  Histology for each of these models is shown in Figure 4.7.  
 
Figure 4.7 Histological appearance of 3D models used to test the ability of C12- resazurin to 
detect regions of cancer within tissue engineered models. 
(a) MCTS + TEOM, region with MCTS on the right, normal mucosa on the left. (b) DOK + 
TEOM epithelium comprised of both NOK and DOK cells. (c) TEOM (note: epithelium 
thinner compared to previous chapters as cultured for shorter time at ALI). n=3. Scale = 
200µm 
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The first model was the MCTS + TEOM model which comprised of a healthy epithelium with 
regions of carcinoma in situ.  This model was made by culturing FaDu MCTS on the surface 
of the TEOM once the TEOM was raised to ALI.  This model of carcinoma in situ had healthy 
regions of mucosa adjacent to areas which resembled carcinoma with necrosis and abnormal 
cell morphology (Figure 4.7) also described in (Colley et al., 2010).  The second model was 
DOK+ TEOM.  This model was initially cultured the same way as the TEOM model; however, 
after 3 days at ALI dysplastic DOK cells which had been previously labelled with CellTrace™ 
were added to the models.  As a healthy control the TEOM model of healthy epithelium was 
used.   
Figure 4.8 shows representative slices from a CLSM z-stack of images for each of the different 
models after they had been exposed to C12- resazurin for 15 minutes. The three different 
models showed different patterns of fluorescence when imaged using CLSM (Figure 4.8).  The 
areas which contained the FaDu MCTS had a dense distribution of cells which was distinct 
from the regions of NOK cells.  The DOK cells were labelled with CellTrace™ so could be 
distinguished from the NOK cells using fluorescence in the far red range.   The appearance of 
these cells was in many cases different to the NOK cells but both cell types were interspersed 
in this model.  Figure 4.8 demonstrates the difference in the appearance of the TEOM exposed 
to C12- resazurin at the upper most surface (d) and deeper into the epithelium (c).   
Differences in nuclear morphology and nuclear to cytoplasmic ratios could also be seen using 
CLSM.  The TEOM had an even distribution of fluorescence throughout the cell cytoplasm 
with dark regions where the nuclei were, in all but the most superficial slices which appeared 
spotty.  There were fewer nuclei per field of view and the area of each cell was large when 
compared to the FaDu and DOK cells in the other models.  The upper most surface of the 
models showed the characteristic pattern seen in Figure 4.8 (d) when the TEOM had been 
cultured for over a week.  This pattern was not seen in the models cultured for less than 1 week 
where the cells were less differentiated. 
When the images from the three models were quantified (Figure 4.9) the normal oral mucosa 
models (TEOM) showed a statistically higher (p< 0.001) fluorescence signal after C12- 
resazurin exposure compared to the DOK + TEOM models and the MCTS + TEOM models. 
The models with cancer cells present were approximately 30% less fluorescent than the control 
model of healthy oral mucosa.   
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Figure 4.8 Representative images of 3D models exposed to C12- resazurin imaged using 
CLSM.  
Red = resorufin fluorescence from metabolically active cells.  Models exposed to C12- 
resazurin for 15 minutes (a) MCTS + TEOM, (b) DOK + TEOM.  (c) Shows TEOM  ~20- 30µm 
deep (d) shows most superficial surface of TEOM.  Scale bar =50µm. n=3 
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Figure 4.9 Median intensity of resorufin fluorescence.  
Resorufin is a marker of cell metabolism. TEOM = Tissue engineered oral mucosa, model of 
healthy epithelium. DOK + TEOM = model of dysplasia, MCTS + TEOM = model of Carcinoma 
in situ. *** = p< 0.001. Error bars = s.d. n=3.  
 
 Impedance spectroscopy: TEOM vs cancer models 
Tissue engineered models cultured from five different cancerous or dysplastic cell lines were 
cultured for at least 7 days at ALI before their impedance values were measured.  The 
histology of these models can be seen in Figure 4.7 on page 185. 
The models cultured from cancer cell lines on DED were compared to DED alone and TEOM 
cultured with normal oral keratinocytes.  The average impedance measurements are shown in 
Figure 4.10.  The impedance values at different frequencies were relatively similar for all 
models except the TEOM.  De-epidermised dermis (DED) demonstrated the lowest impedance 
to the current applied, as would be expected since impedance is created as the electrical current 
is impeded by the cells.  The models cultured from the PE/CA-PJ34 cell line showed the 
highest impedance, with FaDu also showing slightly higher impedance compared to the other 
models.  No significant differences were seen between the TEOM and the cancer cell models 
as the variation between measurements, even on the same model, were large (standard 
deviations, not shown on graph for clarity, but were in some cases over 100 Ohms).   
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Figure 4.10 Comparison of difference impedance values from different tissue engineered 
models cultured from normal cells and cancer cell lines on DED.  n=1 for all except TEOM 
n=5. 
 
 
  
Chapter 4:Novel Diagnostic technologies 
190 
 
 
 
Figure 4.11 Comparison of impedance from TEOM and in vivo buccal mucosa.   
White circles show one measurement taken, black triangles show the average of all TEOM 
readings.   Error bars = s.d. 
 
 Impedance spectroscopy: TEOM vs in vivo buccal 
mucosa 
Figure 4.11 shows the impedance values for the average of all TEOM models (black triangles).  
The black circles show the impedance values obtained from in vivo measurements of a healthy 
buccal mucosa.  There is a large difference in the values obtained from the tissue engineered 
models and the naturally occurring tissue.  The white circles show the readings from one 
TEOM model.  The data obtained here were more similar to the values obtained in vivo 
however, this result was not reproducible.   
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 In vivo impedance measurements 
 
 
Figure 4.12 In vivo impedance measurements of buccal mucosa and tongue.   
Average of 16 readings from one volunteer.  n=1 
 
 
 Impedance spectroscopy: Buccal mucosa vs 
tongue in vivo 
Impedance was measured on the tongue and the buccal mucosa of a healthy volunteer.  The 
impedance values obtained from a single healthy volunteer varied depending on the area of the 
mouth the measurement was obtained from (Figure 4.12).  For example the impedance value at 
2.4 kHz is 114 Ohms for the tongue and 1522 Ohms for buccal mucosa.  Differences can be 
seen at almost all frequencies except for measurements at 300Hz and at the highest 
frequencies.  The variation between measurements from the same region of the mouth was 
very small although it should be noted this data was from only one volunteer.  There may be 
person to person variation.  
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 FTIR on models of OSCC 
The FTIR spectra obtained from sections of four different tissue engineered models are shown 
in Figure 4.13.  MirrIR slides mounted with tissue sections were exposed to MidIR radiation 
(500-4000 cm
-1
). The four different models showed some areas of commonality, representing 
bonds found in our models of healthy, precancerous and cancerous tissues.  However, there 
were however, areas of each spectra which differed between samples.  The following peak 
assignments from Movasaghi et al., have been used to determine the bonds which are 
represented by each peak (Movasaghi et al., 2008).  The main peaks discussed here are listed 
in Table 4.3, for a full list of all bonds and their respective wavenumbers see (Movasaghi et 
al., 2008).   
 
Wavenumber (cm
-1
) Band representation 
1238 Amide III 
1240 Amide III 
1337 Collagen 
CH2 wagging 
1403 CH3 of collagen and of methyl groups of proteins 
1455 Methyl groups of skeletal proteins 
CH3 of proteins  
C-O-H 
1462 Paraffin 
1470 CH2 in lipids 
1549 Amide II 
1644 Amide I 
2848 Cholesterol, phospholipids, creatine 
2916 Cholesterol, phospholipids, creatine 
2955 CH 
3200-3500 Water 
Table 4.3 
Peak assignments of the FTIR spectroscopy bands used in this study (Movasaghi et al., 
2008). 
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Figure 4.13 Average FTIR spectra of four different tissue engineered models TEOM, FaDu, 
DOK and SCC9, aligned according to commonalities.  n=2 
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Figure 4.14 Comparison of FTIR spectra resulting from TEOM and FaDu models.  
(No peaks visible between 1700 and 2500 cm-1).  
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Figure 4.15 Comparison of FTIR spectra resulting from TEOM and DOK models. 
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Figure 4.16 Comparison of FTIR spectra resulting from TEOM and SCC9 models 
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Figure 4.14 compares the spectra from TEOM models and the models of OSCC cultured with 
FaDu cells.  For images of the histological appearance of these models see Figure 2.3 and 
Figure 2.13.  Comparing the spectra resulting from analysis of the TEOM and the model 
cultured with FaDu cells (Figure 4.14) reveals several differences in specific peaks.  The peak 
at 2955 cm
-1
 which corresponds to a C-H bond was far more pronounced in the TEOM 
compared to the FaDu model. The peaks at 2916 cm
-1 
and 2848 cm
-1
 were also more 
pronounced in the TEOM; these bonds correspond to stretching vibrations of CH2 and CH3 
bonds found in cholesterol, phospholipids and creatine.  Peaks at 1644 cm
-1
, 1549 cm
-1
, 1238 
cm
-1
 and 1240 cm
-1
 (representing amides) were all more pronounced in the TEOM spectra 
compared to the FaDu model.  Peaks at 1644cm
-1
 and 1549cm
-1
 corresponding to amide I and 
amide II respectively, were higher in the TEOM model compared to the FaDu model‟s spectra.  
Comparing the spectra of TEOM and spectra from the models cultured with DOK cells (Figure 
4.15), showed very similar peaks in the 1000 cm
-1 
and 1700 cm
-1
 range. However, the peaks at 
2916 cm
-1 
and 2848 cm
-1
, both corresponding to cholesterol, phospholipids and/or creatine 
were elevated in the TEOM model compared to the DOK model (the same trend was seen for 
the FaDu model). Peaks at 1644cm
-1
 and 1549cm
-1
 corresponding to amide I and amide II were 
also slightly higher in the TEOM.  There was a 1cm
-1
 shift although this may be due to the 
detection accuracy of the machine rather than a change in the bonds present.  
The spectra from the SCC9 models (Figure 4.16) showed the opposite trend with higher peaks 
at 2916 cm
-1 
and 2848 cm
-1
 compared to the TEOM implying there were higher levels of 
cholesterol, phospholipids and or creatine in the SCC9 model than were in all the other 
models. There was also a larger peak at 2955/6 corresponding to the C-H bond.   
The region between 3000 and 3500 cm
-1
 varied between spectra however, this region is 
affected significantly by water so it was not analysed.  The peak at 1462 cm
-1
 corresponds to 
paraffin.   
 OCT on models of OSCC  
The ability of optical coherence tomography (OCT) to non-invasively image tissue engineered 
models of healthy oral mucosa and OSCC was next investigated.  Four different OCT systems 
were tested and their ability to clearly image beneath the surface of the epithelium was 
compared.  Details of the four different OCT systems and their specifications can be found in 
Table 4.2. The tissue engineered models used were cultured as described in chapter 2. Figure 
4.17 gives a brief guide to interpreting OCT images.  
Figure 4.18  shows the SCC9 model imaged with all four systems.  All four systems showed a 
distinct difference between the epithelium and the connective tissue and showed the 
topography of the surface of the models.  The MD SS-OCT and TD-OCT systems were able to 
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obtain a signal from deeper into the tissue compared to the other two systems as these systems 
had a higher wavelength light source compared to the FD-OCT and the Optovue® systems.  
Non-homogenous human tissues such as the oral mucosa exhibit high light scattering 
properties, reducing the depth of penetration of light.  Light of longer wavelengths is able to 
penetrate further into tissues as it experiences less scattering, this is why near IR light is used 
for OCT devices.  Axial resolution was best when using the FD-OCT and Optovue® systems 
and clearer images of the epithelial/connective tissue junctions could be obtained.    By 
averaging several images the signal:noise ratio could be increased, as demonstrated in the 
Optovue® system images where 10 scans were averaged.  Due to relative similarities in 
images obtained with the different systems and the ongoing development of the TD-OCT and 
the FD-OCT systems, it was decided that only the Optovue® system and the SS-OCT would 
be used for the remainder of the project.   
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Figure 4.17 A guide to interpreting OCT images.  
Grey scale images were obtained on all OCT systems. White spots on the surface result 
from reflection of liquid on the surface.  The whitest signals result from the areas of tissues 
which reflect the greatest amount of light.  Different shades of grey come from tissues with 
different light scattering and reflection properties.  The black areas show where no signal 
can be obtained.  Image 4mm x 2mm 
 
 OCT images of TEOM and OSCC 
Six different tissue engineered models were imaged using OCT.  OCT images obtained from 
the SS-OCT system and the Optove® system for all 6 models are shown and compared to the 
histology of the corresponding model (Figure 4.19 to Figure 4.24).  All figures show 
representative images.  The experiment was repeated between 1 and 3 times, depending on the 
model and the OCT device. 
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Figure 4.18 OCT images of 3D model cultured from SCC9 cells for 3 weeks at ALI resulting 
from four different devices, compared to histology. 
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Figure 4.19 OCT image of TEOM.  
NB images are from different areas on the model.  
 TEOM 
Figure 4.19 shows the TEOM imaged using OCT.  Unfortunately, the models cultured during 
the time of these experiments had a relatively thin epithelium compared to models cultured at 
other times.  Despite this the epithelium was still able to be distinguished from the connective 
tissue.  The images from both OCT systems clearly show the epithelial connective tissue 
junction in the models.  The epithelium is darker compared to the underlying connective 
tissues implying that the level of light reflected and scattered from the epithelium is less than 
for the connective tissue.  The epithelium appears thinner in the histology image. However, it 
should be remembered that samples shrink (around 30%) during histological processing.  The 
image from the Optovue® system gives better resolution and less noise compared to the SS-
OCT system. 
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Figure 4.20 OCT image of DOK model 
 DOK 
The epithelial connective tissue junction is clearly visible in the image of the DOK model 
obtained from the Optovue® system but it is difficult to distinguish a clear boundary between 
the epithelium and the connective tissue in the SS-OCT image (Figure 4.20). The SS-OCT 
image has a dark superficial region which probably corresponds to the epithelium.  In the 
Optovue® image the axial resolution is better giving more detailed information regarding 
epithelial connective tissue junction morphology.  As with the TEOM, the epithelial region 
appears darker than the underlying connective tissue.   
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Figure 4.21 OCT image of SCC9 model 
 SCC9 
The histology of the SCC9 model showss large amounts of extracellular proteins, stained in 
pink, most likely keratin, in distinct regions of the epithelium (Figure 4.21). In the images from 
Optovue® system the epithelium is as bright as the connective tissue in areas.  This is in 
contrast to the other epithelia which had relatively dark epithelia compared to the connective 
tissue.  This could be due to the higher reflective or scattering properties of the keratin.  Higher 
light back scattering or reflective properties of a tissue region show as a brighter region in the 
image.  The brightness of the epithelium in the image obtained from the SS-OCT system was 
more uniform suggesting that the difference between cells and keratin cannot be distinguished 
when using this system.  
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Figure 4.22 OCT image of SCC25 model.  
Red arrow shows white line, possibly keratin.  
 SCC25 
The SCC25 models also contain large amounts of ECM proteins, most likely keratin, in areas 
of the epithelium.  The range of brightness in the epithelium in images from the Optovue® 
system was clearly apparent for the SCC25 models. In the Optovue® image in Figure 4.22 
there is one area where there is a bright white line (arrow on figure) a few microns superficial 
to the dark line of the epithelial connective tissue junction.  This bright white line could 
indicate the junction between keratin and cells in the SCC25 epithelium (arrow on Figure 
4.22).  
  
Chapter 4:Novel Diagnostic technologies 
 
205 
 
 
 
Figure 4.23 OCT image of D20 model 
 D20 
There was very little difference in the brightness of the epithelium compared to the brightness 
of the connective tissue in the D20 models imaged with both the SS-OCT system and the 
Optovue® system (Figure 4.23).  Despite this, there is a dark region where the epithelial 
connective tissue junction lies suggesting the scattering and reflective properties of the 
epithelial connective tissue junction proteins is different to the optical properties of the tissue.   
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Figure 4.24 OCT image of Cal27 model 
 
 Cal27 
The appearance of the Cal27 model was severely dysplastic and the epithelium formed two 
distinct layers. There was a layer of dysplastic cells adjacent to the epithelial connective tissue 
junction and superficially to this a layer of highly keratinized cells (Figure 4.24).    The models 
also had an unusual surface topography, not flat or smooth as in the TEOM but rather a lumpy 
surface created by the pattern of keratinisation. The surface topography could easily be 
determined using OCT, with a clearer image obtained using the Optovue® system compared to 
the SS-OCT system.   The two layer structure of the model could also be determined in the 
Optovue® system.  The superficial keratin layer was brighter than the underlying epithelium.  
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The portion of the epithelium which is made from non-keratinized cells appeared as a dark 
band below the bright keratin.   A boundary can also be seen between the dark band and the 
underlying connective tissue, corresponding to the epithelial connective tissue junction.  The 
highly reflective and back scattering keratin appears to cause a “banding” deeper in the image.  
This appearance of these white bands is similar to that seen if there is moisture on the surface 
of the model.  This banding was also described by Wilder-Smith et al., (Wilder-Smith et al., 
2009) in OCT images of cancer in vivo (see Figure 1.16 on page 67). 
 In vivo OCT imaging of human oral mucosa 
Figure 4.25 shows an OCT image obtained by the Optovue® system of the inner mucosal 
surface of the lower lip of a healthy volunteer and compares it to the histology of this region of 
the oral cavity.  The OCT image clearly shows a distinction between the epithelial layer and 
the underlying connective tissue.  The connective tissue portion is brighter than that seen in the 
tissue engineered models, most likely due to the high water content of the connective tissue in 
vivo.  Within the connective tissue structures such as the minor salivary glands and blood 
vessels could be made out (features not present in these tissue engineered models).  The 
Optovue® system was able to image roughly 500µm deep into the tissue with good resolution.  
The epithelium appears smooth and has uniform brightness throughout.  
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Figure 4.25 Histology of the mucosal surface of the lower lip from (Slomianka 2009) and 
OCT of the mucosal surface of the lower lip, in vivo in a healthy volunteer. n=1 
 
4.5 Discussion 
An ideal novel detection device for use in the diagnosis of oral cancer should:  
 be non-invasive, 
 be simple to use, 
 enable point-of-care real-time diagnoses,  
 be affordable for general dental practices as well as hospitals,  
 have high specificities and sensitivities,  
 have good patient acceptability. 
Here we evaluated the potential of four different methods for potentially malignant lesion 
diagnosis using tissue engineered models.  
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 C 12 – resazurin as a marker for cancer  
C 12 – resazurin is a tool used in cell culture to measure the metabolic activity of cells in 
culture.  It is well known that cancer cells demonstrate higher metabolic activity compared to 
healthy tissue surrounding them.  The non-toxic, short exposure time and fluorescent nature of 
this marker (Vybrant™ cell metabolic activity kit with C 12 – resazurin) led to the simple 
hypothesis; could a fluorescent metabolic marker be used as a tool to aid the diagnosis of oral 
lesions, and could it differentiate between healthy, premalignant and cancerous tissues? 
 Monolayers 
The C 12 – resazurin metabolic marker was reduced by all cell types tested here after 15 
minutes exposure.  The cell stain remained in the cells when washed and cell monolayers on 
glass cover-slips could clearly be imaged using CLSM.  Different cell types exhibited different 
intensities of fluorescence.  Despite the overlapping variances the differences between many of 
the cancer cell lines and the primary cells were statistically significant due to the very large n 
number (2 experiments, 5 images per cell type in each experiment and 1-5 areas of each image 
quantified depending on the amount of cells and cell colonies per image).   All cell lines except 
the Cal27 and FaDu cells showed higher fluorescence intensity, and therefore metabolic 
activity, compared to the normal oral keratinocytes.  It was expected that the cancerous and 
dysplastic cell lines would all show higher metabolic activity compared to the normal oral 
keratinocytes.  However, this was not the case in 2D cell culture conditions.  It should be noted 
that the differences in intensity were mostly in the order of 10-50% between the cell lines and 
NOK cells.  NOKs are also known to be highly metabolically active in vivo as they continually 
replenish the cells of the oral epithelium.  The 2D in vitro environment is an artificial one and 
this experiment had many limitations.   
The intensity of fluorescence seems to relate to the rate of proliferation that different cell types 
undergo.  It has been observed in the laboratory that the D19 and D20 cell lines proliferate 
faster than other cell types. These two cell lines were the most metabolically active when 
measured using the C12- resazurin metabolic activity kit.  It is logical to expect that metabolic 
rate and proliferation are connected as cell proliferation and division are some of the most 
metabolically demanding processes which the cell undergoes (Skala et al., 2007).  The Cal27, 
FaDu and PE/CA-PJ34 cell lines proliferated slowest in culture (observations from culturing 
these cell lines in the laboratory) and these gave the lowest intensities of resorufin fluorescence 
and therefore metabolism.   
The values obtained from NOK metabolic activity varied greatly between batches of 
keratinocytes from different individuals and different experiments.   
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In conclusion, these experiments showed that C12-resazurin can be used as a marker for 
metabolic activity and is well retained by the cells and can be imaged easily using CLSM.  The 
majority of cell lines tested did show significantly greater metabolism compared to NOK and 
NOF. However, the actual differences in intensities were small and varied greatly.  The 
intensity of fluorescence does appear to be related to cell proliferation but a specific 
experiment testing proliferation alongside resorufin intensity would be needed to confirm this.  
This metabolic marker is non-toxic and the short exposure time, 15 mins, means that 
practically it has potential.  However, the variation in normal cells make this a very inaccurate 
method to identify malignant cells and this method would detect any cells which had an 
increased metabolic activity rather than specifically cancer cells.  This would include cells 
involved in wound healing or non-malignant disease processes involving increased 
proliferation of oral keratinocytes e.g. oral lichen planus, papilloma virus infected cells etc.  
There was also a large variation in the intensity of fluorescence between samples so for a 
clinician to be able to correctly distinguish healthy tissue from tissue with increased metabolic 
activity would be challenging as there will be patient to patient variation as well as sample to 
sample variation.      
 In 3D models of oral cancer and dysplasia 
The 3D models of normal oral mucosa (TEOM), dysplasia (DOK+ TEOM) and carcinoma in 
situ (spheroid +TEOM) gave different patterns of fluorescence and different fluorescent 
intensities post C12- resazurin exposure.  Confocal microscopy was able to image resofurin at 
depths of up to 30µm. Although limited, this depth of imaging was enough to visualise the 
metabolic activity of the most superficial layers of cells.  The limited penetration could be due 
to several factors including penetration of the C12- resazurin stain across the epithelial 
permeability barrier with just 15 minutes exposure, the scattering effect of the tissue on the 
light and the physical limitations of 543nm wavelength light penetration through biological 
tissues.  Further studies could include a time course experiment to see if increased exposure 
time resulted in better penetration. 
Clinically, the restricted depth of imaging could be problematic as the most metabolically 
active cells are the proliferative basal keratinocytes. The most superficial cells of the healthy 
epithelium are not metabolically active as these cells are terminally differentiated and some 
cells lose their nuclei. Furthermore, early dysplastic change in the oral epithelium is evident 
first in the basal 1/3 of the epithelium.  
Vybrant™ Cell Metabolic Assay Kit shows better cell retention compared to alamarBlue® and 
this results in clear imaging of individual cells within an epithelium in 3D (Probes 2001).  The 
most superficial surface of the TEOM showed strong and spotty staining for resorufin.  The 
most superficial cells would not be expected to be metabolically active however, the cells on 
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the uppermost layer of the TEOM model may not have fully differentiated at the time of C12- 
resazurin exposure and therefore the cells would still have some metabolic activity.  In deeper 
cells the staining did not have this spotty distribution but was uniformly stained across the 
cytosol.  This superficial spotty pattern could be due to resorufin becoming bound to the 
keratin in the sample or due to cell damage.  
Although many of the cancer cell lines tested in monolayer gave higher median fluorescence 
intensity compared to normal cells (Figure 4.6), the cells used here to model cancer in 3D did 
not. The FaDu cells had slightly, but not significantly, lower fluorescence than NOK and the 
DOK cells were more fluorescent compared to NOK but not significantly so in the previous 
monolayer studies.   
In 3D the TEOM was significantly more fluorescent compared to the DOK + TEOM and the 
MCTS + TEOM models.  This could be due to NOK cells having a higher metabolism in 3D 
compared to cancer cells.  It could also be due to a limitation of this method for quantifying the 
fluorescence in the 3D models.  The ratio of nucleus to cytoplasm in the TEOM model was 
much lower than in the other two models (Figure 4.6).  The high proportion of nuclei included 
in the measurements of the DOK +TEOM and spheroid + TEOM models could have caused a 
reduction in the median fluorescence of the areas measured as the nuclear region of the cell did 
not take up the stain and was therefore not fluorescent distorting the values. The brightly 
fluorescent spots seen on the TEOM models (potentially due to the keratin) may have also 
affected the values.  
The original aim of this experiment was to see if the C12- resazurin measure of metabolic 
activity could be used as a quantitative marker for cancer in an oral epithelium.  It was hoped 
more metabolically active cancer cells would be distinguishable from healthy epithelium using 
this marker.  The differences in fluorescence in 3D have actually proved to be opposite to the 
initial expectation possibly due to the reasons outlined above.  The differences in fluorescence 
intensities were small making the C12- resazurin metabolic marker not clinically useful when 
looking at the difference in intensity of fluorescence between cell populations.  Despite this, 
the C12- resazurin may be useful for looking at the morphology of cell populations in a 
patient‟s epithelium.  The current gold standard for oral cancer detection is histology.  This is a 
qualitative method which looks at the morphology of cells, their nuclei and the arrangement of 
cells throughout the epithelium.  When resorufin (the reduced product of C 12 – resazurin) is 
retained within cells it clearly shows the morphology of the cell, the size, shape and 
distribution of cell nuclei and the cytoplasm to nuclear ratio.  This could be of benefit 
clinically for imaging changes in cell and nuclear morphology in the most superficial cells.  
These occur in severe epithelial dysplasia and carcinoma in situ. Unfortunately, confocal 
microscopy combined with this stain were not able to penetrate into the deeper layers of the 
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epithelium and would therefore not be able to detect changes when they occur in the basal 
regions of the epithelium, as are seen in moderate and mild dysplasia.    
While it may be useful as a marker for highly proliferative and aggressive carcinoma, the 
greatest need is for a marker for early stage tumours which need to be distinguished from 
suspicious benign lesions which do not require treatment. This approach is unlikely to be 
useful for this purpose.   
Slow imaging capture rates also make this method impractical in vivo as movement artefacts, 
resulting from patients moving during image acquisition, make accurate imaging not feasible 
without an anaesthetic.  This along with the complexity, cost and time consuming nature of 
this type of imaging make it unlikely to be taken up widely for screening of at risk patient 
groups for the detection of oral cancer.   
 Impedance spectroscopy 
Impedance spectroscopy is a non invasive method which is able to detect changes in 
bioimpedance, which in turn give information about the electrical properties of the tissue in 
contact with the probe.  Many factors affect the electrical properties of a tissue including cell 
density inter-cellular junctions and cell type.  These factors are all affected in cancer 
progression.  The probe applies a current to the tissue and changes in the impedance to the 
current can be detected in different tissues.  The impedance spectroscopy system used here has 
been shown to be able to distinguish not just cervical cancer from normal cervix but can also 
distinguish between different cervical intraepithelial neoplasia (CIN) grades of cervical 
dysplasia (Abdul et al., 2006).  A simpler system than the one used here has recently been 
reported as being under investigation for detection of tongue cancer (Sun et al., 2010).  Sun et 
al., have shown in  that cancerous regions of the tongue, which are disordered with less tight 
inter-cellular junctions could be distinguished from healthy tissue as cancerous regions, and 
had lower impedance at low frequencies (20Hz and 50kHz) (Sun et al., 2010).  The impedance 
values are lower in cancerous regions as it is easier for the current to pass around disordered 
cancer cells compared to healthy oral epithelium where the cells were very well organised with 
strong inter-cellular junctions.  The differences were not seen at higher frequencies (1.3MHz 
and above) as the current is able to pass through cells as well as around them at these 
frequencies (Sun et al., 2010).  
This chapter presents data obtained from a quick study to evaluate differences between cancer 
and healthy oral mucosa in vitro. Unfortunately, the tissue engineered model system used here 
failed to show a significant difference between the models cultured from the cancer cell lines 
and the TEOM.  There was a large amount of variation between readings.  The only obvious 
difference was that the TEOM impedance values varied between different frequencies whereas 
the impedance values from the cancer models were not dependant on frequency.   
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There was a large variation in the measurements obtained from the tissue engineered models. 
This could be due to a number of factors including the fragile nature of the cultured 
epithelium, differences in epithelial thickness in different areas and differences in the thickness 
of the DED onto which the epithelium was cultured. The process of taking the measurement 
may have damaged the epithelium, affecting the impedance values.  The method of measuring 
needs to be refined as currently there could be differences in the level of pressure applied to 
get the probe into contact with the model, the temperature of the model and the moisture on the 
surface of the model.   
It was hoped that this technique would allow us to demonstrate the similarities between TEOM 
and naturally occurring buccal mucosa.  Unfortunately, for the most part there was a large 
difference in values obtained from these samples, except in one (non-reproducible) case 
(Figure 4.11).  Unfortunately, for these reasons it appears that the tissue engineered models 
here are not suitable for testing this technology and testing in patients and volunteers will 
provide more robust data and information on this technology.   
The readings, taken in vivo of buccal mucosa and tongue, showed very different patterns of 
impedance depending on the area of the mucosa.  It would be interesting to study this further 
and look at the impedance of all areas of oral mucosa including the palate, floor of the mouth, 
buccal, gingivae and tongue.  Comparing these to histology images for the corresponding 
region of tissue would enable us to gain a better understanding of how the epithelia thickness 
and morphology affected the impedance values.  The variation in impedance in different areas 
of the mouth (apparent in Figure 4.12) means criteria for diagnosing oral cancer in different 
anatomical locations needs to be site specific and the usefulness of this technology may be 
limited to some regions. The value of impedance spectroscopy for determining tongue OSCC 
has already been demonstrated (Sun et al., 2010) and suggests more in vivo testing of healthy 
and diseased tissues could further prove the value of impedance spectroscopy for clinical 
diagnostics in the oral cavity.   
Impedance spectroscopy has the advantage that it is simple to perform, non-invasive and 
practical for oral applications. The accuracy for determining the borders of potentially 
malignant lesions is limited by the electrode spacing on the tip of the probe which may be one 
of the limitations of impedance spectroscopy in the future.  
  FTIR 
FTIR is a method of spectroscopy which enables specific bonds within a sample to be 
determined using IR radiation.  The spectra taken here are preliminary data which have been 
used to develop an effective method to measure tissue engineered oral models spectra to 
evaluate the potential of this technology.   
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In this study, FTIR was not able to get meaningful spectra from live or fixed tissue which had 
not been sectioned due to water absorption of IR radiation and the spectral saturation of 
samples thicker than 15µm.  However, it was possible to collect spectra from wax embedded 
paraffin sections and all the spectra shown in this project were collected this way. This 
highlights the potential for this technology to be used alongside the current method of 
diagnosis, histopathological analysis of surgical biopsies.  FTIR could provide adjunctive 
objective information regarding the chemical make up of a biopsy to improve diagnoses which 
currently rely on subjective opinions of morphological appearances.  Many diagnostic 
procedures also require immunohistochemical staining of specific proteins.  Although this 
procedure is very well established and reliable it is time consuming and subject to personal 
interpretation.  A method such as FTIR which could determine the biomolecular composition 
quickly and accurately could be of benefit in these cases.   
The small sample size and differences in sample area on each slide may have altered the 
results. However, some differences could be seen which could be of interest in the diagnosis of 
oral cancer and pre-malignancy.  Higher peaks at 2848cm
-1
 and 2916cm
-1
 which were seen in 
FaDu and DOK compared to TEOM (but not SCC9).  These peaks which result from 
stretching vibrations in CH2 and CH3 bonds found in cholesterol, phospholipids and creatine, 
have previously been identified as peaks which differ in cancer compared to normal cells 
(Huleihel et al., 2002).  Huleihel et al., attributed this difference to levels of creatine (a cell 
metabolite) which are higher in healthy cells and has previously been shown to inhibit cancer 
cell proliferation in mouse models of human colon adenocarcinoma (Huleihel et al., 2002).  
Meurens et al., found a strong correlation between amide I and II and density of cancer cells 
and the absorption bands in breast cancer tissue (Meurens et al., 1996). The cause of this is not 
yet known. The bands corresponding to amide I and II bonds were higher in the TEOM 
compared to FaDu and SCC9 models (the opposite trend to that seen in (Meurens et al., 
1996)).   
The real aim for improved diagnostics of oral lesions would be a method which was able to 
non-invasively diagnose a lesion.  Novel technology such as attenuated total reflectance (ATR) 
and fibre optic spectroscopy enabled Wu et al., to measure FTIR spectra from freshly excised 
tissue without any prior tissue preparation (Wu et al., 2001).   
ATR FTIR enables imaging of tissues even in the presence of strong IR absorbers such as 
water.  In ATR FTIR the IR light source is directed through a crystal which is transparent to IR 
and has a high refractive index.  This high refractive index creates total internal reflections 
within the crystal enabling the tissue in contact with the probe to be measured despite the 
presence of water (Kendall et al., 2009).   
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Wu et al., demonstrated that FTIR with ATR could be used to differentiate between normal 
and cancerous tissue in recently excised tissue samples.  The wavenumber peak which 
appeared the most useful for distinguishing between normal and malignant oral tissue in (Wu 
et al., 2001) was at 1745 cm
-1
.  They attribute this band to the vibration of carbonyl in ester 
groups found in fat cells.  This peak was not seen in any of the sample‟s spectra. However, this 
is most likely due to the loss of lipids during histological processing. Special fixation with 
potassium dichromate, for over 3 weeks is required to retain fat in paraffin sections (Chou 
1957).  It is also likely that the tissue engineered models used here do not have the same 
distribution of fat cells compared to naturally occurring tissues.  If the spectra obtained from 
freshly excised salivary gland tissue and the spectra from our tissue engineered models are 
compared (Figure 4.13 on page 193) there are some common peaks. However, much more 
work needs to be done in order to fully evaluate this technique and the effect bonds present in 
samples have, not only on the size of the peak, but also to shifts in the wavenumber of peaks. It 
will also be interesting to see if FTIR can be performed in live patients without requiring tissue 
excision.     
This initial study into using FTIR for cancer diagnosis is promising. However, a substantial 
amount of further work is needed to develop this technology into a clinically useful, non-
invasive, fast method to diagnose oral lesions.  
 OCT imaging for cancer diagnostics 
The ability of OCT to image differences in tissue engineered models of OSCC was evaluated 
in this study.  The images obtained from the different OCT devices tested here varied and their 
clarity was dependant on a number of factors including the light source (axial resolution), 
wavelength of light source (depth of penetration) and the number of images averaged, to 
reduce noise, and give the final image.  Depending on the application it is possible for different 
parameters to be adjusted in order to obtain the most useful information from a sample.  The 
SS-OCT device and the TD-OCT system were able to image deeper into the tissue but the 
resolution (axial and transverse) of the commercially available Optovue® system was better 
overall and gave a clearer image.   
Of the four devices tested, all were able to show the epithelial connective tissue junction and 
distinguish between epithelium and connective tissue, thus giving information on the thickness 
of the epithelium.  The surface topology could also be clearly seen.  Within the epithelium and 
connective tissue specific cells or features could not be determined but regions of keratinised 
cells did appear brighter than non keratinised cells making them distinguishable in the SCC25 
model.  
The thickness of naturally occurring oral mucosa epithelium is between 75- 550µm (Nanci 
2003) and the systems tested here were able to image to depths of 500µm or greater (systems 
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described in the literature have been able to image to depth of over 2mm  (Georgakoudi et al., 
2008)).  This means the imaging of mucosal diseases is feasible with this technology.   
While OCT imaging of these in vitro models has real value in the development of OCT 
systems for oral lesion diagnosis, there are limitations.  Tissue engineered models such as 
these were able to give clear images of some features of the epithelium and the boundary of 
epithelium and connective tissue.  However, images taken in vivo (Figure 4.25) appeared 
clearer and more features (many of which were not present in tissue engineered models) were 
visible.  It has been previously noticed that ex vivo and in vitro samples do not give as clear 
OCT images compared to in vivo images (Smith et al., 2010).  Hsiung et al., looked at the 
image quality degradation over time post excision and found a reduction in signal intensity 
over time, most likely due to a loss of blood, cell lysis and subsequent changes in the tissue‟s 
microstructure (Hsiung et al., 2005).   
For clinical applications this is not a problem as real time non-invasive imaging is the ultimate 
aim; however, this may explain the difference in image quality obtained from tissue 
engineered models compared to in vivo tissue.  Tissue engineered models may still have use in 
OCT development, for example, as a tool to test novel contrast agents or to image specially 
designed models with specific features (for example cancer cell invasion or models with 
altered cell densities) to enable researchers to examine the appearance of these features with 
OCT before clinical trials.   
Figure 4.25 shows the real potential for using this technology clinically.  Further clinical 
studies need to be undertaken to study, in more detail, the different appearances which arise 
from OCT imaging of different stages of OSCC and other potentially malignant mucosal 
conditions as well as testing the specificities and sensitivities which can be achieved.  OCT 
devices are still a relatively new technology and for the most part have been optimised for 
ocular applications.  OCT development directed for oral applications may further improve the 
images which can be obtained. 
Pathologically, the appearance of the epithelial connective tissue junction is important when 
diagnosing a number of different conditions, not just OSCC.  Many mucosal diseases including 
lichen planus affect this junction adjacent to basal cells and the diagnosis of these conditions 
may also benefit from OCT investigation.  The ability to visualise not just the epithelium but 
also the adjacent connective tissue including blood vessels, ducts and minor salivary glands 
may mean OCT has just as much, or more, potential for diagnosis of non-malignant or diseases 
e.g. oral ulcerative conditions, Sjögren‟s syndrome, vascular anomolier, superficial cystic 
lesions, submucous fibrosis, orafacial granulomatosis, lichen planus etc.  
The data emerging in the literature from OCT imaging of suspicious oral lesions clinically is 
encouraging (Figure 1.16 on page 67).  This has been reviewed in Chapter 1.  With the ever 
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improving technological advances in OCT combined with the desperate need for a faster, 
simpler and non-invasive method to detect early changes in oral epithelia OCT could soon 
become commonplace in dental surgeries.  Image acquisition from OCT is very rapid and 
could in the future be used to screen at risk patient groups for oral cancer, aiding early 
diagnosis before symptoms appear and improving survival rates.  Currently the gold standard 
of oral cancer diagnosis is by invasive surgical biopsy.  This, while accurate and well 
established, could never be used in the screening of patients at risk with no signs or symptoms.  
OCT has the advantage of being able to obtain data from the same area over several years to 
get longitudinal information on a patient‟s condition, an advantage to this technique which has 
already been adopted by ophthalmologists (Bechtel 2010).   
OCT may in the future help to define surgical margins and provide direct evaluation of the 
effectiveness of cancer treatments (Wilder-Smith et al., 2009).  OCT can also be used to image 
the whole oral cavity of a patient with a malignant lesion and find other areas of malignancy in 
the oral cavity which may not be observable by the naked eye.  OCT can locate these 
secondary malignancies in the oral cavity and give the clinician further information which 
helps them to biopsy the area which is most advanced and thereby helping to determine the 
best treatment for that patient based on a more accurate diagnosis of the severity of the 
patient‟s disease (Keller 2010).  It can also be used for long term monitoring of lesions that are 
being kept under observation and may avoid the necessity for regular repeat biopsy of lesions.  
Another major advantage over biopsy is the ability to produce real time, point of care images 
of the tissues that can be discussed with the patient and enable efficient treatment planning and 
decision making without the need for a repeat visit as is needed following a biopsy.   
As shown in (Wilder-Smith et al., 2009) this imaging technique is relatively easy to use, with 
observers being trained in just 2 hours.  Observers obtained sensitivities and specificities of 
0.931 and 0.931 when diagnosing OSCC and carcinoma in situ from healthy tissue, far higher 
than those obtained from methods such as Toludene blue described in the introduction (page 
54). Tsai et al., devised a technique which could be used to quantify data obtained from OCT 
images removing the subjective nature of diagnosis and determining standardised diagnostic 
parameters (Tsai et al., 2009).   
One hurdle which was highlighted in Fujimoto‟s article in Nature Biotechnology is the length 
of time it takes for biomedical technology, such as this, to reach the clinic (Fujimoto 2003).  
Many stages must be overcome before biomedical technologies can reach the clinic including: 
initial research, prototype development, clinical feasibility studies, clinical trials, regulatory 
approval, demonstration of clinical efficacy and sales into the clinical community (Fujimoto 
2003).  The first in vivo retinal imaging using OCT was demonstrated in 1993 and by 2003 
OCT was rapidly becoming the standard of care in ophthalmology (Fujimoto 2003).  Now, in 
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2010, OCT is commonplace in ophthalmology and its benefits have extended from the retina to 
other areas of the eye (Bechtel 2010).  With OCT imaging for oral lesions gaining momentum 
in the research community it is hoped that OCT for oral applications may follow on from the 
success of retinal OCT imaging and have a real positive effect on the early diagnosis of oral 
cancers and subsequently survival rates.  
Table 4.4 summarises the pros and cons of the four techniques tested here and the next steps 
needed for their development.   
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Technique Pros Cons Potential for 
Development? 
The next step 
C12 
resazurin 
 Can image cell 
morphology using the 
stain and CLSM 
 Difference in fluorescence 
intensity between normal, and 
malignant cells not great 
enough to have diagnostic 
value 
 High magnification imaging  
not suitable for in vivo imaging 
No  Find an alternative marker which is more specific to malignancy 
Impedance 
spectroscopy 
 Non invasive 
 Affordable 
 Simple to use 
 Potential for real time 
point of care diagnostics 
 Size of the probe limits the 
spatial sensitivity 
 
Yes  A clinical trial to determine the values of impedance for each grade 
of tissue (healthy, potentially malignant and benign) in all different 
regions of the oral cavity has recently been funded under the NIHR 
i4i program. 
FTIR  Gives quantifiable data 
of the chemical 
composition 
 Affected by the presence of 
water 
 Data currently must be 
obtained from biopsy sections, 
not in vivo 
Yes  Retrospective study of the FTIR spectra resulting from biopsies of a range 
of oral lesions to determine the bonds  with diagnostic potential 
 Use tissue engineered models to develop FTIR technology so it is possible 
to image live tissues which contain water 
OCT  Non-invasive  
 Non-ionising radiation 
 Depth of imaging 2-
3mm 
 Fast, imaging 
 Already in use in 
ophthalmology 
 Longitudinal monitoring 
possible 
 Adequate resolution 
 Light sources expensive 
 Optimised for retinal imaging 
not oral 
 Detection limits not currently 
sensitive enough for many 
cancers 
Yes  Clinical trials imaging clinical lesions to test the ability of OCT to 
distinguish potentially malignant lesions from benign lesions and other oral 
conditions 
 Use tissue engineered models to develop contrast agents and to optimize the 
technology for oral use 
 Investigate the potential of OCT for imaging other conditions of the oral 
mucosa 
Table 4.4 
Table to summarise advantages and disadvantages of the four techniques tested here.  This table highlights some of the developments which are needed for 
these techniques to have real diagnostic value clinically and the potential for use of tissue engineered models in the future of their development.  
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Chapter 5: Future work and 
conclusions 
This project initially demonstrated the ability to create physiologically relevant tissues in the 
laboratory and then demonstrated some of their potential applications in the development of 
medical technologies.  The models of normal oral mucosa created from primary human oral 
cells (fibroblasts and keratinocytes) were cultured on an acellular skin scaffold creating a 
model which comprised of epithelial and connective tissue components. This model was 
characterised using immunohistochemistry and was shown to have many components seen in 
physiologically normal oral mucosa including basement membrane proteins (collagen IV), 
cytokeratins and proliferative basal cells.  This model was used in this project to test the ability 
of polymersomes, a novel drug delivery vector, to cross the oral epithelium and as a control for 
testing non-invasive diagnostic technologies.  In the future this model could be developed 
further by incorporating endothelial or immune components.  One drawback of this model was 
the variation seen between different batches of primary cells. However, this is commonly 
experienced when using primary cells.  To overcome this immortalised cell lines could have 
been used but these cells do not have a normal phenotype and have been modified to become 
immortal. Hence despite the convenience of using cell lines (as are used in several commercial 
models) these lack the  full range of physiological responses . 
The method for culturing normal oral mucosa was next adapted to test whether it was possible 
to culture dysplastic or malignant epithelium.  While some of the cell lines tested here 
produced epithelia with appearances unlike anything seen clinically, we were able to create 
models of dysplastic epithelia using normal oral fibroblasts cultured with DOK cells and SCC9 
cells.  These models contained features of dysplasia including cytological and architectural 
abnormalities (see Table 2.10 for details). Other models, cultured from D20 and Cal27 cells, 
showed more severely pathological appearances which more closely resembled early invasive 
carcinomas.  All these models could be used in a number of future in vitro applications for 
example, as a model to study factors which cause and are able to inhibit cancer progression. 
This project demonstrated that these models could be useful in testing novel diagnostic 
technologies while future applications could include using these to test therapeutic 
technologies and novel drug delivery vehicles.  It would be interesting to culture the cell lines 
used in these models in co-culture with normal oral keratinocytes to see how the normal and 
malignant cells interact and whether less severe dysplasias could be modelled.  
There were signs of early tumour cell invasion of the connective tissue in the models cultured 
from the DOK, D20, D19, Cal27, PE/CA-PJ34 and FaDu cell lines.  Interestingly, when these 
same cell lines were co-cultured with fibroblasts and screened for their ability to form multi-
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cellular tumour spheroids when cultured on agarose coated plates they did form spheroids.  
The cells which did not invade (SCC4 and SCC9) were the cells which did not form spheroids 
when co-cultured with fibroblasts.  This correlation was not seen when the cell lines were 
screened for MCTS formation in mono-culture.  It is well known that epithelial cell invasion is 
influenced by both epithelial cells and mesenchymal cells.  This correlation further suggests 
fibroblasts may be involved in the establishment of solid tumour islands within the connective 
tissue, once the cells have invaded.  These models will lend themselves to investigations of 
epithelial/stromal interactions in particular. 
The MCTS model cultured from the FaDu cell line modelled many features seen in the intra-
vascular regions of solid expanding tumour islands.  These included the hypoxic centre, caused 
by insufficient oxygen diffusion into the central region of the tissue.  The central region also 
showed signs of necrosis as a result of an accumulation of waste products in the central region 
of the tissue.  The outer cells were proliferative and the MCTS expanded over time.  This 
project used the MCTS model to test the ability of polymersomes to penetrate into the central 
region of the MCTS, and thus model the drug delivery vehicle‟s ability to diffuse into the hard 
to treat core of solid expanding tumour islands.  Polymersomes were able to reach 80% of the 
cells within the MCTS and could be seen throughout the MCTS after 5 days exposure.  The 
uptake of polymersomes by cells within multi-cellular tumour spheroid was slower than the 
uptake seen in cell monolayers, demonstrating the importance of testing drug delivery systems 
in 3D models as well as in monolayer studies.   
One of the most interesting applications for the MCTS is for high-throughput screening of 
potential therapeutic agents before in vivo testing. It has been shown that MCTS are a better 
predictor of clinical success compared to in vitro monolayer studies. A number of different cell 
types were tested for their ability to form MCTS with the aim of expanding the library of 
MCTS models available for the testing of novel therapies against OSCC.  Unfortunately, none 
of the cell lines tested (except the FaDu cell line) were able to form solid expanding tumour 
spheroid models using the liquid overlay method.  Some cells formed spheroids but these did 
not expand over time limiting their usefulness as a model to test the anti-cancer capacity of 
novel therapies.   
The uptake and diffusion of polymersomes were tested in 2D and 3D.  When the relative 
uptake of polymersomes was compared between primary cells (fibroblasts and keratinocytes) 
and cancer cell lines (FaDu, SCC4 and Cal27) both the rate and quantity of polymersomes 
taken up by the cancer cells (FaDu in particular) was significantly greater than the uptake by 
the primary cells.  This is interesting as a potential form of passive targeting to cancer cells in 
vitro.  There are many different possible reasons for this including faster metabolism or 
increased endocytosis by cancer cells but the study of the cell metabolism marker C12-
resazurin in chapter 4 showed very similar levels of cell metabolism between the NOK cells 
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and the FaDu cells.   The proposed mechanism of polymersome uptake is via endocytosis 
(Figure 3.3) therefore it would be interesting to see if FaDu cells had a higher rate of 
endocytosis compared to the primary cells or to see whether the polymersomes bound more 
readily to the surface of the cancer cells compared to the primary cells. It is possible the 
polymersome endocytosis is receptor mediated although the identity of the receptor is 
currently unknown. If polymersome endocytosis is receptor mediated our data suggests that 
head and neck cancer cells may express this receptor more than normal oral keratinocytes and 
fibroblasts. 
The data emerging from polymersome studies here and elsewhere in the Battaglia laboratory is 
encouraging. However, a large amount of further work is needed before the true clinical value 
of this drug delivery technology can be realised.  Data presented in this thesis show that 
polymersomes were able to reach the basal cells of the tissue engineered oral mucosal model 
and the central region of the MCTS but it is currently unknown whether the polymersomes 
reach these cells intact.  It will be interesting to next investigate whether the polymersomes are 
able to deliver an encapsulated cargo into these cells and whether polymersomes are capable of 
transmucosal delivery right across the epithelium and into the blood supply.  If both these were 
achievable using these polymersome formulations, the clinical benefits seen from their use 
could be far reaching.  The synthetic nature of the polymer from which these polymersomes 
are made also increases their versatility; enabling the addition of targeting moieties to the 
external surface and alterations to the polymer changing release profiles, flexibility and size.   
Finally, four different diagnostic technologies were tested using the models developed earlier 
in the project.  The first method for diagnosis which was tested stemmed from a simple 
hypothesis.  Could the enhanced metabolism seen in cancer cells compared to healthy cells be 
detected using a non-toxic cell metabolism marker such as C12 resazurin?  When this was 
tested in three different models (normal oral mucosa, carcinoma in situ model and dysplastic 
epithelium) the opposite result was seen to what was expected.  The normal oral mucosa 
showed the highest intensity and therefore metabolism when exposed to the cell metabolism 
marker C12-resazurin.  This could be due to a number of factors discussed previously but 
discounts the usefulness of this method for cancer detection clinically.   
The second method of detection tested here was impedance spectroscopy.  The benefit of this 
has already been demonstrated clinically as it is able to diagnose and grade cervical neoplasias.  
Unfortunately, the values obtained from the in vitro models using this technique were highly 
variable and did not correspond to the values obtained in vivo. It was therefore concluded that 
this non-invasive diagnostic technology would be best studied further in clinical trials.   
The third diagnostic technology was FTIR.  Currently, this technology is not able to measure 
samples which contain water (including the in vitro models). However, new developments in 
Chapter 5:Future work and conclusions 
 
223 
 
FTIR technology suggest this may be possible in the future.  Bonds present in wax embedded 
sections of our models were measured and a few bonds identified which may be of interest 
clinically.  For this to be developed further it will require the potentially useful bonds to be 
identified using samples from clinical tissues as our models do not include all the components 
which are present in cancerous and potentially malignant tissues such as endothelial and 
immune components.  Tissue engineered models may have a use in developing and optimising 
this technology to be used in the presence of water.   
Finally, we imaged tissue engineered models using optical coherence tomography (OCT).  
This imaging method is rapid and capable of obtaining clear images in vivo in live patients 
without the need for anaesthetic and with little or no motion artefacts.  OCT is already making 
a great difference in the treatment and detection of many ocular diseases but using OCT for 
oral diagnostics is a relatively new idea. The data we obtained from the tissue engineered 
models was promising and clearly demonstrated the ability of OCT to image the epithelial 
connective tissue junction.  The ability to see this junction could enable detection of epithelial 
hyperplasia and disruptions to the basement membrane which are features of potentially 
malignant lesions as well as other diseases of the oral mucosa.  The images obtained from the 
different tissue engineered models were for the most part similar to one another except for the 
models cultured from the Cal27 cell line.  In this model the epithelium was seriously disrupted 
and OCT was able to image the abnormal surface morphology of this model.  A vertical 
banding could be seen throughout the image (Figure 4.24), something which was also observed 
in vivo in a squamous cell carcinoma (Figure 1.16). It has previously been observed that the 
images which can be obtained in vivo have better clarity and resolution compared to images 
taken ex vivo and in vitro.  This was also seen in this project as the images obtained in vivo of 
the mucosal surface of the lower lip using the Optovue® system gave far greater contrast 
compared to our images of the in vitro models.  The clear visual appearance of the epithelium, 
surface topology as well as features in the connective tissue including blood vessels and minor 
salivary glands (Figure 4.25) highlights the potential of this technology in the diagnosis of 
many oral diseases. Further developments are required before OCT can be used clinically, for 
example an endoscopic device is required and the imaging parameters will need to be 
optimised for oral rather than ocular applications.  Once these factors have been considered it 
will be very interesting to see the results which can be obtained from clinical trials using this 
technology.   
In conclusion, the tissue engineered oral models are a great advance on the use of monolayer 
cell cultures for a wide range of laboratory studies. They may be particularly valuable in pre-
clinical studies to develop and evaluate therapeutic and diagnostic technologies, such as the 
polymersome drug delivery vehicles and C12-resazurin metabolic stain used here, before they 
are ready for use in patients. But for more established technologies that have already been 
Chapter 5:Future work and conclusions 
 
224 
 
proven safe for use in patients e.g. impedance spectroscopy and OCT, they may not yet be 
good enough to replace patients in clinical trials. Nonetheless, continuing improvement in 
tissue engineered models to more accurately replicate the in vivo situation will continue to 
expand the areas of research in which they prove valuable. 
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Chapter 6: Appendices 
6.1 Appendix 1 Polymersomes 
Polymersomes are a new technology which is still undergoing significant development and 
optimisation.  Standardised, large scale synthesis of the polymers used here has not yet been 
achieved, resulting in variation in the polymers synthesised by different members in the 
Department of Chemistry at different times.  The synthesis method used to produce these block 
co-polymers is complicated and is dependant on many factors including laboratory 
temperature.  Overcoming these many variable factors and identifying the problems took many 
months to complete. Unfortunately this meant for a crucial period in this project there was a 
lack of comparable polymers available.  For this reason there are some results presented here 
which would have benefited from substantial amounts of further work and repeats however, 
this was not possible with the materials available to me in the time frame allowed for this 
project.   The following information has been included for completeness and serves as an 
illustration of the problems encountered through the project.  
 Variation between polymer batches 
Throughout this project several different polymer batches were used. Table 6.1 shows which 
polymer was used for each experiment and the properties of the polymer.  Figure 6.1 shows the 
variation in cyto-toxicity resulting from the different batches when tested on NOF cells (Figure 
6.1a) and FaDu cells (Figure 6.1b) under the same conditions.   
The difference in viability of FaDu cells exposed to the different bathes of PMPC-PDPA is 
evident in (Figure 6.1b).  After 24hours exposed to batch 12 PMPC-PDPA polymersomes the 
FaDu cells were 51% viable compared to FaDu cells exposed to batch 4 of PMPC-PDPA 
which were 95% viable.  After 48 hours the cells showed lower viabilities for all batches of 
PMPC-PDPA.  The polymer batch JPD70 showed the highest viability with 83% of cells 
remaining viable after 48 hours.  In comparison, 24% of the cells exposed to batch 12 PMPC-
PDPA cells remained viable.     
As well as cell viability there were also issues surrounding polymersome formation and the 
precipitation of polymers. 
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Polymer 
batch 
number 
Block co-
polymer 
composition 
(1H NMR) 
Date 
synthesised 
Synthesised by Initiator Experiments 
used for in 
this thesis 
Original 
WEP049023 
No data  
Target 
PMPC 25 
PDPA 70 
2
nd
 Nov 
2007 
Biocompatibles 
UK 
No data TEOM, 
histology of 
spheroids with 
fluorescent 
Rho 
Polymer 1 
PTP7 (1
st
 
batch 
cleaned) 
PMPC 25 
PDPA 67 
27
th
 June 
2008 
Dept. 
Chemistry, 
University of 
Sheffield 
(Dr. Paul 
Topham) 
Azide Spheroid and 
Monolayer 
FACS and 
toxicity 
Polymer 2 
PTP7 (2
nd
 
batch 
cleaned) 
PMPC 25 
PDPA 67 
28
th
 July 
2008 
Dept. 
Chemistry, 
University of 
Sheffield 
(Dr. Paul 
Topham) 
Azide Spheroid and 
Monolayer 
FACS and 
toxicity 
Polymer 3 
NWG5 
PMPC 25 
PDPA 63 
Summer 
2008 
Dept. 
Chemistry, 
University of 
Sheffield 
(Nick Warren) 
Morpholino-
based 
initiator 
(MEBr) 
Spheroid and 
Monolayer 
FACS and 
toxicity 
Polymer 4 
 
? Summer 
2008 
Dept. 
Chemistry, 
University of 
Sheffield 
 
? Spheroid and 
Monolayer 
FACS and 
toxicity 
Polymers 5-
20 
Variable 2008-2010 Dept. 
Chemistry, 
University of 
Sheffield 
 
Variable 8,10 and 12 
toxicity (Figure 
6.1).  Not used 
for other 
experiments 
because of 
precipitation 
and toxicity 
JPD-70  Jan 2010 Dept. 
Chemistry, 
University of 
Sheffield 
(Jeppe 
Madsen) 
 Batch testing 
(DLS trace not 
polymersomes-
precipitation) 
Table 6.1 
Batches of PMPC-PDPA polymersomes 
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Figure 6.1 Viability of NOF cells exposed to different batches of PMPC-PDPA (a) and FaDu 
cells exposed to different batches of PMPC-PDPA (b) for 24 and 48 hours.  
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6.2 Appendix 2 Fluorescence 
 How to compare the two different polymers  
In order for the PMPC-PDPA and PEO-PDPA polymers to be compared against one another 
they must have comparable detectable characteristics. Throughout this project the 
polymersomes have been fluorescently labelled in two different ways.  The first method of 
labelling the polymersomes fluorescently was by encapsulating an amphiphilic rhodamine dye 
(Rhodamine B octadecyl ester perchlorate) within the membrane of the polymersome.   
Figure 6.2 shows the uptake of the PMPC-PDPA polymersomes compared to the PEO-PDPA 
polymersomes in FaDu cells.  From this experiment it looks as though the PMPC-PDPA 
polymersomes were taken up faster and in larger amounts (as determined by FACS analysis 
looking at the proportion of cells with detectable fluorescence and the median fluorescence 
intensity of each cell).  However, when the fluorescence intensity of the two different 
polymersome solutions were measured after the column at variable concentrations, using a 
fluorescence spectroscopy plate reader, it could be seen that the PMPC-PDPA polymersome 
solution had a much higher fluorescence intensity compared to the PEO-PDPA solution 
(Figure 6.3).  The PMPC-PDPA solution had a fluorescence intensity of 157 a.u when the 
concentration of the polymersomes was 0.34µM however, the same intensity of fluorescence 
in the PEO-PDPA sample corresponds to 4.28µM; 12.5 times higher.  Therefore the result seen 
in the FaDu cells exposed to both polymersome solutions is most likely not an inherent 
difference between the two polymers but instead an artefact created by the difference in 
fluorescence intensities.  One reason for the lower fluorescence intensity is the encapsulation 
efficiency of Rhodamine B octadecyl ester perchlorate dye by the PEO-PDPA polymersomes 
as demonstrated in the profile of the fractions eluted from the GPC column.  It is clear in 
Figure 6.4 that the majority of the amphiphilic rhodamine is not encapsulated in the PEO-
PDPA polymersomes (fractions 6-10ml after first fraction) but are eluted from the column as 
free rhodamine in fractions around 25 -30ml after the first fraction.    
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Figure 6.2 Relative uptake of PEO-PDPA and PMPC-PDPA polymersomes labelled with 
amphiphilic rhodamine by FaDu cells. 
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Figure 6.3 Fluorescence intensity of both polymersome formulations with encapsulated 
amphiphilic rhodamine dye (at various concentrations).  
 
Figure 6.4 Fluorescence profile of fractions leaving the GPC column for PEO-PDPA 
encapsulating amphiphilic rhodamine dye.  
 
The second method of fluorescently labelling polymersome samples was to use a fluorescently 
labelled polymer, with rhodamine 6G covalently conjugated to the terminal of the PMPC block 
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on the PMPC-PDPA polymer chain. The fluorescent polymer chains were added to the 
unlabelled polymer at a 5% molar concentration.  This same PMPC-PDPA polymer could also 
be added to the PEO-PDPA polymer to label this.  When used to label the PEO-PDPA 
polymersomes the rho-PMPC-PDPA was added to the unlabelled PEO-PDPA at 5 molar %.  
The fluorescence intensity for the two polymers using this approach was still significantly 
different (Figure 6.5) however, instead of a 12.5 fold difference the difference was nearer 2.3 
(with the same fluorescence intensity corresponding to 1µM of PEO-PDPA compared to 
0.432µM of PMPC-PDPA).  The drawback of labelling the PEO-PDPA polymersomes in this 
way is that the influence of Rho-PMPC-PDPA chains within the polymersomes may affect the 
uptake profile.  
Some attempts have been made to quantify the amount of polymersomes within cells in a way 
which is not as affected by the differences in fluorescence.  The method described in 
(Massignani et al., 2009) involved lysing the cells after exposure to polymersomes.  The 
intensity of this lysate could then be correlated back to a calibration curve of a known quantity 
of polymersomes in cell debris.  Unfortunately this method did not work for the experiments 
performed in this project, most likely due to the high level of scattering caused by the cell 
debris and the method used to lyse the cells. In conclusion the method for fluorescently 
labelling the 2 different polymers needs to be improved before these two can be directly 
compared 
 
Figure 6.5 Fluorescence intensity of two polymersome formulations with 5 molar % Rho-
PMPC-PDPA. 
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